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 VIRAL AND CELLULAR TARGETS FOR THE VARICELLA-ZOSTER VIRUS 
ORF66 PROTEIN KINASE 
Amie J. Eisfeld, PhD 
University of Pittsburgh, 2007
 
Varicella-zoster virus (VZV) is a human alphaherpesvirus that causes two important diseases, 
chickenpox and herpes zoster, separated by a prolonged period of latent infection in which no 
disease occurs.  VZV remains a serious public health concern despite the availability of licensed 
vaccines for the prevention of chickenpox during childhood and zoster in the elderly.  The VZV 
ORF66 protein kinase is a well-established mediator of VZV tropism and pathogenesis in vivo, 
but information regarding the molecular mechanisms of ORF66 function is limited.  ORF66 is 
orthologous to the alphaherpesvirus US3 kinase family, which is involved in regulating diverse 
aspects of the host environment.  ORF66 has been implicated in nuclear exclusion of the VZV 
principle transcriptional regulator and tegument protein, IE62, during late-stage VZV infection; 
and in downmodulation of class I major histocompatibility complex surface expression, which is 
critical for the identification and elimination of infected cells by the adaptive immune system.  
However, the mechanisms underlying these processes are not well-resolved.  In this work, I have 
significantly extended our understanding of known ORF66 functions during VZV infection, and 
I have established novel functions for both ORF66 and the IE62 protein.  Purification of ORF66 
allowed the development of an in vitro kinase assay, and I used this to prove that ORF66 directly 
phosphorylates IE62 adjacent to its nuclear localization signal to mediate nuclear exclusion.  
Additional investigations of IE62 nucleocytoplasmic trafficking revealed a novel nuclear export 
activity, which was multi-dimensionally regulated by intrinsic IE62 nuclear retention and 
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phosphorylation by kinase(s) other than ORF66.  With regard to the ORF66 role in the regulation 
of MHC-I surface presentation, I developed assays with recombinant VZV expressing enhanced 
green fluorescent protein-tagged ORF66 to establish that ORF66 affects the cellular environment 
such that early MHC-I biogenesis is delayed, resulting in a reduction in total surface MHC-I.  
MHC-I studies indicated highly novel ORF66 nuclear distribution patterns, and a further 
examination of these revealed that ORF66 may regulate nucleocapsid morphogenesis or 
trafficking in VZV-infected nuclei.  In sum, this work represents a major contribution to VZV 
biology and provides insights into a multi-functional mediator of VZV persistence and 
pathogenesis. 
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1.0  INTRODUCTION 
1.1 VARICELLA-ZOSTER VIRUS DISEASE AND PUBLIC HEALTH IMPACT 
Varicella-zoster virus (VZV) causes two clinically significant syndromes in humans: varicella 
(chickenpox) during initial infection and herpes zoster (shingles) following reactivation from 
neuronal latency.  Varicella is characterized by a highly contagious, but typically self-resolving, 
disseminated vesicular skin rash that erupts ~10-21 days following initial inoculation.  
Replication in skin results in the establishment of latent infection in the dorsal root ganglia of 
sensory neurons.  In response to age or stimuli that induce cellular immune dysfunction (e.g., 
acquired immunodeficiency syndrome or immunosuppression due to transplantation), latent 
infections may reactivate, replicate in the ganglia, and cause herpes zoster: an often painful skin 
rash in the dermatome associated with the reactivated neuron (11, 102).  VZV spreads to naïve 
hosts through respiratory inoculation, which can result from exposure to an infectious individual 
with either primary varicella or reactivated zoster disease. 
Serious morbidity and mortality are associated with both varicella and herpes zoster.  
Previous to the licensing of the live, attenuated varicella vaccine in 1995 (Varivax, Merck), 
complications arising from varicella disease resulted in ~11,000 hospitalizations and ~100 deaths 
in the United States (US) annually (33).  The most common cause for hospitalization is bacterial 
(Staphylococcal or Streptococcal) super-infection of VZV skin lesions.  However, more serious 
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complications including invasive group A Streptococcal secondary infections, viral or bacterial 
pneumonia, or encephalitis may lead to mortality (92, 130).  Reactivated VZV disease (herpes 
zoster) occurs once in a lifetime in ~30% infected individuals (102).  A particularly excruciating 
and poorly understood complication associated with zoster is chronic pain at the epidermal site 
of replication, a condition known as post-herpetic neuralgia (PHN).  PHN may persist for greater 
than a year following resolution of zoster skin lesions, and currently no efficacious treatment is 
available (70).  Herpes zoster infection can involve ocular tissues, with serious manifestations 
resulting in vision problems, blindness and ophthalmic PHN (169).  Disseminated varicella and 
zoster infections can occur in immunocompromised patients, such as transplant recipients, 
children with leukemia or lymphoma, and individuals with acquired immunodeficiency 
syndrome (AIDS) (9).  Although VZV can be successfully treated with the herpesvirus-specific 
anti-virals (acyclovir, valacyclovir), extended treatments in AIDS patients have resulted in 
emergence of acyclovir-resistant VZV strains (77).           
The serious nature of varicella and zoster disease provided the impetus for the 
development of the live, attenuated varicella vaccine, which was licensed in the in the United 
States (US) in 1995 for use in children 12 months of age or older (33).  Varivax represents the 
first and only successful introduction of a herpesvirus vaccine among the human population.  
Varivax is estimated to be 70-90% effective in preventing VZV infection, and 90-100% effective 
against moderate to severe varicella disease.  Despite the success of Varivax, several concerns 
remain:  1) Varivax maintains the ability to establish life-long latent infection and vaccine-
associated herpes zoster has been observed (78).  Over the long-term, the potential for Varivax 
reactivation, vaccine-associated herpes zoster, and serious complications is not known.  2) For 
reasons that are not yet completely clear, primary VZV infection acquired during adulthood 
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results in more severe varicella disease and a higher incidence of serious complications (33).  
The reduction in childhood varicella cases and opportunities for initial exposure due to 
implementation of the vaccine may result in an increased number of adult varicella cases among 
people who do not receive childhood vaccination.  3)  The Hope-Simpson model of VZV 
pathogenesis postulates that immunological boosting against VZV occurs from repeated 
exposure to primary varicella infection throughout a lifetime, and suggests that zoster occurs 
when immunological boosts are lacking and VZV-specific immunity wanes (102).  Thus, the 
elimination of the boosting population through vaccination against varicella may inordinately 
decrease the age at which initial zoster episodes appear and increase the incidence of zoster in 
the population in general, possibly giving rise to a higher incidence of serious zoster 
complications (29, 81).  In 2006, the zoster vaccine (Zostervax; Merck) was approved for use in 
the US in people aged 60 years and older.  However, Zostervax does not provide complete 
protection from herpes zoster episodes, and has been reported to reduce the incidence by only 
51%, although cases of PHN were reduced by 66% (190).  
Taken together, these observations accentuate the role of VZV as a significant human 
pathogen and important public health concern, and underscore the requirement for a more 
detailed understanding of the molecular basis of viral replication and the host-pathogen 
relationships that regulate VZV pathogenesis.  A better understanding of VZV biology will 
ultimately assist in both prevention and treatment of VZV disease. 
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1.2 VZV TROPISM AND PATHOGENESIS 
VZV is spread to naïve individuals by inoculation of the airway or conjunctiva with aerosolized 
droplets of infectious cell-free VZV derived from skin vesicles or respiratory secretions of 
persons exhibiting either varicella or zoster disease.  VZV DNA is detected in peripheral blood 
mononuclear cells (PBMC) a few days after exposure, and secondary cell-associated viremia 
occurs just before eruption of vesicles at the skin surface (158).  Varicella lesions are 
disseminated in skin throughout the infected host, and this differs markedly from the localized 
infection observed at the primary inoculation site during herpes simplex virus type 1 (HSV-1) 
infection.  Interestingly, VZV preferentially infects human tonsillar CD4+ T cells that exhibit 
memory and skin homing markers, implying that T cell infection may occur directly after initial 
inoculation, and that these cells may be required for the transfer of virus to epidermal cell layers 
(138).  Additionally, monocyte-derived dendritic cells (DC) are susceptible to VZV infection in 
vitro, and can efficiently transfer infectious virus to co-cultured T cells, suggesting that DC could 
also be an initial target during primary infection (3, 179).  In a third possibility, VZV may 
undergo limited replication in the respiratory epithelium around the tonsils, and these cells may 
mediate subsequent infection of T cells.  In the skin, VZV replicates primarily in keratinocytes 
and works its way to the epidermal surface to result in infectious lesions, but also gains access to 
the axons of innervating sensory neurons.  VZV infects sensory neurons, presumably travels by 
retrograde transport into neuronal cell bodies of the dorsal root (255), and establishes latent 
infection.  In contrast with latency of HSV-1, in which only the latency associated transcript 
(LAT) is abundantly expressed, several VZV lytic antigen transcripts have been detected at 
abundant levels in latently infected human ganglia (44, 45, 170).  Some evidence also exists for 
the expression of viral regulatory proteins during VZV latency, although these may aberrantly 
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localize to the cytoplasm (156).  Although it is well-known that waning cell-mediated immunity 
contributes to reactivation of VZV, the molecular mechanisms that initiate this process remain 
largely unknown. 
The exquisite host specificity of VZV has severely limited our ability to understand VZV 
pathogenesis, as no robust animal model of VZV infection exists.  However, the development of 
a severe combined immunodeficient (SCID)-hu model of VZV infection, in which human tissue 
xenografts are implanted underneath the kidney capsule, has recently been developed to begin to 
unravel this process ((173) and reviewed in (10)).  In SCID-hu mice, VZV transfer to skin 
xenografts can be mediated by release of infectious virus by infected tonsillar CD4+ T 
lymphocytes (139).  VZV replication in the epidermis is slow and spread occurs by cell-to-cell 
contact and fusion of adjacent cell membranes.  A robust interferon α (IFNα) response occurs in 
the cells surrounding the site of VZV inoculation, providing an innate barrier that VZV must 
overcome to cause infectious lesions at epidermal surfaces.  The extended period of growth 
required to overcome the IFNα barrier in skin correlates with the VZV incubation period in 
humans, and suggests that skin may become infected shortly after the initial inoculation.  VZV 
can also mediate infection of dorsal root ganglia implants in the SCID-hu model, and establishes 
latent infections characterized by some viral transcript expression and no replication (255). One 
major disadvantage intrinsic to the SCID-hu model is the lack of an intact host immune system.  
Thus, the contributions of VZV genes involved in evasion of adaptive immunity cannot be 
readily assessed using this model of in vivo infection.         
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1.3 VZV VIROLOGY 
1.3.1 Classification 
Herpesviridae is a family of highly successful viruses that are widely disseminated in nature.  
More than one hundred viral species have been identified and diverse animal groups are affected, 
including mammals, birds, reptiles, fish, amphibians and bivalves (192).  A single herpesvirus 
typically infects a single natural host.  All herpesviruses encode linear, double-stranded (ds) 
DNA genomes ranging from 125-230 kbp in length, and express multiple enzymes involved in 
nucleotide metabolism, viral genome replication, and post-translational protein modification.  
Herpesviruses utilize the host cell nucleus for viral gene expression and genome replication and 
packaging; and progeny virions are assembled in the cytoplasm. In their natural reservoirs 
herpesviruses establish latent infections, in which only a sub-set of viral genes is expressed and 
no progeny virus is released.  Importantly, latent viral genomes persist for the life of the host and 
maintain the capacity to replicate, cause disease and spread to uninfected hosts in response to 
stimuli that induce reactivation.   
Herpesviridae is divided into three sub-families—Alphaherpesvirinae, Betaherpesvirinae, 
and Gammaherpesvirinae—based on biological properties, although more recent genome 
sequencing data validate these sub-classifications at the genetic level (192).  Alphaherpesviruses 
have relatively short replication cycles, cause visible cytopathic effect in cultured cells, and 
establish latent infections primarily in ganglia.  Beta and gammaherpesviruses have longer 
replication cycles, and betaherpesviruses establish latency in secretory glands, lymphoreticular 
cells or kidneys; while gammaherpesviruses are T or B lymphocyte-trophic and establish latency 
in lymphoid tissue.  Humans are the natural reservoir for eight herpesviruses, including species 
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representing each sub-family, and these viruses are responsible for a wide array of clinically 
important diseases (summarized in Figure 1-1).  
 
 
Figure 1-1 Human herpesviruses 
The eight human herpesviruses are shown, along with the corresponding sub-family 
classification and the major clinical manifestation. 
 
VZV is a human restricted alphaherpesvirus that is further classified into the genus 
Varicellovirus, which includes simian varicella virus and several agriculturally significant 
herpesviruses, such as pseudorabies virus (PrV) and bovine herpesvirus 1 (BHV-1).  
Varicelloviruses share the ability to cause widely disseminated infections in the skin, mucous 
membranes, viscera and nervous system tissues of natural reservoirs; and have similar genome 
arrangements with predominant isomeric forms (41).  VZV is the only human varicellovirus, and 
is the prototype virus of the Varicellovirus genus.  Among the human herpesviruses, VZV is 
most similar to herpes simplex virus types 1 and 2 (HSV-1 and HSV-2), which belong to the 
genus Simplexvirus.  Despite their evolutionary digression, the VZV and HSV genomes are 
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remarkably co-linear in arrangement, and only five VZV gene products do not have 
corresponding orthologs in the HSV-1 genome (ORFs 1, 2, 13, 32 and 57) (48, 161-163, 197).  
Thus, many aspects of VZV replication classically have been assumed to emulate those of the 
better studied HSV-1.  However, VZV and HSV-1 pathogenesis differ markedly, and 
accumulating molecular evidence suggests that many aspects of VZV replication are governed in 
a unique manner.   The viral protein functions that underlie these differences are only beginning 
to be elucidated. 
1.3.2 Structure and Assembly 
Herpesviruses are structurally indistinguishable by negative staining in electron microscopy 
(EM).  The herpesvirus particle is spherical in shape, and consists of a central nucleocapsid 
housing the electron-dense viral genome core, a host-derived lipid envelope studded by viral 
glycoproteins and an intermediate proteinaceous layer, known as the tegument, which resides 
between the nucleocapsid and the envelope (Figure 1-2).  
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Figure 1-2 Graphical representation of the herpesvirus structure 
The herpesvirus nucleocapsid (blue) contains one linear, double-stranded DNA genome (yellow) 
packaged in concentric spherical shells.  The tegument (purple) resides between the nucleocapsid 
and the host-derived lipid envelope (grey).  Viral glycoproteins associated with the envelope stud 
the virion surface (red, green, orange).  The drawing is not to scale. 
 
Genome:  The VZV genome is the smallest of all the herpesviruses and consists of 125 
kbp of dsDNA, which encodes at least 69 unique open reading frame (ORF)s (48).  The genome 
is arranged into Unique long (UL) and Unique short (US) regions, each bounded by terminal 
repeat sequences (Figure 1-3).  The terminal repeats of the UL segment (TRL, IRL) are short 
(~88.5 nt), while the terminal repeats of the US segment (TRS, IRS) are much longer (~ 7000 nt), 
code for three viral ORFs in duplicate (ORFs 62/71, ORFs 63/70 and ORFs 64/69), and include 
the origins of replication.  Packaged VZV DNA exists predominantly in two equimolar isomeric 
forms, which differ in the inversion of the US region with respect to the nearly invariant 
configuration of the UL region (128).  The arrangement of VZV DNA within the nucleocapsid is 
not currently known.  However, in HSV-1 the nucleocapsid core contains one linear dsDNA 
molecule, which is arranged in concentric spherical shells within the capsid (259).   
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Figure 1-3 The VZV genome 
The VZV genome consists of 125 kbp of double-stranded DNA, arranged into unique long (UL) 
and unique short (US) regions (gray), bounded by internal and terminal repeats (TRL and IRL, 
red; TRS and IRS black).  The unique regions are indicated by labels below the genome, while the 
repeat regions are indicated by labels above.  The lengths of each segment are drawn to scale, 
except for the TRL, IRL, which have been enlarged slightly for ease of visualization.  The scale 
bar at the top facilitates estimation of the approximate length of each genome segment in 
nucleotides.  The two origins of replication are indicated. 
 
 
Nucleocapsid:  VZV capsids exhibit icosahedral symmetry, contain 162 capsomeres and 
have a diameter of 80-120 nm (41).  The VZV ORF33 protein is the predicted VZV assembly 
protein, and has demonstrated serine protease auto-cleavage activity, which releases the 
ORF33.5 product presumably to act as scaffolding for capsid morphogenesis (72, 165).  ORF33 
can replace its HSV-1 counterpart (VP24) in a baculovirus expression system to promote 
assembly of HSV-1 capsid shell proteins (204), indicating that HSV-1 and VZV mechanisms of 
capsid assembly may be similar.  The VZV ORF40 gene encodes the major capsid protein 
(MCP; HSV-1 ortholog VP5), which is expressed as a 155 kDa nuclear antigen in infected cells 
(236).  By homology with HSV-1, the additional VZV capsid proteins are likely those encoded 
by ORF23 (minor capsid protein; HSV-1 VP26), and ORF20 and ORF41 (triplex proteins; HSV-
1 VP19C and VP23, respectively).  Studies have shown that nucleocapsids are detected in VZV-
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infected cell nuclei at 24-48 hours post-infection (hpi), and greatly increase in number by 72 hpi 
(89).  They are observed both individually and in small clusters.    
Tegument:  The herpesvirus tegument consists of upwards of 20 viral protein products, 
which are released into the cytoplasm upon entry and uncoating and are immediately available to 
assist in the establishment of a pro-viral replication state.  Some recent evidence also suggests 
the presence of cellular proteins and viral mRNAs (16, 17, 27, 222, 230, 239).  The total protein 
complement of the VZV tegument is not known, but many reports indicate that the VZV 
tegument is very different from that of HSV-1.  HSV virions carry a tegument associated non-
specific RNase (UL41 or virion host shutoff, vhs) that is responsible for cleaving host mRNA to 
prevent new host protein synthesis (60, 66, 141).  One vital result of vhs activity is the inhibition 
of interferon production in newly infected cells (35, 56, 183).  The VZV ortholog of vhs is not 
detected in purified VZV particles (217).  In HSV-1, an essential tegument protein is the α-trans-
inducing factor (α-TIF), which is a transcriptional transactivator critical for the expression of 
immediate early viral genes in the absence of de novo viral protein synthesis (248).  The VZV 
ortholog to α-TIF, the ORF10 protein product, is associated with VZV particles (125), but is not 
essential for viral replication in culture (42), although it is necessary for pathogenesis in skin in 
the SCID-hu model (34).  Several other VZV transcriptional regulators are tegument-associated, 
and these may assist in activation of VZV gene expression in the absence of ORF10 protein 
expression.  Specifically, the principle VZV transcriptional transactivator, IE62, is an abundant 
tegument protein (125), whereas its HSV-1 counterpart (ICP4) is present only in minor amounts 
(24, 252).  The VZV ORF4 (HSV-1 ortholog = ICP27) and ORF63 (HSV-1 ortholog = ICP22) 
protein products are also associated with the VZV tegument, but the ORF61 (HSV-1 ICP0) 
protein is not (122).  It is unknown whether HSV-1 ICP22 is a tegument protein; however, while 
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ICP27 is not a tegument component, small amounts of ICP0 have been detected in the HSV-1 
virion particle (251).  The VZV-encoded ORF47 and ORF66 serine/threonine (Ser/Thr) protein 
kinases have both been reported to be associated with the VZV tegument, although the ORF47 
kinase is more abundant and may be responsible for virion kinase activity (123, 226).     
 Envelope and glycoproteins:  VZV encodes 9 putative and known viral glycoproteins that 
are presumed to be involved in mechanisms of attachment and entry, envelopment, cell-to-cell 
spread and egress (127).  The most abundant VZV glycoprotein expressed at the infected cell 
surface is gE, which is also present in the TGN, and is a component of the virion envelope (119, 
171, 242, 261).  gE is responsible for binding the VZV receptor for cell-to-cell fusion in culture, 
the insulin-degrading enzyme (150, 151).  VZV glycoproteins traffic into the Golgi apparatus, 
initially independent of the maturation of the VZV nucleocapsid, in preparation for virion 
assembly in modified cisternae of the trans-Golgi network (TGN) (79, 89, 260). 
1.3.3 Regulation of Viral Gene Expression 
Herpesvirus gene expression during lytic infection occurs in a transcriptional cascade regulated 
by both cellular factors and viral proteins, characterized by temporally-defined waves referred to 
as α, β, and γ (100, 101).  Upon infection with HSV-1, the essential α-TIF protein is released 
from the tegument and enters the nucleus to activate expression of a sub-set of viral genes, 
known as the Immediate Early (IE) or α genes.  α-TIF forms a complex with the cellular Oct-1 
and HCF-1 transcription factors, and together this complex binds to a specific motif 
(TAATGARAT) in the enhancer region of IE promoters (248).  IE transcripts accumulate in the 
absence of de novo protein synthesis, and have roles in regulating the viral transcriptional 
program and suppression of mechanisms of host defense against infection.  The next wave of 
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viral gene expression (Early; E or β genes) is activated by the IE genes, and these mainly include 
factors involved in DNA metabolism and viral genome replication.  As E genes require IE genes 
for expression, they are not made in the absence of de novo protein synthesis.  Late (L or γ) 
genes are viral structural (capsid, tegument or envelope) proteins or those that facilitate genome 
packaging and egress from the infected cell.  L gene expression predominantly ensues following 
initiation of viral genome replication, and L genes are divided into two classes: γ1 and γ2.  γ1, or 
“leaky late”, genes are made to low levels before genome replication but peak in expression after 
replication begins; while γ2, or “true late”, genes are only expressed after genome replication.  
Thus, γ1 genes are made in the presence of genome replication inhibitors, while γ2 genes are not 
expressed in this situation.      
The highly cell-associated nature of VZV infection does not permit high multiplicity 
synchronous infection, and thus classification of the vast majority of viral gene products into 
specific temporal classes of expression has not been performed.  Exceptionally low titer “cell-
free” VZV can be prepared by mechanical disruption of infected cell membranes, and this 
combined with immunofluorescence-based methods has been used to demonstrate that proteins 
from ORFs 4, 62 and 63 (orthologs of HSV-1 ICP4, ICP27 and ICP22, respectively) are IE genes 
(50, 52, 67).  In the absence of experimental data, the regulation of most VZV gene expression is 
assumed to mirror that of corresponding HSV-1 orthologs, although it should be noted that some 
differences have been experimentally identified.  For example, the VZV α-TIF ortholog, ORF10, 
does not encode an acidic C-terminal activation domain as is observed with HSV-1 (164), is a 
non-essential protein in culture (42), and may utilize different cis-acting elements to control IE 
gene expression (176). 
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1.3.4 Cosmid-based system for generation of VZV recombinants 
The highly cell-associated nature of VZV also makes isolation of pure populations of mutant 
virus by standard homologous recombination methods very difficult.  However, cosmid-based 
vectors encoding overlapping segments of the VZV genome have been extensively used to 
generate mutations in specific VZV genes within both the VZV vaccine strain (vOka) and the 
parent of the vaccine strain (pOka) (14, 34, 39, 43, 107, 187, 219, 220, 254).  Isolation of cosmid 
DNAs allows specific manipulation of the VZV genome, and once the intended mutations are 
generated, cosmids are co-transfected into melanoma cells for derivation of isogenic virus 
expressing these mutations.  The cosmid-based recombination system has substantially improved 
our understanding of several VZV protein functions in the context of infection, and is facilitating 
our appreciation of the molecular basis for differences in VZV and HSV-1 pathogenesis. 
1.4 THE VZV ORF66 PROTEIN KINASE 
The goal of this dissertation was to expand our knowledge of the molecular mechanisms of 
function of a VZV-encoded S/T protein kinase, ORF66.  ORF66 was putatively identified as a 
protein kinase based on significant sequence similarity at the primary amino acid level with 
known eukaryotic protein kinases (ePKs), following the initial sequencing of the VZV genome 
(48, 226).  In the proceeding sections, I give an overview of ePKs, an introduction to the VZV 
protein kinases encoded by ORFs 47 and 66, and a more detailed discussion of the fundamental 
molecular properties of ORF66.   
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1.4.1 Context: Eukaryotic Protein Kinases 
Protein kinases (PKs) are enzymes that catalyze the reversible, covalent addition of a phosphate 
group from a high-energy donor molecule (e.g., ATP) to the –OH group in a serine (Ser or S), 
threonine (Thr or T) or tyrosine (Tyr or Y) side chain of a substrate protein, in a reaction termed 
phosphorylation.  A single substrate phosphorylation event adds two negative charges, which 
induces an overall change in protein structure that ultimately may affect catalytic activity or 
protein:protein interactions.  PKs may be dedicated to a single or related group of substrate 
proteins, or may be multi-functional and modify diverse targets.  The specificity of kinase-
mediated substrate phosphorylation is constrained by the ability of the kinase to recognize the 
specific contextual amino acid residues that surround the target S/T/Y phosphorylation site.  
However, additional levels of constraint reside in the expression pattern and spatial distribution 
of the kinase and the substrate within the cell, and their ability to physically associate under 
physiological conditions.  ePKs regulate signaling pathways induced by both extracellular and 
intracellular signals, and are involved in diverse cellular processes including metabolism, 
transcription, cell cycle progression, immune activation, regulation of cellular shape and 
apoptosis.   
 The ePK catalytic domain consists of a contiguous stretch of approximately 250 amino 
acids, which are divided into 11 major conserved sub-domains that are partially defined by a set 
of nearly invariant amino acids (86, 87).  Some universal structural characteristics include an N-
terminal glycine loop motif, which stabilizes nucleotide binding; a nearby invariant lysine 
residue, which is involved in phospho-transfer; and downstream central catalytic core, which 
contains residues involved in ATP interaction, Mg2+ (salt) bridge formation, and phospho-
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transferase activity.  Specific sequences in the C-terminal portion of the ePK catalytic domain 
distinguish S/T kinases from Y kinases. 
1.4.2 VZV Protein Kinases: ORF47 and ORF66 
VZV encodes two genes, ORF47 and ORF66, which contain motifs consistent with catalytic 
domains of eukaryotic S/T PKs (226).  Much is known with regard to the function of the ORF47 
kinase, which is the VZV ortholog to the UL13 protein kinase family conserved among all 
herpesviruses.  ORF47 is critical for VZV replication in both human skin xenografts and thy/liv 
implant-derived T lymphocytes in the SCID-hu model in vivo, and it serves important structural 
and catalytic roles in the viral life cycle (21, 22, 174).  Conditions under which the ORF47 
kinase is active in vitro have been determined, and these include a requirement for poly-amines; 
stimulation in the presence of Mn2+ over Mg2+; the ability to exchange GTP for ATP as a 
phosphate donor; and activity in the presence of heparin, an effective inhibitor of the cellular 
casein kinase II (CKII) (121, 185, 186).  The minimum ORF47 consensus sequence has been 
derived through extensive analysis of ORF47 in vitro targets:  S/T-X-D/E-D/E, (D=aspartic acid; 
E= glutamic acid; X=any amino acid except for arginine/R or lysine/K) (120).  While this is 
similar to motifs recognized by CKII (166), ORF47 kinase activity has been differentiated from 
that of CKII both in vitro and in VZV-infected cells (119, 120, 186).  Several viral protein targets 
have been identified for the ORF47 kinase, including gE and the VZV IE62 transactivator.  
ORF47 phosphorylates the gE cytoplasmic tail, thereby regulating its cellular distribution and 
fusogenic properties in VZV-infected cells (21, 119).  ORF47 phosphorylates IE62 in vitro (121, 
185, 186); mediates phosphorylation of co-precipitated IE62 from infected cells, and may 
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facilitate IE62 nuclear exclusion during late-stage infection in a kinase activity dependent 
manner (22).   
 Much less is known with regard to the functions of the ORF66 kinase during VZV 
infection, although its role in pathogenesis has been firmly established.  The ORF66 gene resides 
within the US region of the VZV genome, and is an ortholog of the US3 kinase family, members 
of which are expressed only among the alphaherpesviruses.  Recombinant VZV lacking ORF66 
expression are minimally impaired for replication in melanoma cells in culture (91, 220), but are 
significantly impaired for replication in cultured T lymphocytes (224).  In vivo data reflect this 
cell-type-specific effect on VZV tropism, in that VZV lacking ORF66 reaches similar titers as 
wild-type virus in skin xenografts in the SCID-hu model, but is severely attenuated for 
replication in thy/liv implant-derived T lymphocytes (174, 220).  Since T cells are critical for 
VZV viremia and dissemination in the infected host, these data indicate that ORF66 expression 
is a major determinant of VZV virulence and pathogenesis in vivo. 
1.4.3 ORF66: Fundamental Molecular Properties 
In the context of infection, ORF66 is likely expressed with early kinetics, similar to orthologous 
US3 kinases from other herpesviruses.  However, this has not been experimentally established, 
and no current literature regarding the regulation of the ORF66 promoter by viral or cellular 
factors is available.  In HSV-1 and PrV infections, long and short US3 transcripts are expressed 
(202, 238), but only the full-length ORF66 transcript has been detected during VZV infection 
(219).  ORF66 is a 393 amino acid protein, encoded by nucleotides 113,037-112,333 in the VZV 
Dumas reference genome sequence.  Early studies identified ORF66 as a 48 kDa phosphoprotein 
when expressed in VZV-infected cells, and demonstrated that ORF66 expressed from a vaccinia 
 17 
virus vector was exclusively cytoplasmic (226).  In contrast with this, studies in our lab have 
shown that HA-tagged ORF66 transiently expressed from a plasmid in the absence of additional 
exogenous protein expression is localized to both the nucleus and the cytoplasm in transfected 
human melanoma cells (124).  More recent studies have identified ORF66 in the cytoplasmic 
fraction during VZV infection, as well as detectable amounts in the soluble nuclear fraction 
(219).  Thus, it ORF66 is both a nuclear and a cytoplasmic protein.  Other than phosphorylation, 
no additional post-translational modifications have been reported for ORF66.  
The ORF66 catalytic domain resides between amino acids 93-378, as determined through 
a query of the Conserved Domain Architecture Retrieval Tool (CDART) (75).  Specific motifs 
within this domain are highlighted in Figure 1-4.  There have been no reports of any mutations in 
ORF66 N-terminal or C-terminal regions that lie outside of the kinase motif, and it is currently 
unknown the extent to which these contribute to ORF66 functions.  I consider it likely they are 
involved in specific protein:protein interactions.   
 
 
Figure 1-4 ORF66 primary amino acid sequence 
The ORF66 primary amino acid sequence is represented in single letter code.  The consensus 
catalytic motif is shown in green, with the conserved regions involved in ATP-binding and 
phosphor-transfer indicated:  ATP-stabilizing glycine loop (orange); invariant ATP-binding 
lysine (red); and catalytic core (purple).  Letters in black are the terminal sequences likely 
involved in specific protein:protein interactions.  The relative amino acid numbers (every 60) is 
indicated to the left.    
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ORF66 induces kinase activity in VZV-infected cells, either due to intrinsic catalytic 
activity, or by activation of cellular kinases (91).  ORF66 is highly insoluble and inefficiently 
immunoprecipitated from VZV-infected or transiently expressing cells (unpublished 
observations).  For this reason, high level purification of ORF66 for the establishment of an in 
vitro kinase assay has not been possible, and thus the specific consensus motif phosphorylated by 
ORF66 has not been determined.  Related US3 kinases preferentially target highly basic 
consensus motifs and phosphorylate S/T residues downstream of these (47, 116, 145, 206, 207).  
The preferred phosphorylation motifs for HSV-1 and -2 are shown in Figure 1-5. 
 
Figure 1-5 Known US3 phosphorylation motifs 
Phosphorylation motifs for HSV-1 and HSV-1 are shown on single letter amino acid code, with 
the phosphorylated residue underlined. 
 
Recent reports have provided evidence that ORF66 transcripts and possibly proteins are 
expressed in latently infected human ganglia (44, 45).  While ORF66 is not required for the 
establishment of latency (218), its expression during latent infection may imply a role in the 
regulation of the neuronal environment or other latency-associated VZV antigens to contribute to 
the maintenance or persistence of latent viral genomes. 
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1.5 VIRAL AND CELLULAR TARGETS FOR ORF66        
While the literature regarding specific functions of the ORF66 protein kinase is somewhat 
limited, US3 orthologs have been studied quite extensively.  This group of kinases is highly 
multi-functional and well known to modulate the cellular environment to promote various 
aspects of infection.  In the sections below, I outline well-characterized US3 kinase functions, 
and describe the proteins and pathways that are known to be affected by ORF66.     
1.5.1 US3 kinases affect diverse aspects of the host environment 
US3 kinases have been primarily implicated in regulation of the cellular environment during 
infection.  Several viral protein targets are known, but the role of these phosphorylations in the 
context of infection have not been clearly defined, and thus are not included here.   
i) Regulation of apoptosis. US3 kinases from HSV-1 and PrV are involved in preventing 
apoptosis induced by exogenous stimuli, pro-apoptotic cellular proteins, and infection with 
mutant viruses (53, 71, 74, 112, 149, 188).  Studies with HSV-1 US3 indicate that this may occur 
through activation of the cellular PKA pathway (19), and may be partially dependent on 
inhibitory phosphorylation of the cellular pro-apoptotic protein BAD (18, 32).  In PrV, inhibition 
of apoptosis has been shown to be dependent on US3 kinase activity, as a point-mutated inactive 
version expressed in the context of infection failed to protect cells from apoptosis or induce BAD 
phosphorylation (53).  Very recent studies in VZV-infected T lymphocytes demonstrate that the 
ORF66 protein kinase prevents activation of caspases in VZV-infected T-cells in a kinase 
activity dependent manner (219, 220).   
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ii) Regulation of capsid egress from the nucleus.  US3 null viruses from HSV-1, PrV, and 
an avian alphaherpesvirus, Marek’s Disease Virus (MDV), accumulate enveloped virions in the 
peri-nuclear space (between the inner and outer nuclear membranes), implying a role in efficient 
capsid egress (131, 212, 215, 221, 241).  Peri-nuclear virions were not evenly distributed in these 
mutants, and rather accrued in clusters.  Recent studies suggest that US3 proteins mediate 
phosphorylation of cellular proteins of the nuclear lamina, including lamins and emerin, and that 
these phosphorylations induce subtle changes in protein localization at the nuclear membrane 
(144, 181) (178).  Such changes may assist in capsid nuclear egress by uncoupling interactions 
between the nuclear lamina, the actin cytoskeleton and chromosomes.  In one study comparing 
VZV expressing or lacking ORF66, fewer capsids were apparent in infected T-cell nuclei, but 
capsid clusters were not observed in the space between the inner and outer nuclear membranes 
(220).  No differences were observed between the two viruses in melanoma cells.   
iii) Regulation of cell-to -cell spread.  The PrV US3 kinase is sufficient to induce actin 
stress fiber breakdown in both transfected and PrV-infected cells (237).  Elegant experiments 
demonstrated that actin stress fiber breakdown was concomitant with the formation of actin and 
microtubule-containing projections in PrV-infected cells, and these contained viral particles that 
moved towards the projection tip (63).  In low-density cells, the ability of US3 to induce 
projections was important for cell-to-cell spread.  Similar effects on actin stress fiber formation 
have been described for MDV (221).  The cellular protein targeted by US3 kinases to induce this 
effect is currently unknown, and it is also not known whether VZV ORF66 can induce these 
effects.    
iv) Regulation of HDAC.  Serendipitously, Poon, et. al. made the discovery that HSV-1 
US3 expression could substitute for the histone deacetylase (HDAC) inhibitor, sodium butyrate, 
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to promote trans-gene expression in eukaryotic cells infected with baculoviruses (201).  This 
suggests that this US3 kinase is involved in the negative regulation of HDACs, and it was 
hypothesized that this may be for the purpose of promoting viral gene expression in HSV-1 
infected cells.  It was subsequently determined that HDAC1 and 2 are differentially post-
translationally modified and possibly translocated to the cytoplasm in a US3-dependent fashion 
(84, 201).  It is not currently known whether ORF66 has the capacity to affect HDACs, either 
alone of in the context of VZV infection. 
v) Regulation of the cellular response to viral infection.  The deletion of US3 in the 
context of HSV-1 infection resulted in increased sensitivity to type I interferon (198).  ORF66 
was reported to have the ability to attenuate cellular signaling in VZV-infected T cells treated 
with γ-interferon, in that the levels of phosphorylated Stat1 were reduced (220).      
vi) Known ORF66 targets are unique compared to other US3 kinases.  At the outset of 
this project, it was unknown whether ORF66 affected any of these processes. However, two 
unique roles had been identified for the ORF66 kinase, including: 1) nuclear exclusion of the 
VZV principle transcriptional transactivator, IE62, in late-stage VZV infection (127); and 2) the 
possible downregulation of class I major histocompatibility complex (MHC-I) surface expression 
(2). 
1.5.2 A viral target for ORF66: VZV IE62 
Studies in our lab have identified the only known viral protein target affected by the ORF66 
protein kinase: the principle transcriptional regulator and major tegument protein, IE62 (124).  
IE62 is completely nuclear during early VZV infection, but becomes predominantly cytoplasmic 
in late-stage infected cells as a result of the expression of ORF66.  In transiently expressing cells, 
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ORF66 co-expression is sufficient to mediate IE62 nuclear exclusion, establishing that additional 
VZV gene expression is not required for this ORF66 function.   
IE62 is a 1310 amino acid, heavily phosphorylated protein in VZV-infected cells, which 
is resolved at ~175 kDa by SDS-PAGE analysis.  The IE62 gene is encoded in duplicate in the 
VZV genome at ORFs 62 and 71, residing in the US region internal and terminal repeats.  Based 
on sequence similarity with ICP4 and IE62 truncation mapping studies, five distinct functional 
domains have been assigned within the IE62 primary sequence (15, 162).  A scheme of these 
regions and a summary of domains involved in transactivation activities are summarized in 
Figure 1-6.  Significant homology with HSV-1 ICP4 is observed in region 2, the DNA-binding 
and dimerization domain (DBDD); and the C-terminal region 4, for which no specific function 
has been determined.  Lesser homology is observed in regions 1, 3 and 5.  Region 1 contains a 
potent N-terminal activation domain (aa 1-86), and a poly-serine/acidic tract (pSAT; aa 353-
371).  The function of the pSAT is not known, but is likely a major substrate for phosphorylation 
by the cellular casein kinase II (CKII) or the VZV ORF47 kinase (58, 119, 120, 186).  Region 3 
contains the IE62 nuclear localization signal (NLS), which is of the classic type and is 
arginine/lysine (R/K)-rich (677RLRTPRKRK685) (129).  Interestingly, region 5 contains a unique 
repeat of the N-terminal pSAT, which is not encoded by ICP4, and which may represent an 
additional CKII or ORF47 phosphorylation site (aa 1285-1295).  A segment at the joint of 
regions 4-5 may be involved in both transactivation and repression activities (15), but no other 
function has been assigned to regions 4 or 5. 
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Figure 1-6 IE62 functional and protein interaction domains 
A. IE62 homology with ICP4: dark gray regions are representative of low homology, while light 
gray regions have high homology.  Regions involved in binding specific viral or cellular proteins 
are indicated above and below, respectively.  B. Known IE62 functions and the regions to which 
they map are represented by the black boxes.  IE62 functions are indicated to the right.  C. Poly-
serine/Acidic tract (pSAT) amino acid sequences in single letter code, with the position within 
the IE62 annotated.  All components of the drawing are to scale.   
 
At the primary amino acid level, IE62 exhibits homology with the HSV-1 ICP4 
transcriptional regulator, and the IE62 gene can complement HSV-1 expressing ICP4 mutants or 
replace ICP4 in the HSV-1 genome (54, 64).  Since HSV-1 carrying IE62 in place of ICP4 
exhibits reduced replication relative to wild-type HSV-1, the mechanism of ICP4 and IE62 
transactivation may involve slightly different processes.  IE62 transactivates expression from all 
putative classes of VZV promoters (15, 40, 195), positively and negatively influences its own 
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promoter activity (55, 196), and substantially enhances the infectivity of VZV DNA (177).  The 
specific mechanism whereby IE62 transcriptional regulation occurs is not known, but is likely 
similar to that of ICP4, involving recruitment and stabilization of components of the general 
transcription machinery on viral promoters (31, 253).  IE62 is phosphorylated by viral and 
cellular protein kinases (124, 125), is an abundant tegument protein (125), and has multiple 
experimentally mapped protein:protein interactions with both viral and cellular factors 
(summarized in Figure 1-6A) (22, 37, 157, 194, 209, 225).  IE62 is also an abundant VZV 
tegument protein (125).  Studies performed in our lab have clearly demonstrated that the 
expression of the VZV ORF66 protein kinase was responsible for most of the IE62 tegument 
association (123), and this occurred due to aberrant retention of IE62 in the nucleus in the 
absence of ORF66 expression.  Thus, through regulation of IE62 cellular distribution, the ORF66 
kinase mediates a critical switch in IE62 function, from a transcriptional regulator in the nucleus 
in early infection to a virion structural protein in the cytoplasm during late infection.   
Interestingly, IE62 transcripts have been detected by multiple groups in latently-infected 
human ganglia (118, 170), and some evidence suggests that IE62 proteins are also expressed 
with aberrant localization to the cytoplasm (156).  The authors of the latter study suggested that 
IE62 nuclear exclusion in neurons may contribute to the maintenance of VZV latency, given that 
IE62 has powerful transactivation activities and the VZV genome persists in the nucleus.  Recent 
evidence suggests that ORF66 protein is also expressed in latently infected neurons (44, 45).  
Thus, ORF66 may contribute to the maintenance of VZV latency by inducing IE62 nuclear 
exclusion and compartmental separation of the VZV genome and this powerful transcriptional 
activator.  The mechanisms underlying ORF66-mediated IE62 nuclear exclusion have not been 
defined in detail. 
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1.5.3 Overview of the classical nuclear import and export pathways  
The double membrane of the nuclear envelope (NE) provides a basic structural barrier between 
the nucleus and the cytoplasm, and restricts the nucleocytoplasmic exchange of macromolecules 
by means of the nuclear pore complex (NPC).  Molecules <40 kDa can freely diffuse across the 
NPC, while larger molecules (>40 kDa) must be recognized and actively transported by soluble 
receptors of the karyopherin family (i.e., importins and exportins). 
Classical nuclear import, the pathway likely used by the VZV IE62 protein to enter the 
nucleus, is mediated by the importin α (IMPα) adaptor, which recognizes a basic R/K-rich NLS 
in a cargo protein and is, in turn, recognized by the importin β1 (IMPβ1) transport receptor 
(Figure 1-7A) (reviewed in (143, 180, 193)) .  IMPβ1 interacts transiently with the F/G repeats of 
nucleoporins that line the NPC to facilitate movement of the ternary complex into the nucleus.  
Once in the nucleus, the activated form of Ran (RanGTP) binds IMPβ1 to dissociate and release 
IMPα and the cargo protein.  Additional factors mediate the final release of cargo, and IMPα is 
recycled back into the cytoplasm by the specific exportin receptor, CAS, via the RanGTP-
regulated nuclear export pathway.  Human cells express 9 IMPβ proteins in addition to IMPβ1, 
and these recognize their cargoes without the assistance of the IMPα adaptor (143). 
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Figure 1-7 Nucleocytoplasmic transport 
Overview of classical nuclear import (A) and nuclear export (B).  All components are labeled, 
and brief descriptions of each step in import (red) and export (blue) are shown.   
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In humans, 7 karyopherin receptors are known to deliver cargoes into the cytoplasm, but 
only 5 of these have been shown to carry proteins: Crm1, exportin 4, exportin 6, exportin 7, and 
CAS (140, 193).  Of these, only the Crm1 nuclear export receptor recognizes an identifiable 
motif in cargo proteins, characterized by an abundance of leucine or other bulky hydrophobic 
residues: φ-x2-3-φ-x2-3-φ-x-φ; φ=[L,I,V,F,M], where x=any amino acid (140).  Nuclear export 
occurs after cargo is recognized in the nucleus by exportin (Figure 1-7B).  Following association 
with RanGTP, the entire complex moves across the NPC in a manner similar to the 
IMPα/β1/cargo complex.  The Ran GTPase activating protein (RanGAP) is tethered to 
nucleoporins on the cytoplasmic face of the NPC, and RanGTP hydrolysis to GDP facilitates the 
release of the cargo and the exportin protein into the cytoplasm.  RanGDP is recycled back into 
the nucleus via the specific NTF2 receptor, and once inside the nucleus, the GDP is exchanged 
for GTP by the Ran guanylnucleotide exchange factor, RCC1, to facilitate another round of 
nuclear import or export.  Interestingly, recent reports have also indicated that many nuclear 
hormone receptors are exported from the nucleus by calreticulin in a Ca2+-dependent manner, via 
export motifs localized in the DNA-binding domains (25, 98, 99).      
One of the most common mechanisms for the regulation of nuclear trafficking is through 
intra- or intermolecular masking of the NLS or NES.  Intramolecular masking may occur if the 
NLS/NES is not accessible due to the addition of a charge (e.g., phosphorylation) or a change in 
the conformation of the protein.  Intermolecular masking occurs through the binding of a 
heterologous protein to prevent the recognition of the NLS/NES by its specific receptor.  Many 
examples of both NLSs and NESs that are regulated by these mechanisms exist, and are 
thoroughly reviewed in (203). 
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1.5.4 A cellular target for ORF66: MHC-I 
A screen of a plasmid library of VZV regulatory proteins for affects on MHC-I surface 
expression revealed that cells expressing the ORF66 protein kinase had reduced levels of surface 
MHC-I compared to vector-transfected negative controls and cells transfected with plasmids 
expressing six other VZV regulatory proteins (2).  A similar function has not been described for 
any other US3 kinase, thus implying a highly novel ORF66 interaction with the cellular 
environment, and a possible new mechanism for herpesvirus mediated immune evasion.    
                                          
Figure 1-8 MHC-I Structure 
MHC-I expressed at the cell surface consists of a heavy chain with a single transmembrane 
domain and three luminal domains referred to as α1, α2, α3 (blue); the non-covalently associated 
β2-microglobulin (yellow); and a proteasome-derived peptide (pink).  In transit to the surface, 
MHC-I is core glycosylated at a highly conserved residue  in the α1 region of the heavy chain. 
   
MHC-I is an integral molecule of the adaptive immune system, which signals 
intracellular infection to CD8+ T lymphocytes.  MHC-I expressed at the cell surface is a 
heterotrimeric complex, consisting of a 44 kDa type I membrane protein referred to as class I 
heavy chain (HC), a 12 kDa non-covalently associated protein known as β2-microglobulin 
(β2M), and an 8-11mer intracellularly-derived peptide (Figure 1-8A).  The MHC-I HC consists 
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of three highly variable globular luminal regions (α1, α2, and α3), a transmembrane domain, and 
a short cytoplasmic tail.  The peptide-binding cleft is formed by the α1 and α2 regions, and the 
α3 region is membrane-proximal and exhibits structure similar to the immunoglobulin (Ig) 
constant domain (216).  MHC-I protein bearing a foreign peptide, expressed at the cell surface, is 
recognized by CTL bearing a cognate T cell receptor (TCR).  The consequence of TCR:MHC-I 
ligation is induction of TCR signaling pathways and subsequent activation of an antiviral 
response,  which may include production of γ-interferon and/or the release of exocytic granules 
designed to instigate infected cell lysis.  Because this is detrimental to viral replication, and 
ultimately to the establishment and persistence of latent viral genomes, herpesviruses have 
evolved an impressive repertoire of mechanisms directed at inhibition of MHC-I surface 
expression and the resultant evasion of CTL-mediated adaptive immunity. 
1.5.5 MHC-I antigen presentation   
Class I HCs are co-translationally inserted into the membrane of the ER via the Sec61p 
translocon (189), and are core-glycosylated at a single highly conserved asparagine residue (N86) 
in the α1 domain (Figure 1-9) (257).  HC molecules associate with the ER-resident chaperones, 
immunoglobulin binding protein (BiP) and calnexin, which assist with folding since HCs are not 
stable in the absence of β2M and peptide (257).  Subsequently, calnexin dissociation occurs, 
followed by association with β2M in the presence of calreticulin and the protein disulfide 
isomerase Erp57 (132).  Erp57 mediates the formation of disulfide bridges, which stabilize the 
maturing HC molecule.  β2M, which also displays an Ig-like fold, makes several contacts with 
the HC α3 region.   
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Peptides for loading onto the MHC-I binding groove are continuously generated by the 
multi-catalytic protease complex, the proteasome, from substrate proteins that have been tagged 
with poly-ubiquitin, and are transported into the ER by the transporter associated with antigen 
processing (TAP).  Substrates are primarily derived from unwanted proteins and defective 
ribosomal products (DRiPs) (146) and can be of either nuclear or cytoplasmic origin.  The TAP 
is an ER-resident, heterodimeric ATP-binding cassette (ABC) transporter, consisting of one 
molecule each of TAP1 and TAP2 (1).  The TAP1 and TAP2 proteins have 10 and 9 
transmembrane domains, respectively, which associate to form a pore in the ER membrane.  
Proteasomeally-derived peptides are processed by cytosolic peptidases, and 8-12mer peptides are 
selectively transported into the ER lumen by the TAP in a manner dependent on ATP-binding 
and hydrolysis mediated by the cytosolic nucleotide binding domains.   
 To form the peptide loading complex (PLC), the MHC-I specific chaperone, tapasin, 
binds the TAP and recruits the HC- β2M-Erp57-calreticulin complex.  Tapasin is necessary for 
the proper function of the PLC, and performs multiple roles including bridging TAP to MHC-I, 
stabilizing TAP, coordinating peptide transfer to the MHC-I binding groove, and selection of 
high-affinity peptides for MHC-I (132).  Following peptide binding, MHC-I is released from the 
PLC and is transported to the cell surface where it is surveyed by CTL for the presence of 
foreign peptides.   
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Figure 1-9 MHC-I antigen presentation 
Overview of the MHC-I antigen presentation pathway.  All proteins and cellular domains, as 
well as a brief numbered description of each step in the pathway, are summarized in the body of 
the image.   
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1.5.6 Herpesvirus subversion of MHC-I antigen presentation 
Since there was no precedence for MHC-I downregulation mediated by a viral protein kinase, I 
looked to the extensive body of literature regarding herpesvirus subversion of MHC-I surface 
expression as a starting point for understanding the mechanism of ORF66’s effect on this 
pathway.  Herpesviruses target MHC-I by a variety of mechanisms, and these can be grouped 
according to the strategy used to disrupt MHC-I biosynthesis.  These are described below, and 
are summarized in Figure 1-10.  As there is an abundance of review articles dedicated to the 
various mechanisms of herpesvirus-mediated immune evasion, these were used to reference 
specific interactions, when possible, to save bibliographic space.   
i)  Host protein synthesis shutoff:  In alphaherpesviruses, a non-specific RNase (UL41 or 
virion host shutoff, vhs) mediates cleavage of host mRNA and induces a global reduction in host 
protein synthesis.  vhs activity contributes to downregulation of MHC-I surface expression in 
several viruses (76, 82, 135), and has been shown to diminish recognition of infected cells by 
virus-specific CTL (97).  The VZV ortholog to vhs, the ORF17 gene, can induce mRNA 
degradation (217), but its role in the reduction of host protein synthesis is currently unknown.     
ii) Peptide loading complex inhibition:  HC-β2M heterodimers lacking peptide are not 
stable, and are not released from the ER for transport to the cell surface.  Thus, peptide 
translocation by the TAP complex represents a rate-limiting step in the efficiency of MHC-I 
maturation, and not surprisingly, TAP function is targeted by representatives of the alpha-, beta- 
and gammaherpesvirus sub-families (reviewed in (95, 175, 210)).  In cells infected with the 
human alphaherpesviruses HSV-1 and HSV-2, the 10 kDa soluble immediate early protein, 
ICP47, binds to the cytosolic domain of TAP with high affinity to competitively inhibit the 
binding of proteasomeally-derived peptides.  Additionally, ICP47 prevents ATP hydrolysis and 
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conformational changes in TAP that are required for peptide transport.  Other alphaherpesviruses 
of agricultural importance (BHV-1, EHV-1 and PrV) have also been shown to inhibit the TAP 
complex (5-7, 136).  For these viruses, the 9 kDa UL49.5 ER-localized type I membrane 
glycoprotein has been implicated, which operates by arresting TAP in a functionally incompetent 
conformation and promoting TAP degradation by the proteasome (134).  In the betaherpesvirus 
HCMV, the 21 kDa ER-resident membrane protein, US6, binds to TAP in the ER lumen by 
means of its own luminal domain and indirectly and specifically interferes with ATP binding on 
the TAP cytosolic tail, but does not inhibit peptide binding.  Human gammaherpesviruses have 
also been shown to inhibit TAP-mediated peptide transport (211).  The HCMV US3 ER-resident 
glycoprotein (unrelated to the alphaherpesvirus US3 kinase) utilizes a slightly different approach 
to impede peptide loading.  It specifically targets tapasin, which is required to bridge TAP and 
MHC-I, resulting in inhibition of high affinity peptide loading and MHC-I retention in the ER 
(191).   
iii) HC degradation.  In lymphotrophic beta- and gammaherpesvirus infections, viral 
proteins mediate active degradation of MHC-I HCs.  HCMV encodes two proteins, US2 and 
US11, sharing 20% sequence identity at the amino acid level, which hijack the ER-associated 
protein degradation pathway (ERAD) to induce retro-translocation of ER-localized immature 
HCs, lacking β2M, through the Sec61p translocon (153).  Retro-translocation results in HC 
deglycosylation, poly-ubiquitination and degradation by the proteasome.  This process requires 
the presence of the HC cytoplasmic tail, which may be used to pull HC molecules into the 
cytoplasm.  In KSHV two proteins, kK3 and kK5, also related by sequence homology (~40%), 
target MHC-I molecules for degradation.  kK3 and kK5 are PHD/LAP zinc finger domain-
containing E3 ubiquitin ligases that attack mature, peptide-bearing MHC-I expressed at the cell 
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surface, promoting ubiquitination of HC cytoplasmic tails (reviewed in (147).  Ubiquitination 
results in clathrin-mediated endocytosis of MHC-I and subsequent sorting into the acidic late 
endosomal/lysosomal compartment, where degradation is mediated by acidic proteases.  The 
related mK3 protein of murine gammaherpesvirus 68 is also an ubiquitin ligase, but mediates 
ER-associated HC ubiquitination and disposal via the the proteasome.  Interestingly, mK3 also 
promotes degradation of the TAP (147).   
iv) Aberrant MHC-I trafficking.  In HHV-6 and -7 infections, the 60 kDa U21 membrane 
protein binds properly folded MHC-I molecules and diverts them directly from the Golgi 
complex for sequestration in a peri-nuclear endo/lysosomal compartment (95).  Murine 
cytomegalovirus, another betaherpesvirus, encodes three viral chaperones (m152/gp40, 
m06/gp48, and m04/gp34) that negatively influence MHC-I surface presentation (94).  The 
m06/gp48 protein functions similar to U21, in that it binds mature class I molecules and diverts 
them to a lysosomal compartment.  The m152/gp40 proteins retains class I molecules in the ER-
cis-Golgi intermediate compartment (ERGIC).  The m04/gp34 protein utilizes a unique 
mechanism, binding MHC-I in the ER and escorting it to the cell surface where it cannot be 
sufficiently recognized by CTL.  The HCMV US10 gene encodes a glycoprotein that binds 
MHC-I and impairs its transport through the endoplasmic reticulum (95).  Finally, the HCMV 
soluble pp71 tegument protein mediates MHC-I downregulation by promoting its retention in 
infected cells, and is critical for downregulation immediately upon infection (233). 
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Figure 1-10 Herpesvirus subversion of MHC-I antigen presentation 
Overview of herpesvirus effects on MHC-I biogenesis and surface presentation.  All viral and 
cellular components are labeled in the document, and viral proteins are represented by striped 
objects.  Generalized mechanisms of subversion are indicated in red. 
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1.5.7 MHC-I subversion in VZV-infected cells 
VZV does not encode an HSV-1 ICP47 ortholog, and yet maintained the ability to induce MHC-I 
downregulation in HFF, MRC-5 fibroblasts and melanoma cells in culture, as well as T 
lymphocytes in vivo and in culture (2).  In HFF, folded MHC-I accumulated in the Golgi 
apparatus.  This mechanism of subversion of MHC-I surface expression has not been observed 
for any other human herpesvirus studied to date.  VZV-infected cells incubated with an inhibitor 
of late gene synthesis revealed that either an immediate early or early protein was involved.  As 
described above, the ORF66 kinase was implicated in this process, as HFF cells transiently 
expressing ORF66 exhibited reduced MHC-I surface levels.  It is currently unknown whether 
ORF66 is responsible for the observed Golgi accumulation, and the mechanism of ORF66 
mediated MHC-I downregulation is not known. 
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2.0  RATIONALE AND SPECIFIC AIMS 
2.1 OVERALL RATIONALE 
ORF66 is a critical mediator of VZV pathogenesis in vivo, but the molecular mechanisms of 
ORF66 function remain largely unresolved.  A firmly established role for ORF66 in VZV-
infected cells is the nuclear exclusion of the VZV IE62 protein.  IE62 is an essential viral gene 
that regulates many aspects of the VZV transcriptional program, and is also a major virion 
tegument component.  In the absence of ORF66 expression IE62 aberrantly accumulates in the 
nucleus and fails to incorporate into the tegument, thus providing a functional link between 
ORF66-induced nuclear exclusion and an IE62 cytoplasmic structural role during late-stage 
infection.  A similar relationship has not been described for US3 kinase proteins of other 
alphaherpesviruses.  One additional function for ORF66 in VZV infection is suggested by the 
report that ORF66 can induce a reduction in MHC-I surface expression in the absence of 
additional VZV gene expression.  MHC-I is a cellular protein involved in the activation of 
adaptive immunity in response to intracellular infection.  As this function has not been attributed 
to any US3 kinase, or any other viral protein kinase, it may represent a highly novel mechanism 
of immune evasion.   In this work, my original aims were targeted at understanding the specific 
mechanisms underlying the ORF66 roles in IE62 nuclear exclusion and MHC-I surface 
downregulation.  However, new observations and hypotheses derived from these were extended 
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into a third and a fourth aim that addressed aspects of IE62 and ORF66 cellular trafficking.  
These are described in brief below and are further delineated in Chapters 3-6. 
2.2 SPECIFIC AIM 1 
Development of an ORF66 in vitro kinase assay to establish whether the IE62 protein is a 
direct phosphorylation target, and to delineate any IE62 residues phosphorylated by 
ORF66 to mediate nuclear exclusion. 
While there are several possible explanations for the functional significance of ORF66-
mediated IE62 nuclear exclusion in VZV-infected cells, the molecular mechanisms that govern 
this process have only been partially elucidated.  Point mutations in the predicted ORF66 ATP-
binding lysine (K122) or two critical catalytic loop residues (D206 and K208), which putatively 
render ORF66 catalytically inactive, abolished the ability of ORF66 to mediate IE62 nuclear 
exclusion, suggesting this function is dependent on ORF66 kinase activity (124).  In addition, 
orthophosphate labeling analyses of truncated IE62 peptides in ORF66-co-transfected or VZV-
super-infected cells narrowed the region of IE62 affected by ORF66 to amino acids 602-730.  
Within this region, only two possible sequences exhibit similarity to the consensus derived for 
other US3 kinases (see Figure 1-5), with multiple basic amino acid residues preceding a S/T 
residue:  1) the IE62 NLS (RLRTPRKRKS686); and 2) a motif just downstream of the IE62 NLS 
(KAKRRVS722).  From this, I hypothesize that a direct ORF66-mediated phosphorylation of 
IE62 in the region containing its NLS leads to its inability to undergo nuclear import, thus 
inducing IE62 cytoplasmic accumulation during late-stage VZV infection. 
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To identify any ORF66-mediated specific IE62 phosphorylation events, it was essential 
to develop an ORF66 in vitro kinase assay and establish that ORF66 is catalytically active.  As 
previously mentioned, the ORF66 protein is highly insoluble and could not be expressed and 
immunoprecipitated to sufficient levels in transfected cells to allow for use in an in vitro assay.  
Thus, I chose to express hemagglutinin (HA) epitope-tagged ORF66 from a baculovirus vector in 
insect cells.  While ORF66 remained ≥95% insoluble in this system, the tremendous level of 
ORF66 overexpression allowed for immunopurification of significant levels of ORF66 using an 
antibody to the HA epitope tag (data not shown).  I then used intrinsic ORF66 
autophosphorylation to define the optimal conditions for kinase activity.  For the identification of 
IE62 residues phosphorylated by ORF66, I also developed multiple IE62 peptide substrates fused 
to maltose binding protein (MBP) and affinity purified these substrates, after expression in 
bacteria, for use in the in vitro kinase assay.  These results are presented in their entirety in 
Chapter 3.   
2.3 SPECIFIC AIM 2 
Determine whether IE62 is a nuclear shuttling protein, and if so, map regions involved in 
nuclear export. 
In the preceding study, we clearly established that ORF66 mediates IE62 phosphorylation 
at two serine residues (S686 and S722), with phosphorylation at S686 being sufficient for IE62 
nuclear exclusion.  Based on its similarity with other US3 kinases, it is generally assumed that 
ORF66 is expressed with early kinetics, after the expression and nuclear import of the IE62 
protein at immediate early times post-infection.  Thus, ORF66 phosphorylation may not be 
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sufficient for the efficient IE62 nuclear clearance observed in many late-stage VZV-infected 
cells.  From these observations, I hypothesize that efficient IE62 nuclear exclusion is dependent 
on a combination of direct ORF66 phosphorylation and intrinsic IE62 nuclear export activities. 
Initially, I used recombinant VZV expressing enhanced green fluorescent protein tagged 
ORF66 (discussed in more detail in Aim 3) in a cell-free infection/immunofluorescence-based 
assay to investigate the IE62/ORF66 spatio-temporal expression relationship, identify potential 
cellular sites of interaction, and obtain information regarding the timing of IE62 cytoplasmic 
accumulation and nuclear exclusion.  To determine the ability of IE62 to undergo nuclear export, 
I developed an interspecies heterokaryon assay with an intrinsic control for the assessment of the 
nuclear membrane integrity.  I used an existing panel of IE62 truncation mutants and developed 
several additional mutations within the IE62 sequence, and tested these in the heterokaryon assay 
to delineate specific structural determinants involved in IE62 nuclear export.  These results are 
presented in their entirety in Chapter 4. 
2.4 SPECIFIC AIM 3 
Characterize the role of the ORF66 kinase in MHC-I downregulation during VZV 
infection. 
VZV mechanisms of MHC-I downregulation must differ from that of HSV-1, since VZV does 
not encode an ortholog to the HSV-1 ICP47 TAP inhibitor.  A previous study of the effects of 
VZV on MHC-I surface expression identified a possible role for ORF66 in this process in 
transiently expressing cells lacking any additional VZV gene expression (2).  I confirmed this 
using a transient co-transfection assay in which an EGFP reporter gene was used to identify 
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expressing cells (data not shown). While no other US3 kinase has been shown to mediate this 
effect, US3 kinases are well-established modulators of the host-cell environment.  From this, I 
hypothesized that ORF66 may have a unique role in the regulation of MHC-I surface expression 
during VZV infection. 
A variety of novel reagents and methods were developed for this Aim.  Specifically, we 
generated recombinant VZV expressing EGFP-tagged ORF66 under the control of the native 
ORF66 promoter, or a truncated version lacking the C-terminal catalytic domain; and replication 
defective adenovirus vectors expressing EGFP-66 or a point-inactivated version that lacks 
specific kinase activity.  VZV expressing EGFP-tagged ORF66 kinase proteins provided a 
superior method for determining the percentage of infected cells, and enabled me to establish the 
required multiplicity of cell-associated VZV to achieve similar end-points for viruses either 
expressing or lacking the ORF66 catalytic domain.  I chose to use replication defective 
adenoviruses because they efficiently infect VZV-permissive MRC-5 cells, which are a non-
transformed diploid cell line and are likely more representative of in vivo infection with respect 
to the melanoma cells used in many other studies.  I used these novel reagents to comparatively 
assess the effects of ORF66 kinase proteins on MHC-I surface expression, biosynthetic 
trafficking in the early secretory compartment, and general cellular distribution.  These results 
are presented in their entirety in Chapter 5.   
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2.5 SPECIFIC AIM 4 
Utilize VZV expressing EGFP-tagged ORF66 kinase proteins to investigate novel ORF66 
nuclear trafficking as a function of kinase activity and time. 
Studies with VZV expressing EGFP-tagged ORF66 kinase proteins revealed highly novel 
ORF66 distributions in the nucleus, including the appearance of nucleoplasmic and putative 
nucleolar speckles during late-stage VZV infection.  A similar distribution pattern has not been 
observed for prototypical US3 kinases expressed by HSV-1 and PrV, and I considered that this 
distribution may be reflective of a novel ORF66 process in VZV infected cells.  Furthermore, I 
hypothesize that a better understanding of ORF66 spatio-temporal trafficking will facilitate 
identification of novel ORF66 functions in VZV-infected cells. 
I used fixed and live-cell microscopy assays to study ORF66 trafficking in VZV-infected 
cells as a function of time and kinase activity.  Co-localization analyses were performed with 
antibodies against major cellular nuclear bodies that are known to associate with the nucleolus, 
as well as VZV proteins that demarcate nuclear genome replication and capsid assembly 
compartments.  Additonally, live-cell time lapse microscopy was employed to provide a clearer 
understanding of the dynamic process of ORF66 nuclear trafficking.  These results are presented 
in Chapter 6.      
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3.0  PHOSPHORYLATION OF THE VARICELLA ZOSTER VIRUS (VZV) MAJOR 
TRANSCRIPTIONAL REGULATORY PROTEIN IE62 BY THE VZV ENCODED OPEN 
READING FRAME 66 PROTEIN KINASE 
Amie J. Eisfeld2,3, Stephanie E. Turse1, Sara Jackson4, Edwina C. Lerner2 and Paul R. 
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Note: For this study, I developed the ORF66 in vitro kinase assay.  This included 
derivation of baculovirus constructs for expression of the ORF66 and the IE62/MBP peptide 
substrates, and determination of optimal conditions for ORF66 in vitro kinase activity.  In 
addition, I performed all the experiments requested by the reviewers of Journal of Virology.  
Thus, my contributions are represented in Figs. 1-3, 1-5, 1-8, and 1-9.  All of the writing was 
done by me.  
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3.1 ABSTRACT  
IE62, the major transcriptional regulatory protein encoded by varicella zoster virus (VZV), is 
nuclear at early times of VZV infection, but then becomes predominantly cytoplasmic as a result 
of expression of the protein kinase encoded by open reading frame (ORF) 66.  Cytoplasmic 
forms of IE62 are required for its inclusion as an abundant VZV virion tegument protein. In this 
work, we show that ORF66 directly phosphorylates IE62 at two residues, with phosphorylation 
at S686 being sufficient to regulate IE62 nuclear import.  Phosphotryptic peptide analyses 
established an ORF66 kinase mediated phosphorylation of complete IE62 protein in transfected 
and VZV infected cells.  Using truncated and point-mutated IE62 peptides, ORF66 directed 
phosphorylation was mapped to residues S686 and S722, immediately downstream of the IE62 
nuclear localization signal.  IE62 protein carrying an S686A mutation retained efficient nuclear 
import, even in the presence of functional ORF66 protein kinase, but IE62 protein containing 
S686D alterations imported to the nucleus inefficiently.  In contrast, nuclear import of IE62 
carrying S722A was still modulated by ORF66 expression, and IE62 with S722D mutation 
imported efficiently to the nucleus.  An in vitro phosphorylation assay was developed using 
bacterially expressed IE62-maltose binding protein fusions as substrates for immunopurified 
ORF66 protein kinase from recombinant baculovirus infected insect cells. ORF66 kinase 
phosphorylated the IE62 peptides with similar specificity for residues S686 and S722.  These 
results indicate that IE62 nuclear import is modulated as a result of direct phosphorylation of 
IE62 by ORF66 kinase.  This represents an interaction that is so far unique among the 
alphaherpesviruses. 
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3.2 INTRODUCTION 
Varicella zoster virus (VZV) is the human herpesvirus that causes chickenpox upon primary 
infection and herpes zoster following reactivation from a latent state.   These diseases are 
separated by a prolonged period of neuronal latency in which no clinical disease is apparent, but 
a few select viral genes are expressed (83, 118).    In a VZV lytic infection, approximately 70 
VZV proteins are expressed in a temporally regulated manner (214), most likely in a typical 
α−β−γ cascade which is transcriptionally regulated in a manner similar to that seen in herpes 
simplex virus type 1 (HSV-1) infected cells (100, 101).    Several VZV proteins have been 
implicated to regulate VZV gene expression, based on studies demonstrating their influence on 
viral promoter-reporter activities in transfection assays.  These include the proteins encoded by 
open reading frames (ORFs) 4, 61, 62, 63, 10 and 29 (127).    
Of these, the principal transcriptional transactivator of VZV transcription is IE62, 
encoded by VZV ORF62.  This 1310 amino acid, heavily phosphorylated protein (124, 125) is 
expressed with immediate early kinetics (67, 124), stimulates transcription from VZV promoters 
in transfection assays and enhances the infectivity of VZV DNA (15, 40, 177, 195).  It also 
positively and negatively regulates its own transcription, depending on cell type (55, 196).  
While the exact mechanisms underlying IE62-mediated transactivation of viral genes have not 
been well defined, they are likely similar to those of ICP4 of HSV-1, as IE62 can complement 
ICP4 HSV-1 mutants and functionally replace ICP4 in the HSV-1 genome (54, 64).   ICP4 has 
been shown to interact with and recruit specific components of the general transcription 
machinery to viral promoters and stabilize their formation for transcriptional initiation (31, 253).   
VZV IE62 has also  been shown to co-operate and interact with both cellular and viral proteins in 
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gene regulation, including USF (209) and SP-1 (194), and the viral regulatory proteins from 
ORFs 4 (225), 47 (22, 186) and 63 (157).     
The extensive phosphorylation of IE62 has led to several investigations of its possible 
interactions with cellular and viral encoded kinases.  IE62 is phosphorylated by cellular kinases 
in the absence of other viral proteins (124, 186).  It has two poly-serine tracts, one located 
internally and the other near the C terminus, which are strongly predicted to be sites for casein 
kinase II.  The internal serine tract is conserved in other alphaherpesvirus orthologues and in 
HSV-1 ICP4, it is a site for phosphorylation by casein kinase II, protein kinase A and protein 
kinase C (249, 250).   IE62 is also the target of the VZV ser/thr specific protein kinase encoded 
by ORF 47.  ORF47 directly phosphorylates IE62 in vitro, and targets sequences resembling 
those phosphorylated by casein kinase II (121, 186).  Whether ORF47 phosphorylates IE62 in 
vivo and what the consequences of ORF47 directed phosphorylation are on IE62 functions have 
yet to be defined.   While not essential (90),  the ORF47 kinase is a tegument protein that is 
required for efficient virion assembly (21, 22, 137) and efficient growth and viral pathogenesis in 
the SCID-hu mouse model (177).  IE62 is also a possible target for the ORF66 protein kinase, 
as ORF66 expression affects the cellular distribution of IE62.  In VZV infected cells, IE62 
expressed at early times of infection  enters the cell nucleus using a single classical 
arginine/lysine rich nuclear localization signal (NLS) mapping to amino acids 677-685 (129).   
However, at late stages of infection, IE62 accumulates predominantly in the cytoplasm (127, 
129).  This activity is mediated by ORF66 protein kinase, as IE62 remains nuclear in cells 
infected by recombinant VZV that do not express ORF66.  Furthermore, progeny virus from 
VZV infected cells not expressing ORF66 do not incorporate IE62 as an abundant virion protein 
(123). Thus, either IE62 cytoplasmic accumulation and/or its targeting by ORF66 are required 
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for virion inclusion of IE62 as an abundant tegument protein (123, 125).  Co-transfection studies 
indicate the ORF66 kinase is sufficient to induce the cytoplasmic accumulation of IE62 
independent of other VZV proteins (124, 129).   As VZV recombinants lacking ORF66 
expression demonstrate considerable impairment for growth in human T lymphocytes (174, 220, 
224), the ORF66 induced effects on IE62 cellular distribution and IE62 inclusion into the virion 
structure may be important in the pathogenesis of VZV.  Furthermore, a single report has 
suggested that ORF66 is expressed during VZV latency in human ganglia (45).  While not yet 
confirmed, this could mechanistically explain reports of a predominantly cytoplasmic 
distribution of IE62 found in latently infected neurons (83, 156).  The cytoplasmic accumulation 
of IE62 induced by ORF66 requires the integrity of the ORF66 kinase activity, suggesting that 
phosphorylation is a necessary step to affect IE62 cellular redistribution.  In agreement with this, 
small IE62 peptides responsive to ORF66 mediated cytoplasmic redistribution were found to be 
preferentially phosphorylated in cells co-expressing the ORF66 kinase (124).  
 It has not been determined whether IE62 phosphorylation occurs as a result of ORF66 
activation of cellular pathways, or if IE62 represents a direct target for the ORF66 protein kinase.  
In this work, we precisely map ORF66 mediated phosphorylation of IE62, show that ORF66 
directly phosphorylates the IE62 protein in vitro and demonstrate that one of the phosphorylation 
events leads to IE62 cytoplasmic accumulation.  Thus, IE62 represents a new viral target for the 
US3 kinase group. 
 48 
3.3 MATERIALS AND METHODS 
3.3.1 Cells and virus 
VZV was grown on the human melanoma cell line MeWo (obtained from C. Grose, University 
of Iowa) as detailed previously (123).  293T cells (ATCC) were maintained in DMEM 
supplemented with 5% FBS, 100 U penicillin, 100 µg/ml streptomycin and 0.25 µg/ml 
amphotericin B.  Cosmid-derived recombinant VZV ROka, ROka47S (not expressing ORF47) 
and ROka66S (not expressing ORF66) have been detailed previously (90, 91) and were a kind 
gift of J. I. Cohen (Laboratory of Clinical Investigation, NIH).   VZV stocks were prepared and 
stored as previously described (122, 125).  For transient expression studies, MeWo cells at 70% 
confluence were transfected using Lipofectamine with the PLUS reagent (InVitrogen Corp. 
Carlsbad, CA), as detailed previously (124).  293T cells were transfected at 50-70% confluence 
using either a modified calcium phosphate co-precipitation method, with 30 µg total plasmid 
DNA transfected in 1 ml total of HEPES buffered saline, divided between two 60 mm dishes 
containing 5 ml of media/dish.  Cells were exposed to the precipitate in media overnight, 
followed by media replacement.   In all comparative transfection studies, the total amount of the 
human cytomegalovirus major IE promoter used to drive gene expression was equalized by 
adding a corresponding amount of empty vector.   Baculoviruses were grown in SF9 cells 
(InVitrogen Corp.) at 28oC in Grace’s insect media supplemented with 5% FBS and antibiotics, 
as detailed by the supplier. 
 49 
3.3.2 Antibodies and immunological methods 
Polyclonal rabbit antibodies that recognize IE62 and the ORF66 protein kinase have been 
described previously (45, 123, 124).  Antibodies to the nine amino acid epitope YPYDVPDYA 
of  the influenza virus hemagglutinin (HA) protein were initially obtained from Santa Cruz 
Biotechnologies, Inc. (Santa Cruz, CA) or were later derived using a monoclonal antibody 
(48EC) developed against the synthetic peptide by the Hybridoma Core Facility of the University 
of Pittsburgh Department of Ophthalmology.  Immunofluorescence, immunoblotting and 
immunoprecipitations were carried out as detailed previously (124), except that bound antibodies 
in immunoblotting studies were detected using secondary goat anti-rabbit or goat anti-mouse 
antibodies coupled to horseradish peroxidase (ICN/Cappel, Aurora, OH), followed by detection 
with West Dura chemiluminescent substrate (Pierce, Inc., Rockford, IL).  Quantitation of protein 
band signal was achieved either by a Biorad GS525 phosphorimager, or by densitometry of 
autoradiographs exposed to be in the linear range of the film. 
3.3.3 Plasmids and DNAs for transfection 
The following constructs have been detailed previously (124, 129): pG310 expression vector, 
pGK2-HA expression vector, pKCMV62, pKCMV47, pGK2-HA47, pKCMV66, pGK2-HA66 
and pGK2-HA66-K122A.  Briefly, the pG310 or pGK2-HA vectors contain the complete HCMV 
IE promoter, followed by EcoRI and BamHI sites for gene insertion, and a polyadenylation 
signal derived from the HCMV IE1 gene.  pGK2-HA is similar to pG310 but additionally 
contains an initiating methionine, followed by the sequence encoding the HA epitope, followed 
by the same cloning sites.  Plasmid pKCMV66 and pKCMV66 K122A express wild-type ORF66 
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or a point inactivated kinase dead ORF66 altered at K122A, the residue suspected to be required 
for binding ATP, respectively; pGK2-HA66 and pGK2-HA66-K122A express the same proteins 
as N terminal HA tagged forms. Plasmid pGK2-HA47 expresses HA tagged ORF47 and 
pKCMV62 expresses untagged, full-length IE62 protein.    
The following new IE62 peptide-expressing constructs were developed using PCR 
amplification with the proof-reading polymerase Expand (Roche Biochemicals, Inc.): pGK2-
HA846, pGK2-HA825, pGK2-HA819, pGK2-HA821, pGK2-HA823, pGK2-HA810, pGK2-
HA828, and pGK2-HA811.  pGK2-HA846 was generated by EcoRI linker addition (New 
England Biolabs, Inc., Beverly, MA) to an EcoRV-BstXI DNA fragment of IE62 (122,010 to 
123,232, residues 414 to 823 of IE62 with respect to the Dumas VZV sequence), followed by 
digestion with EcoRI and BamHI (BamHI site is at 122,962, residue 735 of IE62).  Cloning this 
fragment into the pGK2-HA vector resulted in expression of IE62 residues from 414-735 in 
frame with the HA epitope tag.  Additional constructs from pGK846 were derived by 
replacement of a DNA fragment defined by a unique KpnI site at 122,475 (residue 571 of IE62) 
and the unique BamHI site, with either double-stranded complementary oligonucleotide primers, 
or with KpnI- and BamHI digested PCR amplification products.  Accordingly, pGK2-HA810 
expressed residues 414-687; pGK2-HA828 expressed residues 414-571 fused in frame to 673 to 
735; pGK2-HA825 expressed residues 414-571 fused in frame to residues 656-735;  pGK2-
HA811 expressed residues 414-571 fused to 677-735; pGK2-HA819 expressed residues 414-571 
fused to the nuclear localization signal of IE62, defined by residues 677-686 (129);  pGK2-
HA821 expressed residues 414-571 fused to residues 386-394 of the VZV ORF61 protein, 
corresponding to the ORF61 nuclear localization signal (ARGAKRRL) (227);  pGK2-HA823 
expresses 414-571 fused in frame to the nuclear localization signal for SV40 (PPKKKRKV) 
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(213).  A second set of constructs was derived from the plasmid pGK2-HA846, containing point 
mutations resulting in substitution of alanines at specific serine /threonine residues between 
amino acids 680-735 of IE62.   Mutations were carried out by site-specific mutagenesis using the 
Gene Editor system (Clontech Corp., Palo Alto, CA).   To derive IE62 full length proteins with 
select amino acid changes, the KpnI-BamHI fragment from pKCMV62 was replaced with the 
corresponding KpnI-BamHI fragment derived from the site-specifically altered pGK2-HA846 
derivative, resulting in plasmids pKCMV62-S686A, pKCMV62-S686D, pKCMV62-S722A and 
pKCMV62-S722D.  All DNAs were prepared for transfection using Qiagen columns.  
To derive maltose binding protein (MBP) IE62 fusions, the portion of the IE62 gene 
defined by the KpnI-BamHI sites in IE62 (residues 571 to 735) was inserted into the KpnI and 
BamHI sites of pMalcR1 (New England Biolabs), followed by in-frame alignment of the maltose 
binding protein and IE62 ORF by digestion with KpnI, treatment with T4 DNA polymerase and 
dNTPs, and subsequent re-ligation.  For expression of forms of MBP- IE62 fusion proteins 
containing mutations, the corresponding NotI-BamHI fragments (encoding residues 602-735) 
were switched between the pGK2-HA846 based constructs and the maltose binding protein-IE62 
residue 571-735 derivative.   
3.3.4 Phosphorylation analyses   
[32P]-labeled IE62 peptides for phosphotryptic peptide analysis were generated from transfected 
cells incubated in growth media containing 5% serum, 1/20th the normal phosphate and [32P]-
orthophosphate at 500 µCi/ml for 8 to 12 h, initiating at 16 h post transfection.  
Immunoprecipitations were carried out as detailed previously (124) using a modified buffer to 
solubilize proteins (50 mM HEPES-KOH pH[7.4], 150 mM NaCl, 1% Nonidet-P 40, 0.5% 
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sodium desoxycholate, 1 mM EDTA and 1 mM DTT) containing protease inhibitor cocktail 
(Complete miniEDTA free,  Roche Applied Sciences, Indianapolis, IN) and the phosphatase 
inhibitors 2 mM NaVO4 and 25 mM NaF.  Labeled proteins were separated by SDS 
polyacrylamide gel electrophoresis (SDS PAGE) and identified by autoradiography.    
Two dimensional phosphopeptide analyses were carried out as detailed previously (26).   
Briefly, immunoprecipitated, SDS PAGE separated, [32P]-phosphate labeled IE62 proteins were 
transferred to Immobilon-P membrane, identified by autoradiography and the membrane 
fragments containing the labeled proteins were excised.  Membranes were washed sequentially 
in 0.5% polyvinyl pyrolodone in 100 mM acetic acid for 30 min, water for 10 min and then 50 
mM ammonium bicarbonate for 10 min.  IE62 peptides were released by two sequential 
digestions in 200 µl of 5 mM ammonium bicarbonate containing 10-20 µg TPCK-treated trypsin 
at 37oC for 24 h and then again for 4 h.  Released peptides were concentrated by freeze drying 
and then spotted onto silica TLC sheets in a 1-3 mm spot.  Resolution of peptides in the first 
dimension was by electrophoresis in pH 1.9 buffer of formic acid:glacial acetic acid:water at a 
ratio of 25:78:897.  TLC sheets were dried and peptides were subsequently resolved in the 
second dimension by ascending chromatography in phosphochromatography buffer (15:10:3:12 
ratio of n-butanol:pyridine:glacial acetic acid:water).  [32P]-labeled IE62 peptides were then 
identified by autoradiography, using Kodak Biomax imaging screens and film. 
3.3.5 Baculovirus construction and in vitro phosphorylation analyses 
Baculoviruses expressing the HA-tagged ORF66 protein kinase were derived using the 
BaculoGold system (BD Pharmingen, San Diego, CA). The complete HA-tagged ORF66 gene 
with the HCMV-IE1 polyadenylation signal was excised from pGK2-HA66 and cloned into the 
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baculovirus transfer vector pVL1392 (BD Pharmingen).  Following co-transfection with 
BaculoGold DNA into SF9 cells, progeny virus was isolated and amplified.  Expression of the 
HA-ORF66 protein kinase in infected SF9 cells was verified by immunoblot analyses with HA 
specific antibodies.  The baculovirus generated ORF66 protein of 55 KDa was the same size as 
HA-ORF66 protein present in extracts of pGK2-HA66 transfected 293T cells.   For in vitro 
kinase activity and in vitro phosphorylation, immunoprecipitates were prepared from SF9 cells 
infected with either a baculovirus expressing HA-tagged ORF66 (Bac-HA66) or a control 
baculovirus expressing glutathione-S-transferase (Bac-GST).  Proteins were solubilized using a 
radio-immunoprecipitation buffer (RIPA) (20mM Tris HCl [7.4], 50mM KCl, 1% NP40, and 
0.5% desoxycholate) plus protease inhibitor cocktail and phosphatase inhibitors (as just detailed) 
and ORF66 was precipitated using monoclonal antibodies specific for the HA epitope tag.  An 
unrelated, non-specific control monoclonal antibody was used for control immunoprecipitates 
where indicated (a gift of N. Sundar-Raj, Department of Ophthalmology, University of 
Pittsburgh).  In some studies, competing HA peptide or a non-specific peptide derived from the 
VZV ORF29 C terminal domain (126) were added to the SF9 cell extracts at a final 
concentration of 0.2 mg/ml prior to addition of monoclonal antibody.  Following extensive 
washing in the RIPA buffer, beads were washed in a kinase buffer (20 mM HEPES [7.5], 50 mM 
KCl, 0.1 mM EDTA, 10 mM MgCl2 or 50 mM MnCl2 as indicated in the text), and then 
incubated in 50 µl kinase buffer containing 10 µg/ml heparin and 5 µCi of  [γ-32P] ATP (6000 
Ci/mmol), at 35oC for 30 min.  Reactions were halted by addition of SDS sample buffer, proteins 
were separated by SDS PAGE, and phosphorylated bands were detected by autoradiography.   
 MBP-IE62 protein substrates for the in vitro phosphorylation reactions were expressed in 
E. coli and purified as detailed previously (122) and as by the manufacturer (New England 
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Biolabs, Inc.), except that induction of MBP fusion proteins was carried out at 30oC for 3 hours, 
and pellets were sonicated 4 x 30 seconds at 4oC to release fusion proteins.  In vitro kinase 
assays were performed using approximately 5 µg of MBP fusion substrates with an equally 
divided HA-ORF66 immunoprecipitate, so that each reaction received identical kinase amounts. 
3.4 RESULTS 
3.4.1 Phosphopeptide analysis of IE62 expressed with and without the VZV encoded 
protein kinases 
Previously, we showed that the dramatic redistribution of the VZV IE62 nuclear localizing 
protein to the cytoplasm was dependent on the integrity of the VZV-encoded ORF66 kinase 
activity (124, 129).  However, it was difficult to demonstrate specific ORF66-mediated IE62 
phosphorylation within full-length IE62 protein, because the extensive phosphorylation of IE62 
protein by cellular kinases masked any ORF66 mediated events (124, 125, 186).   Increased 
phosphorylation induced by ORF66 could only be demonstrated on IE62 peptides missing large 
regions that are strong targets for cellular protein kinases (124).  While these data implied that 
the ORF66 kinase influenced phosphorylation of IE62, we considered it important to 
demonstrate differential phosphorylation induced by ORF66 in the context of the complete IE62 
protein. We also reasoned that similar approaches might reveal whether the ORF47 kinase can 
mediate novel phosphorylation of IE62 in vivo, as suggested by in vitro (121, 186)  studies.   
   To characterize the complexity of IE62 phosphorylation, we used a tryptic 
phosphopeptide mapping procedure detailed previously (26).  Phosphorylation of IE62 was first 
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examined in the presence of the VZV protein kinases (at a 1:1 ratio) in co-transfected 293T cells.  
Following metabolic labeling in media containing [32P]-orthophosphate for 8 h, IE62 was 
immunoprecipitated, separated by SDS PAGE, and transferred to Immobilon P membranes.  The 
amount of [32P] label incorporated into IE62 proteins obtained under all conditions was similar, 
and the mobility of [32P]-IE62 in SDS PAGE was not detectably different in each condition (data 
not shown).   Tryptic phosphopeptides released from membrane-immobilized IE62 proteins were 
extracted, separated in two dimensions and detected by autoradiography as detailed in Materials 
and Methods.  As the technique shows some variability in separate runs, all comparative studies 
were carried out in parallel and under identical conditions.  Autoradiographs revealed complex 
tryptic phosphopeptide maps for IE62, even in the absence of any VZV protein kinases, 
substantiating IE62 as a target for cellular kinases.  At least 11 peptides could be readily 
identified (Figure 3-1A).   The peptide maps for IE62 expressed alone and IE62 expressed in the 
presence of ORF47 were very similar, with most peptides migrating to similar positions (Figure 
3-1B).  Only very minor differences were apparent, suggesting that ORF47 did not greatly affect 
the phosphorylation state of IE62 in vivo.  In contrast, the peptide map of IE62 expressed in the 
presence of ORF66 showed numerous changes, both in the relative abundance of several 
phosphopeptides (spots 5, 8, 9 and 10 were reduced), and in the appearance and/or movement of 
at least two novel phosphopeptide spots (Figure 3-1C, arrows).  In particular, peptide 11 in the 
map of IE62 expressed in the absence of any kinase was altered in maps of ORF66 co-expressed 
IE62 to at least two, possibly three peptides (indicated by arrows), and peptide 7 migrated further 
in the electrophoresis direction from the origin.  We conclude that ORF66 induces a differential 
phosphorylation state of the complete IE62 protein.    
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 Similar approaches were used to address IE62 phosphorylation in the context of VZV 
infected MeWo cells, using recombinant VZV that do not express the kinases (Figure 3-2).   
Following equivalent infection with VZV-ROka, ROka47S (not expressing ORF47) or ROka66S 
(not expressing ORF66) at a ratio of 1 infected cell per 20 uninfected cells, and a 12 h metabolic 
labeling period with [32P] orthophosphate initiating at 18 h post infection, IE62 was 
immunoprecipitated and analyzed by phosphotryptic peptide mapping.  The phosphopeptide map 
of ROka66S IE62 (produced in the absence of ORF66 expression) exhibited a general reduction 
in many of the IE62 phosphopeptides compared to Roka IE62, despite equal loading of counts on 
to the TLC plates (Figure 3-2C).   Furthermore, we observed one IE62 peptide spot (labeled 7b) 
that was abundant in both ROka and ROka47s IE62, which demonstrated a considerably reduced 
signal in ROka66S IE62 (arrowed, Figure 3-2C).  These observations indicated that ORF66 
induced novel phosphorylation events of the whole IE62 protein in the context of VZV infection.  
Comparison of ROka and ROka47S IE62 protein maps revealed very minor differences in the 
resolved phosphopeptide maps (Figure 3-2A and B), indicating that ORF47 does not grossly 
affect most of the phosphorylation events that occur on IE62 in the context of VZV infection in 
MeWo cells. 
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 Figure 3-1 Full-length IE62 is differentially phosphorylated in the presence of ORF66 kinase 
IE62 was expressed in the absence (A) or presence of ORF47 (B) or ORF66 kinase (C) in 
transfected 293T cells, metabolically labeled with [32P]orthophosphate, immunoprecipitated, and 
subjected to tryptic phosphopeptide mapping as described in Materials and Methods. The X in 
the lower left corner of each map indicates the origin of spotting of the peptides. The horizontal 
axes represent electrophoresis of the peptides on TLC plates, and the vertical axes represent the 
chromatography step. Phosphopeptide spots are labeled with numbers to facilitate reference from 
panel to panel, and arrows in panel C indicate the differences in spots generated by co-expression 
of IE62 with the ORF66 kinase that are discussed in the text. 
 
 
 
 
 
 
Figure 3-2 IE62 is differentially phosphorylated in the presence of ORF66 in the context of VZV infection 
Tryptic phosphopeptide maps were generated from IE62 obtained from 32P-labeled VZV-
infected cells by immunoprecipitation, as described in Materials and Methods and in the legend 
to Figure 1. IE62 was derived from MeWo cells infected with VZV ROka47S (not expressing 
ORF47) (A), VZV ROka (B), and VZV ROka66S (not expressing ORF66) (C). The X in the 
lower left corner of each map indicates the origin of spotting of the peptides. The arrow in panel 
C indicates a phosphopeptide which is reduced in ROka66S IE62. 
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3.4.2 Fine mapping of ORF66 mediated phosphorylation of IE62 
Because novel phosphorylation of IE62 induced by ORF66 has not been reported for the 
corresponding orthologous proteins in other alphaherpesviruses, we took approaches to map the 
phosphorylation sites in detail.   We were unable to unambiguously identify the novel ORF66 
induced peptides seen in the ORF66 co-transfection IE62 peptide map (Figure 3-1C) using 
peptide mass spectrometry approaches.  Therefore, we used a series of IE62 deletion and peptide 
expression plasmids to map the ORF66 mediated phosphorylation of IE62.  In previous studies, 
ORF66 induced the phosphorylation of a peptide of IE62 of residues 571-735, although much 
more efficient phosphorylation occurred with IE62 peptides spanning residues 414-823 (124).  
The more efficient phosphorylation of the larger peptide was suspected to be a consequence of 
the presence of the predicted DNA binding and dimerization domains of IE62, which may act to 
stabilize the IE62 peptide in transfected cells.  We therefore used a larger peptide, and deletions 
of it, as a basis for further mapping (Figure 3-3A).  Each HA-tagged IE62 peptide was co-
expressed in transfected 293T cells with either functional untagged ORF66 protein kinase or 
empty vector control, metabolically labeled with [32P]-orthophosphate and immunoprecipitated 
with HA antibody.     The immunoprecipitated IE62 peptide of residues 414-735 expressed from 
plasmid pGK2-HA846 demonstrated strong phosphorylation in cells co-expressing the ORF66 
protein kinase and little detectable phosphorylation in the absence of the kinase, confirming that 
this domain contained sites of ORF66 directed phosphorylation (Figure 3-3B, lane 2).  An IE62 
peptide that contained an in-frame deletion of the residues between 571 and 656 (HA825) was 
also efficiently and preferentially phosphorylated in ORF66 co-expressing cells (Figure 3-3B, 
lane 4).   However, IE62 peptides containing residues 414-571 fused to only the IE62 nuclear 
localization signal (HA819) did not show [32P] incorporation in ORF66 co-expressing or control 
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cells (Figure 3B, lane 6), and a peptide representing residues 414 to 687 (HA810) showed only 
minor labeling in both ORF66 expressing and not expressing cells (lane 16).  Of note, the HA810 
peptide contains a predicted cdk2 consensus site at T680, and cdk2 regulates the nuclear import 
of SV40 T antigen (109).  The implied phosphorylation of residues C terminal to the nuclear 
localization signal was strengthened by examining IE62 peptides containing amino acids 414-
571 fused to 673-735 (HA828) containing T680, and a peptide containing residues 414-571 
fused to 677-735 (HA811), which lacks the residues preceding T680 (Figure 3-3B, lanes 14 and 
12).  Both of these peptides were efficiently phosphorylated, suggesting ORF66 mediated 
phosphorylation events occur between residues 686 to 735, which are carboxyl to the IE62 NLS 
(Figure 3-3A).  In other studies, we noted that the peptide expressed from HA810, terminating at 
residue 687, was not efficiently imported into the nucleus (data not shown). As it was possible 
that the lack of phosphorylation of the peptide may have been a consequence of nuclear import, 
we examined two additional IE62 peptides in which the 414-571 peptide was fused to residues 
encoding NLSs from either ORF61 (HA821) or SV40 T antigen (HA823). These peptides were 
predominantly nuclear (data not shown), yet both were poor phosphorylation substrates (Figure 
3-3B, lanes 8 and 10).  Thus, the differential phosphorylation events identified reflect the 
presence or absence of target motifs for phosphorylation, rather than differences in cellular 
localization.  Finally, it was possible that the observed phosphorylation differences could be due 
to unstable peptides, so we examined the expression of the peptides in transfected cells.   All the 
IE62 peptides used in this study were found to be efficiently expressed in transfected cell 
extracts, although we noticed a somewhat more efficient expression of most peptides in the 
presence of the kinase in some studies (Figure 3-3C).  However, the differences in expression do 
not account for the differences in phosphorylation seen in Figure 3-3B. Thus, the different 
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phosphorylation levels more likely reflect presence or absence of phosphorylation sites.  We 
additionally note that an ORF66-specific phosphorylated protein of approximately 17 KDa was 
found in many (Figure 3-3B, indicated by a hatched circle, lanes 2, 4, 6, 8, 10 and 16) but not all 
(Figure 3-3B lanes 12 and 14) IE62 peptide immunoprecipitates from ORF66 kinase positive 
cells.  The identity of this protein has not yet been resolved.   
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Figure 3-3 Mapping of VZV ORF66 kinase-induced phosphorylation of IE62 peptides 
(A) Schematic representation of IE62 peptides used for this work. The top line represents the 
full-length IE62 protein and the relative position of its NLS (33), which is shown above the line 
in single-letter code, with key residues numbered according to their positions in IE62. Lines 
beneath full-length IE62 represent the peptides expressed relative to the complete IE62 protein. 
The precise residues expressed from each construct are indicated to the left of each 
representation, and for constructs expressing NLSs of other proteins in conjunction with a 414-
571 IE62 peptide, the NLS sequences are indicated in single-letter code to the right of the 
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representations. ORF66-specific phosphorylation of the peptide (Target?) is indicated to the 
right. (B) SDS-PAGE-separated, immunoprecipitated, 32P-labeled IE62 peptides expressed from 
the constructs shown in panel A, either in the presence (+) or in the absence (–) of ORF66 
kinase. Arrowheads indicate the expected sizes of the expressed IE62 peptides for reference in 
the text. Nonspecific phosphopeptides detected in both the presence and absence of ORF66 in 
some studies are indicated by an open circle, and an unidentified protein co-precipitating with 
the IE62 peptide expressed in ORF66 kinase-positive cells is identified by a hatched circle. Lane 
numbers are indicated at the bottom of the radiograph. (C) Immunoblot detection of the same 
respective peptides expressed in 293T cell extracts obtained from a similar transfection, showing 
the relative levels of peptides expressed in the absence (–) or presence (+) of a 1:1 ratio of the 
ORF66 protein kinase. The peptides were detected with an HA-specific antibody. Molecular 
masses of marker proteins and their relative mobilities are shown to the left of the blots. 
 
To further delineate the ORF66-specific target residues within IE62, a site-specific 
mutagenesis approach was used, in which single or clusters of the nine candidate threonine and 
serine residues between the IE62 NLS and amino acid 735 were mutated to alanine (Figure 3-
4A).  Each point mutated construct was generated in the background of the 414-735 peptide and 
then co-expressed and metabolically labeled in transfected 293T cells with either functional 
ORF66 protein kinase or dead kinase expressed from the plasmid pCMV66-K122A (111).   In 
this study, we detected a low level of IE62 peptide labeling in the absence of the functional 
ORF66 kinase, reflecting a weak activity of cellular protein kinases on the 414-735 peptide.  
This was also observed for peptide expressed from construct 810 (Figure 3-3B).   In the presence 
of the ORF66 protein kinase, there was enhanced labeling of the wild-type peptide, as expected 
(Figure 3-4B, lane 11).  In peptides containing serine to alanine mutation of residues 
691/693/701 as a group, and of residues 726/728/729 as a group, there was ORF66-specific 
phosphorylation comparable to the wild type peptide (Figure 3-4B, lanes 1 and 7).  However, in 
peptides that contained S722A or S686A mutations, either alone or with other residues, there was 
a significant reduction of the level of phosphorylated peptides found, although in no 
circumstance was all phosphorylation abrogated by a single point mutation.  These results 
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suggested that both S686 and S722 are target residues in IE62 for the phosphorylation induced 
by the ORF66 protein kinase.   Densitometric analyses from this experiment indicated that the 
S686A and S722A mutations abrogated 64% and 54% of the IE62 peptide phosphorylation in the 
presence of the ORF66 kinase, respectively, as compared to the unaltered peptide.  Similar 
results were obtained from peptides expressed in transfected MeWo cells, although the level of 
basal phosphorylation of the peptides in the absence of the ORF66 kinase, presumably 
representing activity of cellular kinases, was found to be higher (data not shown).    
 
 
Figure 3-4 Identification of ORF66-induced phosphorylation of IE62 peptides 
(A) Representation of the region of IE62 containing ORF66-directed phosphorylation sites, with 
the amino acid sequence in single-letter code and the position of each serine or threonine residue 
indicated with the residue number above. (B) Radiograph showing SDS-PAGE-separated 
immunoprecipitates of 32P-labeled IE62 peptides expressed in the absence (–) and presence (+) 
of a 1:1 ratio of functional ORF66 protein kinase. All peptides contain residues 414 to 735 of the 
IE62 peptide, but with specific serine/threonine transitions to alanine, as indicated above each 
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pair of lanes. The arrowhead indicates the expected size of the phosphorylated IE62 peptides. 
Lane numbers are indicated at the bottom of the radiograph for reference in the text. 
 
To further evaluate the ORF66 protein kinase-induced phosphorylation at IE62 S686 and 
S722, we carried out in vivo labeling studies of peptides lacking one or both targets in the IE62 
414-735 residue peptide background; wild type, S686A, S722A and a double mutated peptide 
S686A/722A.  MeWo cells were transfected with ORF66:IE62 plasmid ratios of 0:1, 1:1, 3:1, 
and 5:1 to determine if higher levels of phosphorylation could be achieved with more transfected 
kinase.  The IE62 wild-type peptide exhibited an increase in phosphorylation of 3.7 fold at the 
1:1 ratio over the peptide expressed in ORF66 negative conditions (0:1). At higher ratios of 
kinase to peptide, this level of phosphorylation did not increase significantly (peptide HA846, 
Figure 3-5A).  Peptides containing either S722A or S686A single mutations exhibited an overall 
reduction in their level of phosphorylation when expressed with ORF66, although ORF66 
induced phosphorylation was still apparent at all ratios of ORF66:IE62 peptide, as compared to 
no kinase.  In contrast, when both S686 and S722 were altered to alanines, IE62 peptide 
phosphorylation in the presence of ORF66 was reduced to background phosphorylation levels 
seen in the absence of transfected ORF66.  Densitometric analyses of the level of the 
phosphorylation of the double mutant IE62 peptide indicated only a 1.3X  increase in 
phosphorylation at the 1:1 and 3:1 ratios and no relative phosphorylation increase at the 5:1 ratio, 
as compared to peptide expressed in the absence of ORF66 (0:1).  Immunoblot analyses of the 
IE62 peptides expressed in transfected cells with different levels of the protein kinase indicated 
that they were efficiently expressed (Figure 3-5B). Overall, the differences seen in Figure 3-5A 
were concluded to reflect [32P] incorporation levels and not peptide expression levels.   These 
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data support the conclusion that ORF66 mediated phosphorylation of the IE62 peptide is largely 
restricted to two sites carboxyl to the IE62 NLS, namely residues S686 and S722.   
 
 
 
Figure 3-5  Expression and [32P]orthophosphate labeling of IE62 wild-type and serine mutant peptides 
expressed in the absence or presence of different levels of ORF66 
 
(A) Autoradiograph showing SDS-PAGE-separated, [32P]orthophosphate-labeled, 
immunoprecipitated peptides expressed from plasmid pGK2-HA846 (HA846) or similar 
plasmids with S686A, S722A, or S686A/S722A mutations. Immunoprecipitates were prepared 
from cells transfected with equal levels of plasmid expressing the IE62 peptide and with an 
empty vector or plasmid expressing ORF66, adjusted to give ORF66-to-IE62 peptide ratios of 
0:1, 1:1, 3:1, and 5:1, as indicated at the top of the figure. The exposures of the autoradiographs 
were equivalent, except for that of the IE62 double mutant (S686A/S722A), which was 
overexposed approximately threefold compared to the others to show the minor level of 
phosphorylation by cellular kinases. (B) Immunoblots showing the expression of each HA-
tagged IE62 peptide expressed in cells following similar transfections to those performed for 
panel A in order to show expression of the peptides at the different IE62 peptide-to-ORF66 
ratios. The peptides were identified with HA-specific antibodies. Numbers at the bottom refer to 
lanes discussed in the text. 
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3.4.3 Identification of the ORF66 induced phosphorylation events affecting nuclear 
import of IE62 
Both of the IE62 residues S686 and S722 are carboxyl to the mapped NLS of IE62 (127, 129), 
and have similarities in contextual sequence (see Figure 3-4A).  Both are preceded by 3 basic 
amino acids at the -4, -3 and -2 positions, and are followed by a proline at the +2 position and a 
valine at the +3 position.   Interestingly, only the arginine/lysine rich region preceding S686 acts 
as an NLS in MeWo cells (129).  If phosphorylation of IE62 at S686 (immediately adjacent to 
the NLS) or S722 (37 residues downstream of the NLS) affects IE62 nuclear import, the 
alteration of the key target serine should result in the generation of a nuclear IE62 protein in the 
presence of the ORF66 kinase.  To this end, the cellular distribution of wild-type and mutant full-
length IE62 proteins containing serine to alanine mutations were analyzed (Figure 3-6).   In these 
studies, functional, HA-tagged ORF66 kinase was used to facilitate the identification and cellular 
location of the protein kinase in transfected cells by immunofluorescence.  All co-transfections 
were performed with a 1:1 ratio of ORF66:IE62.  Two hundred IE62 positive cells were scored 
for the cellular distribution of IE62 under each condition.  
Full-length, wild-type IE62 expressed in the absence of ORF66 showed typical nuclear 
localization in greater than 94% of IE62 positive cells, with both a diffuse nuclear staining, 
negative nucleolar staining and a sub-nuclear concentration to distinct dots adjacent to the 
nucleolus (Figure 3-6A).  Rare cells (less than 5% of the total positive) showed some 
cytoplasmic distribution of IE62, and these were suspected to represent cells with poorly defined 
nuclear membranes that may have recently undergone cell division. Only one cell of 200 counted 
showed an exclusively cytoplasmic form of IE62.   Virtually identical nuclear distribution 
patterns were found in IE62 S686A (Figure 3-6B) and IE62 S722A (Figure 3-6C) proteins in the 
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absence of ORF66 kinase expression.  In the presence of the ORF66 kinase, approximately 70% 
of the wild-type IE62 positive cells demonstrated a predominantly cytoplasmic staining for the 
IE62 protein, with the remaining cells demonstrating both nuclear and cytoplasmic forms of IE62 
(Figure 3-6D).  No cells expressing both wild-type IE62 and ORF66 demonstrated a 
predominantly nuclear phenotype for the IE62 protein, and nuclear IE62 was only detected in 
those few transfected cells which failed to co-express ORF66.  The ORF66 protein demonstrated 
a predominantly nuclear speckled localization in many cells in the presence of wild-type IE62, 
with some cytoplasmic distribution, similar to that observed in previous studies (124).  Like 
wild-type IE62, IE62 containing S722A co-expressed with the ORF66 protein kinase resulted in 
predominantly cytoplasmic localization of the IE62 protein in all ORF66 co-expressing cells 
(Figure 3-6E).   In contrast, IE62 carrying the S686A mutation demonstrated predominantly 
nuclear localization both in the presence and the absence of the ORF66 protein kinase in nearly 
all cells, similar to wild type IE62 expressed alone (Figure 3-6C and F).  The ORF66 kinase 
showed a mostly nuclear distribution but nucleolar exclusion, and confocal analyses indicated a 
predominant overlap of the signals of the two proteins.  IE62 S686A remained nuclear even in 
the presence of higher ratios of ORF66:IE62, suggesting that the kinase insensitivity of nuclear 
localization could not be overcome by expressing higher levels of protein kinase (data not 
shown).  These results strongly suggest that ORF66 mediated phosphorylation of S686 is the 
event that causes the cytoplasmic accumulation of IE62. 
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Figure 3-6 IE62 protein containing S686A, but not S722A, mutation is resistant to ORF66-mediated nuclear 
exclusion 
 
IE62 proteins carrying either the wild-type residues or an S686A or S722A mutation were 
expressed in the presence or absence of functional HA-tagged ORF66 in VZV-permissive MeWo 
cells, and their cellular distributions were determined using indirect immunofluorescence at 24 h, 
as described in Materials and Methods. IE62 was detected using rabbit anti-IE62 with secondary 
Alexa fluor 488-conjugated antibodies, and ORF66 was detected using mouse anti-HA with 
secondary Alexa fluor 546-conjugated antibodies. The left panels exhibit full-length IE62 
proteins transfected in the absence of ORF66 (A to C), the middle panels display IE62 protein 
staining in cells co-expressing the live HA-tagged ORF66 kinase (D to F), and the right panels 
(G to I) show the expression of HA-tagged ORF66 in the same cells as those shown in the 
middle panels. 
 
To further support this interpretation, we derived and expressed IE62 proteins that 
contained S686D or S722D mutations, designed to place a permanent, primary structure-based 
negative charge at S686 or S722, to mimic the negative charges exerted by phosphorylation.   In 
transfected MeWo cells, IE62 S722D protein showed a nuclear distribution similar to wild type 
protein, including a sub-nuclear concentration adjacent to nucleoli (Figure 3-7B).  In contrast, 
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S686D IE62 proteins demonstrated an inefficient nuclear import, with most cells displaying at 
least some cytoplasmic accumulation.   Some cells expressing the IE62 S686D protein had little 
nuclear distribution (upper left, Figure 3-7C), but many demonstrated some nuclear 
accumulation with obvious cytoplasmic accumulation (lower right, Figure 3-7C).  Confocal 
sectioning indicated that there was nuclear import of IE62 S686D protein in these cells.  These 
results are consistent with the ORF66 mediated phosphorylation and addition of a negative 
charge at IE62 residue S686, which negatively regulates the activity of the immediately adjacent 
NLS.  The partially inhibited nuclear import phenotype likely resulted from the inability of the 
aspartate residue to fully mimic the negative charge exerted by phosphorylation.  
 
 
Figure 3-7 Mimicking phosphorylation through aspartic acid replacement of S686, but not S722, results in 
partial inhibition of nuclear import 
 
Full-length IE62 proteins with the wild-type sequence or with an S686D or S722D mutation 
were individually transfected into MeWo cells, and cells were fixed and stained for IE62 
expression using anti-IE62 and Alexa fluor 488-conjugated secondary antibodies as described in 
Materials and Methods. Representative cells are shown. The specific S D mutation is indicated 
above each panel. 
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3.4.4 Baculovirus mediated expression and in vitro autophosphorylation of the ORF66 
kinase 
The observed phosphorylation of IE62 in ORF66 expressing cells could be either a consequence 
of direct phosphorylation by the ORF66 kinase or the result of an indirect mechanism, such as 
ORF66 activation of a cellular kinase or pathway that leads to IE62 phosphorylation.  We 
therefore considered it necessary to determine if the ORF66 kinase could directly phosphorylate 
IE62.  Extensive attempts to develop an in vitro kinase assay with ORF66 obtained from VZV 
infected cells were not successful, because the ORF66 protein kinase has proven to be highly 
insoluble in buffers designed to solubilize the kinase and retain its kinase activity.  Therefore, we 
expressed the HA tagged ORF66 protein kinase in SF9 cells using a recombinant baculovirus 
(Bac-HA66).  Following high multiplicity infection and 48 hours of expression, approximately 
5% of the total HA-ORF66 protein was soluble after cell lysis in a mild RIPA buffer.  
Immunoblotting of HA-ORF66 with HA specific antibodies resulted in identification of two 
closely migrating but distinct forms on SDS-PAGE, as seen in transfected cells (124) (data not 
shown).   
 We first examined autophosphorylation of the SF9 expressed protein kinase.  ORF66 
autophosphorylation was implied from the observation that point inactivated ORF66 kinases do 
not exhibit the slower migrating form on SDS PAGE gels (124).   Extracts of SF9 cells 
expressing either the HA-ORF66 kinase or glutathione-S-transferase (GST) control were 
immunoprecipitated with HA specific or non-specific antibodies, either in the presence or 
absence of blocking HA peptide or an unrelated peptide.  The washed immunoprecipitates were 
incubated with a standard kinase buffer containing 10 mM MgCl2, [γ−32P] ATP and 10 µg/ml 
heparin (to block casein kinase II activity (186).  The latter was found through preliminary 
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studies not to affect ORF66 kinase activity. SDS-PAGE and autoradiography revealed a heavily 
phosphorylated band of 55 KDa, consistent with the size of HA-tagged ORF66, only in 
immunoprecipitates from SF9 cells infected with the Bac-HA66 (Figure 3-8, lane 2).  This band 
was efficiently detected when a non-specific peptide was used with the antibody-antigen mix, 
and its immunoprecipitation was inhibited by addition of HA peptide (Figure 3-8, lane 4).  There 
was no equivalent 55 KDa phosphorylated band in extracts immunoprecipitated from Bac-GST 
infected cells under any conditions (Figure 3-8, lanes 5-8).  These data show that the HA-ORF66 
kinase is specifically precipitated from Bac-HA66 infected cell extracts and can 
autophosphorylate.    
The optimal conditions for ORF66 in vitro kinase activity were determined by evaluating 
cation choice (Mn2+ or Mg2+) and concentration (2 to 100 mM), different pH (pH 6.0 to 9.0), and 
variable salt concentrations (0 to 1M KCl).  These were performed for auto-phosphorylation 
activities, but the optimal conditions were found to be suitable for trans-phosphorylation of a 
highly purified IE62-MBP 571-735 peptide.  Kinase activity was found to be optimal with 50 
mM Mn2+, physiological pH [7.5], 50 mM KCl and was not inhibited by 10 µg/ml heparin.  As 
such, the optimized buffer was used for all remaining kinase assays.  We note the preference for 
Mn2+ ions was also found for the phosphorylation activity of the VZV ORF47 kinase (186).  
While sites for autophosphorylation of ORF66 have not yet been determined, two ORF66 
candidate sequences (KRS331SRKPGSR and RHRPS368) have serines proximal to multiple basic 
residues, as found for the target residues for ORF66 directed phosphorylation in IE62. 
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 Figure 3-8 Development of immunocomplexed ORF66 in vitro kinase assay 
Protein antigens (Ag) from SF9 insect cells infected with Bac-HA66 or control Bac-GST were 
solubilized in a modified RIPA buffer and immunoprecipitated with either anti-HA (HA) or a 
nonspecific (C) antibody in the presence of either 0.2 mg/ml specific (HA) or nonspecific (29) 
competitor peptide. Washed immunoprecipitates were then incubated with [ -32P]ATP in kinase 
buffer as described in Materials and Methods. Proteins were resolved by SDS-PAGE and 
detected by autoradiography. SDS-PAGE standards are marked at the right, and lanes are marked 
at the bottom of each panel for reference in the text. The 55-kDa HA-ORF66 autophosphorylated 
protein band is indicated by an arrow to the left of the autoradiograph. 
3.4.5 ORF66 phosphorylates IE62 peptides in vitro with the same specificity as in vivo 
To determine if ORF66 could directly phosphorylate IE62, immunoconjugated HA 
ORF66 was incubated with purified MBP-IE62 peptide fusion substrates under optimal kinase 
conditions (Figure 3-9).  Four purified MBP-fusion proteins containing IE62 amino acid region 
571-733 fused to MBP were analyzed, with or without changes at the specific serine residues 
identified in the in vivo phospholabeling studies (WT, S686A, S722A, and S686A/S722A; 
Figure 3-9A).  Equal amounts of these fusion proteins (Figure 3-9B, lanes 11-14) were incubated 
with HA-immunoprecipitates from Bac-HA66 (Figure 3-9B, lanes 1-5) or Bac-GST-infected cell 
lysates (Figure 3-9B, lanes 6-10) and analyzed by SDS PAGE.  In the Bac-GST control 
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immunoprecipitates, virtually no phosphate labeling was detected for any of the IE62 peptides 
(Figure 3-9B, lanes 6-10; the first and second panels represent equally exposed autoradiographs).   
However, incubation of MBP-IE62 fusion proteins with Bac-HA66 immunoprecipitates resulted 
in strong phosphorylation of the wild-type MBP-IE62 fusion (Figure 3-9B, lane 1).  Importantly, 
the MBP-IE62 fusion with point mutations in both S686 and S722 was a much poorer substrate 
for the HA-ORF66 kinase, despite loading of equivalent levels of each MBP-IE62 peptide into 
the assay.  Furthermore, individual mutation of one serine to alanine resulted in reduced 
phosphorylation of the peptide, but not to the extent of wild type IE62-MBP fusions (Figure 3-
9B, lanes 3 and 4).  The phosphorylated protein of 55 KDa was the autophosphorylated protein 
kinase, as it was present in the immunoprecipitates lacking any MBP fusions and was not present 
in Bac-GST control immunoprecipitates.  Similar results were obtained in two replicate 
experiments.   
 Phosphorimaging analysis of phosphorylated MBP-IE62 peptides was performed for 
three replicate experiments, and the average percent optical density (compared to wild-type) of 
each phosphorylated band is plotted in Figure 3-9C.   A marked ~75% decrease in signal was 
observed with the double mutant peptide, and a reduced signal was seen with single mutation of 
either S686 or S722 individually.  We conclude that IE62 is a direct substrate for the ORF66 
protein kinase, and that the activity observed in our in vitro reactions reflects a direct ORF66-
mediated IE62 phosphorylation event.  Thus, IE62 represents a new target for the US3 group of 
kinases. 
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 Figure 3-9 Immunopurified ORF66 specifically phosphorylates MBP-IE62 peptides at S686 and S722 in vitro 
 
(A) Representation of MBP-IE62 fusion proteins that were constructed and purified for the in 
vitro kinase assay. The residues at positions 686 and 722 are shown in single-letter code for the 
IE62 portion of the fusion peptide. (B) Autoradiographs of in vitro kinase assays using 
equivalent amounts of each purified MBP-IE62 substrate protein shown in panel A. The purified 
proteins were incubated in optimal kinase buffer with immunocomplexed HA-ORF66 (lanes 1 to 
5) or with similar HA-tagged immunoprecipitates obtained from Bac-GST-infected cell lysates 
(lanes 6 to 10). Lanes 1 and 6 contain the wild-type IE62 peptide, lanes 2 and 7 contain the 
double mutant peptide, lanes 3 and 8 contain the S686A mutant peptide, lanes 4 and 9 contain 
the S722A mutant peptide, and lanes 5 and 10 contain the respective baculovirus 
immunoprecipitates with no added maltose binding protein fusions. Both autoradiographs were 
exposed equally. The lower panel (lanes 11 to 14) shows SDS-PAGE-separated input MBP-IE62 
substrate proteins used for lanes 1 to 4 and 6 to 10 following staining with Coomassie brilliant 
blue to show the purified proteins. To the right of the radiographs are shown the approximate 
positions of molecular mass markers, in kDa. (C) Average values from densitometric 
quantification of autoradiographs of three replicate experiments, including that shown in panel B. 
Densitometric values of phosphorylated MBP-IE62 fusion proteins were normalized to the wild-
type MBP-IE62 peptide densitometry value (set to 100%) after subtracting the background signal 
for each lane. Error bars represent standard deviations from the means. Only the region of the gel 
indicated by a bar to the left of the autoradiograph in panel B was evaluated. DM, double mutant. 
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3.5 DISCUSSION 
Taken together with previous results (123, 124, 129), we have now shown that VZV IE62, the 
principal transcriptional transactivator and a major component of the VZV virion tegument, is a 
direct target for phosphorylation by the VZV ORF66 protein kinase.  Phosphorylation occurs at 
two residues, but the targeting of residue S686 is sufficient to induce IE62 to become 
cytoplasmic.  These observations are consistent with a model in which one role of the ORF66 
protein kinase is to directly phosphorylate IE62, negating its nuclear import to possibly 
negatively regulate IE62 mediated transcriptional activation of viral gene expression, and/or to 
potentially enable virion inclusion of a preformed transactivator into the VZV virion tegument.  
As ORF66 negative viruses are impaired for growth in T lymphocytes and in the SCID-hu thy/liv 
model of VZV infection (174, 220, 224), the interaction of ORF66 with IE62 may be an 
important for efficient viral pathogenesis.    
Several lines of evidence were presented to support the conclusion that the ORF66 
protein kinase phosphorylates IE62.  Previously, nuclear exclusion of the IE62 protein by the 
ORF66 protein was shown to occur only if the protein kinase activity of ORF66 was intact and 
this correlated with enhanced phosphorylation of IE62 peptides by the ORF66 kinase in the 
context of both transfection and VZV infection (124).   In a second study, IE62 demonstrated 
slightly different mobilities in SDS PAGE if the ORF66 kinase was not expressed (123).  Here 
we used tryptic phosphopeptide mapping studies to further establish that ORF66 directs new 
phosphorylation events in full length IE62, in both co-transfections and in VZV infections.  Two 
novel IE62 phosphopeptides were observed when IE62 was co-expressed with ORF66 
transiently, and one IE62 phosphopeptide spot that was abundant in both ROka and ROka47S 
IE62 peptide maps was considerably reduced in IE62 from ROka66S.  These differential levels 
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of phosphopeptide spots do not discriminate between direct phosphorlyation and ORF66 induced 
cellular kinase activity.  We also note there was an overall reduction in many other IE62 
phosphopetides found in the presence of ORF66, although they migrated to the same relative 
positions.  One possible reason for the reduction is that IE62 is phosphorylated by 
compartmentalized cellular kinases, which act differentially on IE62 as a result of the ORF66 
induced cellular re-localization of IE62.   Another possibility is that ORF66 activates host cell 
signaling cascades and the activities of cellular kinases that subsequently lead to an increased 
level of IE62 phosphorylation.  Other alphaherpesvirus US3 kinases have been implicated to 
affect host signaling cascades, because they have multiple effects on host cell function, such as 
multiple cytoskeletal reorganization effects (74, 221, 237).  Studies are currently under way to 
determine the general phosphoprotein state of the cell expressing the ORF66 kinase.   
IE62 peptides demonstrated the same phosphorylation specificity in both in vivo 
phospho-labeling studies in the presence of ORF66 and the in vitro ORF66 kinase assay, 
strongly suggesting IE62 is a direct target.  Individually mutated IE62 peptides with S686A or 
S722A showed reduced phosphorylation, and mutation of both residues resulted in peptides that 
were much less sensitive to ORF66 phosphorylation.   For an intermediate cellular kinase to act 
as the go-between for ORF66 mediated phosphorylation of IE62, it would have to efficiently co-
purify with the baculovirus-expressed immunopurified ORF66 and have activity in the same 
buffer used for the kinase assays. The use of the divalent cation Mn2+ and heparin exclude 
activity of contaminating cellular CKII, and we consider that other cellular kinase contamination 
seems highly unlikely.  Further proof will require high-level purification of the ORF66 protein 
kinase and demonstration of its affinity for its substrates.  A suitable approach for this was 
recently elegantly demonstrated with the HSV-1 US3 kinase of HSV-1, in which purified GST-
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US3 protein specifically phosphorylated several viral and cellular target–MBP protein fusion 
substrates (117).  For ORF66, this has proven to be quite difficult because the protein kinase is 
very insoluble from VZV infected cells, and we have found that GST addition to the N terminus 
of ORF66 appears to inactivate or interfere with the kinase activity of ORF66 (A. Erazo, K, Fite, 
and P. R. Kinchington, unpublished data).   Nevertheless, strategies to purify ORF66 may enable 
a more rigorous in vitro phosphorylation assay to be developed.     
Of the two IE62 residues phosphorylated by ORF66, only S686 was shown to be 
involved in the nuclear exclusion of IE62.  In conventional nuclear import, a basic 
arginine/lysine-rich NLS is recognized by one or more of the six importin α proteins, which in 
turn complex with importin β and are translocated through the nuclear pore via the GTP-binding 
protein Ran  (reviewed in references (110, 180)).  IE62 S686 is immediately adjacent to the IE62 
NLS (aa 677-685) (129), and the close proximity strongly suggests an underlying mechanism in 
which phosphorylation inhibits nuclear import.   Nuclear import of many proteins is highly 
regulated by phosphorylation close to their NLSs (reviewed in references (88, 110).  Recent 
studies have shown that either direct phosphorylation or mutations mimicking phosphorylation 
through acidic residue replacement of the target residue at a site immediately N terminal to an 
NLS results in decreased affinity of the NLS for importin α (88).   N-terminal phosphorylation 
events that impair nuclear import of proteins are common, and occur in proteins such as SV40 T 
antigen, parathyroid hormone-related protein (PTHrP), and v-jun (109, 142, 213, 229).   As far as 
we are aware, IE62 is one of a much rarer group of proteins that are nuclear import regulated by 
phosphorylation at a residue carboxyl to the NLS.  One other such protein is the adenomatous 
polyposis coli (APC) protein (256).   Mechanistically, the simplest explanation is that the strong 
negative charge exerted by phosphorylation at a site proximal to the NLS reduces importin 
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binding affinity.  However, there are some suggestions that more complex issues affect nuclear 
distribution of IE62.  In transfected cells, the majority of ORF66 protein localizes to the nucleus, 
with only a fraction remaining cytoplasmic (124).  With the simple model, phosphorylation of 
newly translated IE62 at S686 would be mediated by the small fraction of cytoplasmic ORF66.  
In an alternative explanation, the phosphorylation of IE62 by ORF66 would occur in the nucleus, 
and coupled with a possible nuclear export mechanism of phosphorylated IE62, IE62 would exit 
and be unable to re-enter the nucleus.  In a VZV infection, the latter scenario would enable 
nuclei to empty of IE62 at late stages of VZV infection, and we and others have observed that 
many late stage nuclei in wild-type VZV plaques appear devoid of IE62 (unpublished data; see 
also figures in reference (22)).  The possible nucleocytoplasmic shuttling capability of IE62 in 
VZV infection is currently under investigation. 
The functional significance of phosphorylation at residue S722 is not yet clear.  While 
residues immediately amino terminal to S722 have similarity to canonical NLSs (see Figure 3-
4A), the sequence cannot act as an NLS in the absence of the 677-685 NLS sequence in MeWo 
cells (129).  Furthermore, phosphorylation of S722 (in S686A mutants of IE62) does not inhibit 
IE62 nuclear import in multiple cell types tested.  However, we postulate that the IE62 716-720 
basic residue region may function as an NLS in specific cell type(s) not yet identified. The six 
known importin α proteins each demonstrate variable binding specificity to cargoes and also 
show cell-type dependent regulation of expression (180, 208).   VZV infects multiple cell types 
during the natural course of infection, including epithelial cells, T-lymphocytes, dendritic cells 
(179), skin cells and sensory neurons (138, 139), and it is possible that the IE62 716-720 region 
may be a functional or preferred NLS in one of these cell types.  Therefore, we suggest that the 
phosphorylation of both S686 and S722 is maintained to abrogate IE62 nuclear import at later 
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stages of VZV infection in multiple host cell types with different importin α expression 
characteristics. 
IE62 is the first viral target reported for the VZV ORF66 kinase, and the corresponding 
interaction demonstrated in this work has not been reported in other alphaherpesviruses.   We 
previously postulated that IE62’s role as a tegument protein may be, in part, to supplement 
transactivation of IE viral gene expression (123), as VZV that does not express ORF10, the 
HSV-1 VP16 homolog, can still grow well in culture (42).    Several viral targets of the 
orthologous US3 kinase have been identified, but it is not yet clear whether these are conserved 
in VZV.  While ORF66 is not “essential” for tissue culture growth, disruption of ORF66 
expression results in low virus production and poor capsid assembly (220).  Recent data suggests 
that ORF66 may affect additional functions in the host cell in addition to IE62.  ORF66 induces 
the downregulation of MHC-I surface expression ((2) and A. Eisfeld, P. Kinchington, 
unpublished data).   In addition, comparison of ORF66 expressing and not expressing viruses in 
T cells has suggested that ORF66 may have roles in resistance to interferon as well as inhibition 
of virally induced apoptosis (220).   Both of these activities have been attributed to US3 protein 
kinases (182, 188, 198).  It thus seems that US3 kinases may share some common host cell 
targets, but that viral targets have differentiated as VZV and other alphaherpesviruses have 
evolved and separated from a presumed common ancestor.   The effects of ORF66 on the host 
cell are now under investigation.   
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4.1 ABSTRACT 
The varicella-zoster virus (VZV) IE62 protein is a critical nuclear transcriptional regulator that is 
re-distributed to the cytoplasm as a result of direct phosphorylation by the VZV ORF66 protein 
kinase.  Based on the putative early expression kinetics of the ORF66 protein, we hypothesized 
that IE62 may require both ORF66 phosphorylation and nuclear export activities to account for 
its efficient nuclear exclusion in late-stage infected cells.  Here, we utilized the recently 
described VZV.GFP-66 in cell-free time-course infections to establish for the first time that 
ORF66 expression ensues following that of IE62, and that ORF66 nuclear localization is not 
sufficient for IE62 nuclear exclusion.  We assessed IE62’s nuclear export abilities using 
interspecies heterokaryon analyses, which revealed IE62 shuttling into murine nuclei in both 
transfected cells expressing only IE62 and VZV infected cells where IE62 was insensitive to 
ORF66-mediated nuclear exclusion.  Shuttling was specific, as a human nuclear resident protein 
remained associated only with human nuclei; and Crm1-independent, as it occurred in the 
presence of leptomycin B.  Similar analyses of IE62 truncation peptides identified amino acids 
733-995 as critical for nuclear export.  Interestingly, disruption of the DNA-binding and 
dimerization domain resulted in enhanced shuttling, suggesting that IE62 nuclear retention may 
occur by recognition of cellular DNA or a dimerization-induced nuclear protein interaction.  
These studies also indicated a possible role for phosphorylation of the N-terminal poly-serine 
tract in facilitating nuclear export.  In sum, IE62 nuclear exclusion is a complex process, likely 
regulated through phosphorylation by multiple kinases and active nuclear export through a 
Crm1-independent pathway. 
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4.2 INTRODUCTION 
Varicella-zoster virus (VZV) is a human alphaherpesvirus, closely related to herpes simplex 
virus type 1 (HSV-1), that causes chickenpox upon primary infection and herpes zoster 
(shingles) following reactivation from latency.  The VZV genome consists of ~125 kbp of 
dsDNA, and codes for ~70 unique open reading frame (ORF)s that are expressed during lytic 
infection.  Gene expression likely occurs in a typical α-β-γ transcriptional cascade similar to that 
of HSV-1 (100, 101), and is regulated by the viral proteins from ORFs 4, 10, 29, 61, 62/71 and 
63/70 (127).  Of these, the principal transcriptional regulator of VZV gene expression is the 
immediate early protein encoded in duplicate by ORFs 62 and 71 (known as IE62).   
IE62 activates expression from all putative temporal classes of VZV promoters (15, 40, 
177, 195), positively and negatively influences its own promoter activity (55, 195), and 
substantially enhances the infectivity of VZV DNA (177).  The IE62 primary sequence is similar 
to that of the HSV-1 ICP4 protein, and IE62 can partially complement ICP4 mutants and replace 
ICP4 in the HSV-1 genome (54, 64).  However, HSV-1 carrying the IE62 gene exhibits an 
impaired replication phenotype, implying that unique processes govern IE62 and ICP4-mediated 
viral gene expression.  The specific mechanism of IE62-mediated transactivation is not known, 
but likely involves recruitment and stabilization of components of the general transcription 
machinery on viral promoters (31, 253).  IE62 structural motifs that contribute to its 
transactivation abilities include a potent N-terminal activation domain (aa 1-83) (40, 195), a 
DNA-binding and dimerization domain (DBDD; aa 486-641) (23, 234, 235, 247), and a nuclear 
localization signal (NLS; aa 677-685) (129).   In marked contrast with ICP4, IE62 is major 
component of purified viral particles and is associated with the VZV tegument (123).  This 
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implies a unique virion structural role and/or an important function during the initial stage of 
infection following entry and uncoating.   
IE62 undergoes temporally defined spatial re-distribution, from the nucleus during early-
stage infection to the cytoplasm during late-stage infection (124).  This change in IE62 
compartmentalization divides known roles of IE62 as a transcriptional regulator in the nucleus 
and as a viral structural protein assembled into virions in the cytoplasm.  IE62’s mass (175 kDa 
in VZV-infected cells) precludes free diffusion across the size-constrained nuclear pore complex 
(NPC), and IE62 nuclear import relies upon its arginine (R)/lysine (K)-rich NLS 
(677RLRTPRKRK685) (129).  The IE62 NLS is likely recognized by a karyopherin α adaptor and 
actively transported into the nucleus after karyopherin β1 association, followed by release into 
the nucleoplasm as a result of Ran-GTP binding at the nucleoplasmic face of the NPC.  IE62 
cytoplasmic accumulation in late-stage VZV infection is dependent upon expression and 
functional catalytic activity of the VZV ORF66 protein kinase (123, 124, 219). Specifically, 
ORF66 mediates a direct phosphorylation of IE62 at the serine residue immediately downstream 
of the IE62 NLS, (S686), which may sterically inhibit karyopherin α binding to impede IE62 
nuclear import (58).  Importantly, ORF66 expression is required for the abundant tegument 
association of IE62 (123).   
ORF66 is expressed in the nucleus and the cytoplasm in VZV-infected cells (58, 219), 
and thus IE62 phosphorylation may occur in either compartment.  Assuming that ORF66 is 
expressed with early kinetics during infection, similar to its HSV-1 ortholog US3, 
phosphorylation of IE62 restricted to the cytoplasmic compartment would result in nuclear forms 
of IE62 throughout infection, since IE62 is expressed with immediate early kinetics (67) and can 
enter the nucleus in the absence of ORF66 expression.  Alternatively, ORF66-mediated IE62 
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phosphorylation may occur in the nucleus, and combined with a mechanism of nuclear export, 
may result in more efficient nuclear clearance of IE62 during late-stage VZV infection.  
Coincidentally, we and others have reported quite efficient IE62 nuclear exclusion in late-stage 
VZV infections in multiple cell types, supporting the latter scenario and implying that IE62 may 
undergo nuclear export to facilitate nuclear exclusion (58).   
In this study, we sought to further delineate the processes involved in IE62 nuclear 
exclusion during VZV infection.  Utilizing the recently described VZV.GFP-66, we demonstrate 
for the first time that ORF66 is expressed with early kinetics, and that ORF66 expression and 
nuclear localization are not sufficient for IE62 nuclear exclusion.  Interspecies heterokaryon 
analyses revealed that IE62 undergoes Crm1-independent nuclear export, and IE62 amino acids 
733-995 were critical for this.  Similar analyses also uncovered IE62 DNA-binding and 
dimerization domain (DBDD)-dependent nuclear retention and poly-serine tract 
phosphorylation-dependent nuclear export.  These results begin to elucidate a complex cycle of 
IE62 nuclear import, retention and export during VZV infection, which ultimately controls the 
switch in IE62 function between transcriptional regulation and virion assembly. 
4.3 MATERIALS AND METHODS 
4.3.1 Cells, viruses and antibodies 
HEK-293T cells and MRC-5 human lung fibroblasts (ATCC, Manassas, VA), human melanoma 
(MeWo) cells (kindly provided by C. Grose, University of Iowa, Iowa City, IA) and the B6WT3 
murine fibroblast cell line (kindly provided by R. Hendricks, University of Pittsburgh, 
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Pittsburgh, PA) were maintained as previously detailed (58).  VZV.GFP-66 and VZV-S686A2 
have been described elsewhere (58, 61).  Briefly, VZV.GFP-66 was created using VZV-pOka 
cosmids, and expresses EGFP-tagged ORF66 in place of wild-type ORF66.  VZV-S686A2 was 
derived using the VZV bacterial artificial chromosome and encodes IE62 proteins (from both the 
ORF62 and ORF71 genes) carrying a point mutation (S686A), which renders IE62 resistant to 
ORF66-mediated nuclear exclusion (58).   
 Polyclonal rabbit antiserum directed against the IE62 protein (124) was used at 1:800 for 
immunofluorescence or 1:2500 for immunoblotting.  For primary detection of cellular antigens 
in immunofluorescence, we used a mouse monoclonal antibody against p230, a marker of the 
trans-Golgi network (BD-Biosciences, Pharmingen; used at 1:500), and a mouse monoclonal 
antibody specific for the human nuclear protein, Ku86 (Santa Cruz Biotechnology, Santa Cruz, 
CA; used at 1:200).  Alexa Fluor conjugated Fab fragments (goat anti-mouse or goat anti-rabbit; 
used at 1:400; Invitrogen Corp.) were used for secondary detection by immunofluorescence.  
Excitation spectra are indicated in the Figure Legends. 
4.3.2 Plasmids 
All plasmids were purified using Qiagen columns (Qiagen, Inc., Valencia, CA), according to the 
manufacturer’s instructions.  All IE62 ORF coordinates described here correspond to the 
sequenced and annotated VZV-Dumas strain.  pKCMV62, which expresses the full-length IE62 
protein under the control of the minimal HCMV IE promoter, has been previously described (58, 
124).  Several derivatives of this plasmid expressing truncated IE62 protein forms have been 
previously described:  pKCMV62∆26-602, pKCMV62∆161-506 and pKCMV62∆733-end 
pCMV62∆733-995, pCMV62∆968-end, pCMV62∆865-end pCMV62∆161-272 (127).  
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Additional IE62 internal truncation mutants were derived from pKCMV62 using primers with 
restriction endonuclease overhangs corresponding to natural restriction sites within the IE62 
ORF.  For these, one primer per set was designed to include a restriction site overhang attached 
to sequences internal to the native site, taking into account the open reading frame, to generate 
PCR fragments lacking specific regions.  Following PCR amplification, these were cloned into 
the pKCMV62 backbone.  These plasmids include: pCMV62∆272-347 using Mfe I (nt 814) ? 
Eco RV (nt 1246), with Eco RV internal; pCMV62∆735-853 using Bam HI (nt 2199) ? Pml I 
(nt 2901), with Pml I internal; and pCMV62∆942-968 using Bam HI ? Pml I, with Bam HI 
internal.  In some cases, the restriction sites used were not unique in the pKCMV62 backbone.  
For these, we prepared pKCMV62 by performing limiting digestion with ethidium bromide. To 
generate a deletion of the IE62 N-terminal poly-serine/acidic tract pSAT (pCMV62∆pSAT), we 
used a splicing by overlap extension (SOE) method (103).  In the first step, 5’ and 3’ overlapping 
IE62 fragments were generated by PCR amplification using external primers corresponding to 
the 5’ Mfe I and the 3’ Kpn I site (nt 1712), and extended internal complementary primers that 
lacked IE62 amino acids (aa) 352-375 (352VSSSSSSSSWGSSSEDEDD EPRRV375) (nt 1054-
1125).  Internal primers also carried a novel Eco RI site that was inserted by silent mutagenesis.  
The products from the first reaction were used to self-prime in a second PCR reaction, and the 
resultant fragment was cloned into pKCMV62 using the Mfe I and Kpn I restriction sites.  To 
generate pSAT mutations in which all serine residues were replaced with alanine 
(352VAAAAAAAAWGAAAEDEDDE PRRV375) (pCMV62pStoA) or glutamic acid 
(352VEEEEEEEEWGEEEEDEDDEPRRV375) (pCMV62pStoA), we inserted hybridized 
complementary oligonucleotides at the novel Eco RI site after ethidium bromide-mediated partial 
digestion of pCMV62∆pSAT.  Importantly, no changes other than the specific S?A or S?E 
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mutations described above were inserted in the IE62 sequence at this site.  A similar SOEing 
approach to used to generate a partial deletion of the DNA-binding and dimerization domain, 
pCMV62∆484-515 (484PSGETREGHWEDEAVRAARARYEASTEPVPLY515) (nt 1449-1545), 
using 5’ Eco RV and 3’ Kpn I primers in the first PCR step.  For this mutant, an internal Sac I 
site was inserted by silent mutagenesis in the internal primers.  All oligonucleotide primers were 
obtained from IDT Inc. (Coralville, IA), and PCR reactions were carried out using the 
proofreading polymerase Expand (Roche Applied Science, Indianapolis, IN).  The accuracy of 
all truncations and mutations of IE62 was verified by sequencing. 
4.3.3 Infections and transfections 
Cell-free VZV was prepared from VZV.GFP-66-infected MeWo cells exhibiting >75% EGFP-66 
fluorescence and CPE as follows: infected cells were harvested in the absence of trypsin; 
resuspended in ice-cold SPGA buffer (218 mM sucrose, 3.8 mM KH2PO4, 7.2 mM K2HPO4, 4.9 
mM sodium-glutamate, 1% BSA, 10% FBS; pH 8.0) to stabilize infectivity; vortexed 3 x 15 s 
with 0.5 mm glass beads; transferred to a fresh, pre-chilled tube; and cleared by centrifugation at 
4ºC.  Resultant supernatents were used to directly infect confluent MRC-5 fibroblasts on 24 x 30 
mm coverslips.  Each coverslip was exposed to cell-free VZV extract equivalent to ~1/6 of one 
T175 flask for 1 h at 37ºC, followed by medium replacement and fixation at the times indicated in 
the text.  For heterokaryon analyses in VZV-infected cells, VZV-S686A2 was used to infect 
MeWo cells grown on coverslips at a ratio of 1 infected cell to 50 uninfected cells.  All 
transfections were performed in slightly sub-confluent MeWo or HEK-293T cell cultures using 
the Lipofectamine 2000 reagent (Invitrogen Corp., Carlsbad, CA), according to the 
manufacturer’s instructions.   
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4.3.4 Interspecies heterokaryon assay 
All medium, buffers and solutions used in heterokaryon formation were warmed to 37ºC prior to 
use.  Transfected or infected human melanoma cells grown on coverslips were overlaid with an 
equal number of briefly trypsinized murine B6WT3 fibroblasts.  B6WT3 cells were allowed to 
settle and adhere, and then co-cultures were incubated in medium containing 100 µg/ml 
cycloheximide (CHX; Sigma-Aldrich, St. Louis, MO) for one hour at 37ºC, to inhibit protein 
expression.  To fuse cells and form interspecies heterokaryons, coverslips were first washed with 
1X PBS, and then subjected to 50% polyethylene glycol (PEG; Hybri-Max molecular weight 
3000-3700, Sigma-Aldrich, St. Louis, MO) in medium for exactly two minutes, followed by 
extensive washing with 1X PBS to remove PEG.  Subsequently, heterokaryons were incubated 
for an additional 3-4 hours at 37ºC in the presence of 100 µg/ml CHX to allow protein shuttling 
in the absence of additional protein expression, and then fixed with 4% paraformaldehyde for 15 
minutes.  In some experiments, the Crm1 inhibitor leptomycin B (LMB; LC Laboratories, 
Woburn, MA) was included in the pre- and post-fusion incubation media, and was used at 20 
ng/ml.  Pre-incubation in LMB experiments was performed for two hours to ensure efficient 
disruption of Crm1-mediated nuclear export. 
4.3.5 Immunological methods 
Indirect immunofluorescence, two-dimensional microscopy and image processing and 
immunoblotting was performed as previously described (58, 59).  Nuclei were identified and 
differentiated using Hoechst 33258 (Sigma-Aldrich). 
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4.4 RESULTS 
4.4.1 IE62 and ORF66 spatio-temporal dynamics in VZV-infected cells suggest both 
nuclear retention and nuclear export activities for IE62 
Recent reports have indicated that ORF66 is localized to both the nucleus and the cytoplasm 
during VZV infection (59, 219), but compartment-specific interactions with IE62 and the precise 
point of IE62 nuclear exclusion have not been assessed.  Additionally, while it assumed that 
ORF66 is expressed with early kinetics after the expression of IE62, this has not been 
experimentally demonstrated.  Such studies have been impeded, in part, by the lack of 
availability of a highly specific ORF66 antibody (127).  However, we have recently described a 
novel recombinant VZV, which expresses EGFP-tagged ORF66 in place of the wild-type gene 
under the control of the native promoter (VZV.GFP-66) (59).  Here, we utilized VZV.GFP-66 in 
cell-free infections to study ORF66 expression kinetics and the IE62-ORF66 spatio-temporal 
distribution relationship during VZV infection.  MRC-5 human lung fibroblasts were infected 
with cell-free VZV.GFP-66; fixed at 4, 8, 12, 16 and 24 hours post-infection (hpi); and stained 
with polyclonal rabbit anti-IE62 and monoclonal mouse anti-p230, a protein marker of the trans-
Golgi network (TGN).  As expected, initial inspection of IE62 and ORF66 localizations 
suggested some variability at time-points beyond 4 hpi, likely due to cell-to-cell variation in 
multiplicity of infection (MOI) or cell cycle stage upon viral entry.  Thus, to monitor the 
progression of VZV infection and quantitate IE62 and ORF66 localization dynamics, we 
assessed the specific cellular distribution patterns of IE62 and ORF66 in 20 individual cells from 
each time point.  This analysis revealed 5 progressive phenotypes of IE62-ORF66 distribution, 
and representative cells exhibiting each phenotype are shown in Figure 4-1.           
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At 4 hours post-infection (hpi), cellular debris from cell-free VZV extracts were 
detectable in the cytoplasm of all cells, and were both EGFP-autofluorescent and reactive with 
anti-IE62 antibodies.  Scattered individual cells displayed specific diffuse IE62 staining 
throughout the nucleoplasm, with 3-10 prominent nuclear foci that were distributed in a non-
polar manner, frequently in the vicinity of the nucleolus (Figure 4-1A; “62Nuc/No66”).  These 
cells did not express detectable levels of EGFP-66, establishing that IE62 is expressed and 
localizes to the nucleus in the absence of ORF66 expression at immediate early times post-
infection.  The TGN appeared normal in cells at 4 hpi, exhibiting peri-nuclear cisternal 
distribution.  Only ~20% of cells displayed IE62 nuclear localization in the absence of ORF66 
expression at 8 hpi, and the presentation of this distribution phenotype progressively declined by 
12 and 16 hpi.  At 8 hpi, the majority of cells (~80%) expressed detectable levels of GFP-66, 
which was distributed in one of two manners:  1) in fine, grainy foci evenly distributed 
throughout the nucleoplasm, with no apparent cytoplasmic distribution (Figure 4-1B; 
“62Nuc/66Nuc”); or 2) similar grainy nuclear distribution combined with diffuse cytoplasmic 
localization and some accumulation in the TGN (Figure 4-1C; “62Nuc/66Nuc high-Cyt low”).  
In both cases, IE62 exhibited nucleoplasmic staining with bright nuclear foci, and lacked the 
diffuse cytoplasmic forms observed in late-stage VZV-infected cells, similar to what was 
observed at 4 hpi.  The majority of ORF66 did not appear to co-localize with IE62 in these cells, 
although two slightly enlarged GFP-66 nuclear foci were observed in association with IE62 
nuclear foci in Figure 4-1B; and both IE62 and ORF66 were observed in one bright peri-nuclear 
focus at the opposite side of the nucleus from the TGN in Figure 4-1C.  Similar minor sub-
populations of co-localization were observed in many cells with these distribution phenotypes, 
suggesting these regions may be sites for an IE62-ORF66 interaction.  Interestingly, in cells 
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where cytoplasmic ORF66 expression was observed, IE62 nuclear foci appeared to have 
expanded and frequently localized near each other at one side of the nucleus (Figure 4-1C).  
These data clearly demonstrate that ORF66 expression and nuclear localization is not sufficient 
for IE62 nuclear exclusion at early times post-infection.    
A significant transformation in IE62 distribution was observed in 36% of cells at 12 hpi 
and 77% of cells by 16 hpi (Figure 4-1D; “62RC-Cyt/66Nuc high-Cyt high”).  Namely, abundant 
levels of IE62 accumulation were observed in the cytoplasm, and high levels of IE62 were 
recruited into large nuclear globules, which were identified as viral replication compartments 
(RCs) in other studies (Chapter 6).  Almost no IE62 signal was detected in nucleoplasmic areas 
that were not shrouded by the RC.  Concurrent with IE62 recruitment into RCs and accumulation 
of cytoplasmic forms, GFP-66 exhibited enhanced nuclear localization and accrual in bright foci 
in a circular arrangement, possibly surrounding the nucleolus.  The GFP-66 grainy nuclear 
distribution was no longer apparent, and nucleoplasmic GFP-66 displayed no specific 
accumulation in the RC compared to other regions of the nucleus.  In the cytoplasm, both GFP-
66 and IE62 co-localized with the TGN, which was no longer distributed in a peri-nuclear 
manner and was completely independent of the nucleus.  While GFP-66 was evenly distributed 
across the TGN cisternae, IE62 appeared to preferentially accumulate at one side, and did not 
completely overlap with GFP-66 fluorescence.  Notably, in the displayed micrograph, a cell 
adjacent to the late-stage VZV-infected cell exhibits IE62 nuclear foci in the absence of IE62 
nucleoplasmic staining or GFP-66 auto-fluorescence, indicating that this cell is newly infected 
(Figure 4-1D, arrowheads).  By 24 hpi, individually-infected cells were observed with high 
levels of cytoplasmic IE62 that did not co-localize with the TGN, and little or no nuclear IE62 
(Figure 4-1E; “62Cyt/66NucCyt”).  In these cells, GFP-66 was localized diffusely in the nucleus, 
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in putative nucleolar foci, diffusely in the cytoplasm and in the TGN, which formed a ring-
shaped structure similar to previously described Golgi reorganization in VZV-infected cells (59).  
Many newly infected cells were observed at the periphery of the late-stage infected cell 
boundaries, and these exhibited IE62 and GFP-66 localizations reminiscent of the phenotype 
shown in Figure 4-1D.  Syncytia exhibiting high levels of IE62 in the cytoplasm and nuclear RC 
were also observed at 24 hpi (Figure 4-1F; “Multi-Nucleate Syncytium”).  Interestingly, in some 
syncytial nuclei, ORF66 appeared to co-localize with early RC, further indicating a possible 
interaction with IE62 in this compartment (Figure 4-1F, arrowhead).    
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Figure 4-1 IE62 and ORF66 spatio-temporal relationship revealed by infection with cell-free VZV.GFP-66 
 
MRC-5 fibroblasts grown on coverslips were infected with cell-free VZV.GFP-66 extracts, 
incubated for 4, 8, 12, 16 or 24 h and fixed with 4% paraformaldehyde for 15 minutes.  
Permeabilized cells were stained with polyclonal rabbit anti-IE62 and monoclonal mouse anti-
p230, and staining patterns were assessed by EGFP auto-fluorescence or following staining with 
Alexa Fluor conjugated secondaries (goat anti-rabbit [ex 546] or goat anti-mouse [ex 647]), 
using epifluorescent microscopy.  (A-D) Representative micrographs show the first four stages 
of IE62 and ORF66 spatio-temporal distribution, and images were captured of cells fixed at 4 hpi 
(A), 8 hpi (B-C) and 16 hpi (D).  Each panel consists of an enlarged color-combined image with 
EGFP-66 (green), IE62 (red) and p230 (blue) fluorescence patterns; smaller black-and-white 
images of individual staining patterns, including Hoechst dye; and quantification of the 
percentage of cells displaying the depicted phenotype at 4, 8, 12, and 16 hpi.  Individual infected 
cells exhibiting the fifth IE62 and ORF66 distribution phenotype (E), and syncytia showing 
varying patterns (F) were readily observed at 24 hpi, and representative micrographs are shown 
exactly as described for (A-D), without quantification.  In all micrographs, the depicted protein is 
indicated in the lower left corner.   
 
Collectively, these data indicate that several factors may be involved in triggering IE62 
nuclear exclusion and eventual nuclear clearance during infection.  The predominant GFP-66 
nuclear localization throughout infection and its association with IE62 in early RC also suggests 
that ORF66-mediated IE62 phosphorylation could occur in the nucleus.  Hence, IE62 likely 
requires a nuclear export mechanism to facilitate nuclear exclusion in late-stage VZV infected 
cells.         
4.4.2 Interspecies heterokaryon analysis reveals IE62 nuclear shuttling capabilities 
To ascertain whether IE62 undergoes nuclear export, we utilized interspecies heterokaryon 
analysis with human melanoma (MeWo) cells either transfected with plasmids expressing IE62 
(pCMV62) or infected with VZV-S686A2.  VZV-S686A2 encodes an IE62 serine 686 to alanine 
(S686A) point mutation in both copies of the IE62 gene (ORF62 and ORF71), and the IE62 
protein in this virus is insensitive to ORF66-mediated nuclear exclusion (61).  Co-cultures of 
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transfected or infected human melanoma cells (donor cells) and murine B6WT3 fibroblasts 
(acceptor cells) were incubated with CHX for one hour to repress IE62 translation, treated with 
polyethylene glycol to fuse cells and form heterokaryons, and then incubated for an additional 3-
4 hours post-fusion in the presence of CHX to allow protein shuttling from donor to acceptor 
nuclei in the absence of new protein expression.  Cells were fixed and stained with antibodies 
against IE62; an antibody specific for the human 86 kDa sub-unit of the heterodimeric DNA end-
binding complex (huKu86), which is a non-shuttling nuclear resident protein (65); and Hoechst 
dye to identify nuclei.  Hoechst localizes to bright punctate foci in murine nuclei, but exhibits 
diffuse nuclear localization in primate cells, allowing for straight-forward resolution of nuclear 
species in heterokaryons.  Additionally, the huKu86 antibody does not recognize murine Ku86, 
thus providing an additional means of differentiation of donor and acceptor nuclei, as well as a 
specificity control for protein shuttling into acceptor nuclei.   
 In fusions performed with pCMV62-transfected MeWo cells, IE62 fluorescence was 
observed in Hoechst-punctate/huKu86-negative murine nuclei, displaying both diffuse 
nucleoplasmic fluorescence and some accumulation into foci at the periphery of the nucleolus.  
Similar staining patterns have been previously observed in cells expressing IE62 (58).  These 
results indicate that IE62 undergoes nuclear export in heterokaryons when expressed in the 
absence of additional VZV proteins (Figure 4-2A).  The maintenance of huKu86 in transfected 
Hoechst-diffuse donor human nuclei and its lack in the murine acceptor nuclei support the 
conclusion that IE62 nuclear export was authentic and not the result of decreased nuclear 
membrane integrity.  Typically, the IE62 fluorescent signal was more intense in donor nuclei 
relative to acceptor nuclei and was present only in murine nuclei in close proximity of the donor 
nucleus.  Importantly, we also detected IE62 nuclear shuttling in heterokaryons formed with 
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VZV-S686A2-infected cells (Figure 4-2B).  Similar results were observed in replicate 
experiments. 
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 Figure 4-2 IE62 shuttles to mouse nuclei in heterokaryons formed with both transfected cells expressing IE62 
and VZV-infected cells expressing IE62 that is resistant to nuclear exclusion 
 
MeWo cells were transfected with pCMV62 (A), or infected with VZV-S686A2 (B), and 
subjected to heterokaron formation at 48 h post-transfection or infection.  Cells were overlaid 
with murine B6WT3 fibroblasts, incubated with 100 µg/ml CHX for 1 hour at 37ºC, fused with 
50% PEG, and incubated with CHX for an additional 3-4 hours to allow for protein shuttling into 
murine nuclei.  Cells were fixed and stained with polyclonal rabbit anti-IE62 and monoclonal 
mouse anti-huKu86, and proteins were detected by indirect immunofluorescence and 
epifluorescent microscopy following staining with Alexa Fluor-conjugated goat anti-rabbit (ex 
488) and goat anti-mouse (ex 546) secondaries.  In each panel, an enlarged color-combined 
image of Hoechst (blue), IE62 (green), and huKu86 (red) distribution in heterokaryons is shown, 
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with individual staining patterns for each in smaller black-and-white panels (i, ii, and iii, 
respectively).  The depicted proteins are indicated in each micrograph panel.  White arrowheads 
in colored panels point out murine nuclei contained within the heterokaryon. 
4.4.3 IE62 uses a Crm1-independent mechanism for nuclear export 
Nuclear export of large proteins occurs through karyopherin receptors called exportins.  Many 
proteins are transported out of the nucleus by the exportin-1 protein (a.k.a. Crm1), which 
recognizes leucine-rich consensus motifs (φ-x2-3-φ-x2-3-φ-x-φ; φ=[L,I,V,F,M], x=any amino 
acid) (140).  Amino acids that roughly conform to this consensus are interspersed throughout the 
IE62 primary sequence, and we hypothesized that IE62 may interact with Crm1 to facilitate 
nuclear export.  To address this, we performed heterokaryon analysis of pCMV62-transfected 
MeWo cells incubated in the presence or absence of 20 ng/ml leptomycin B (LMB), a specific 
inhibitor of Crm1-mediated nuclear export (246).  As shown in Figure 4-3A, IE62, but not 
huKu86, shuttling was readily observed in the presence of LMB, suggesting that IE62 nuclear 
export does not utilize the Crm1 export receptor.  Interestingly, IE62 was more prominently 
localized to bright peri-nucleolar speckles in both donor and acceptor nuclei with LMB co-
incubation (Figure 4-3A). 
 Since we did not observe IE62 shuttling in every heterokaryon, either in the presence or 
absence of LMB, we considered the possibility that LMB reduced the efficiency of IE62 nuclear 
export without completely abrogating export in all cases.  To determine whether LMB partially 
affects IE62 shuttling or has no effect, we quantified the percentage of heterokaryons exhibiting 
detectable IE62 fluorescence in murine nuclei, in the presence or absence of LMB (Figure 4-3B).  
To eliminate bias, IE62-expressing nuclei were identified by scanning multiple regions of 
coverslips in straight lines, and all heterokaryons with expressing nuclei within a field of 
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observation were assessed for IE62 nuclear shuttling.  As previously described, the integrity of 
the MeWo nuclear membrane was established by maintenance of huKu86 fluorescence and the 
lack of huKu86 fluorescence in murine nuclei.  In two independent experiments, we counted a 
total of 54 heterokaryons incubated without LMB and 76 heterokaryons incubated with LMB, 
and we report that LMB induced no detrimental effects on IE62 shuttling.  On average, shuttling 
into murine nuclei was observed in ~50% of heterokaryons in both cases.  Thus, IE62 nuclear 
export does not rely upon Crm1, and instead utilizes a Crm1-independent mechanism to mediate 
IE62 clearance in late-stage VZV infections.  In support of this, efficient IE62 nuclear exclusion 
was observed in VZV-infected cells incubated with the same amount of LMB (data not shown). 
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 Figure 4-3 IE62 shuttling in heterokaryons incubated with the Crm1 nuclear export inhibitor, LMB 
Heterokaryon analyses were performed in pCMV62-transfected MeWo cells in the presence or 
absence of 20 ng/ml leptomycin B (LMB).  (A) A representative heterokaryon incubated with 
LMB, shown exactly as described in Figure 4-2, and clearly showing IE62 shuttling to a murine 
nucleus.  In the large panel, a color-combined image is shown of Hoechst in blue, IE62 in green, 
and huKu86 in red; while individual staining patterns for each in smaller black-and-white panels 
are indicated by i, ii, and iii, respectively.  The white arrowhead indicates the murine nucleus.  
(B) Quantification of the per cent shuttling observed in parallel cultures with and without LMB, 
from two independent experiments.  The number of total heterokaryons quantified for each 
condition in two replicate experiments is shown above each bar. 
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4.4.4 Distinct nuclear retention and nuclear export domains map to the IE62 N and C 
termini 
To begin to identify the IE62 regions involved in nuclear export, we performed similar 
heterokaryon analyses and quantifications of nuclear shuttling in cells transfected with plasmids 
expressing truncated IE62 peptides lacking large segments of either the N or C terminus (Figure 
4-4).  Surprisingly, two peptides consisting of predominantly C-terminal IE62 amino acids 
(IE62∆26-602 and IE62∆161-506) exhibited highly promiscuous shuttling into most surrounding 
nuclei, which was observed in nearly 100% of heterokaryons quantified (Figure 4-4B).  An 
example of an IE62∆161-506 heterokaryon is shown in Figure 4-4C.  Both IE62∆26-602 and IE62∆161-
506 exhibited IE62 nuclear localization with punctate foci throughout the nucleoplasm, but no 
accumulation was observed in the nucleolar region.  Importantly, both peptides were resolved at 
the expected molecular mass by SDS-PAGE (Figure 4-4A), and were at least two times larger 
than the cutoff for free diffusion across the NPC (40 kDa).  Thus, it appears that the IE62 N-
terminal region may be important for nuclear retention, whereas the C-terminus, or possibly the 
first 26 amino acids, contains sequences involved in nuclear export.  We point out, however, that 
the enhanced expression of these peptide mutants with respect to full-length IE62 may also 
contribute to the observed efficient nuclear shuttling phenotype (Figure 4-4A). 
 C-terminal truncation mutants, IE62∆968-end and IE62∆865-end, shuttled with similar 
efficiency as full-length IE62.  In marked contrast, deletion of the C-terminal half of IE62 
(IE62∆733-end) and an internal truncation mutant (IE62∆733-995) displayed almost no ability to 
shuttle to murine nuclei in heterokaryon assays.  While IE62∆733-end was detected at lower levels 
by polyclonal IE62 antiserum in both heterokaryons and immunoblots (Figure 4-4A and data not 
shown), IE62∆733-995 was expressed at least as efficiently as full-length IE62 (Figure 4-4A, D).  
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This supports data acquired with N-terminal truncation peptides suggesting that C-terminal 
motifs were involved in nuclear export, and indicates that the IE62 733-995 region is critical for 
this IE62 activity. 
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Figure 4-4 Analysis of truncated IE62 peptide shuttling in heterokaryons 
(A) Immunoblot analysis of IE62 peptide sizes and expression levels.  Lysates of 293T cells 
expressing IE62 peptides were separated by SDS-PAGE, transferred to PVDF and probed with a 
polyclonal rabbit anti-IE62 antibody, and peptides were detected following incubation with 
horseradish peroxidase conjugated goat anti-rabbit secondaries.  Protein size markers (kDa) are 
indicated to the left of the immunoblot panel, and letters or numbers corresponding to the 
transfected peptide are shown above each lane.  A map of full-length IE62 and truncation 
peptides is shown to the right of the immunoblot panel, and includes the peptide lane numbers. 
The red line on full-length IE62 represents the location of the NLS.  (B) Bar graph of per cent 
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shuttling of truncated IE62 peptides in heterokaryons.  Results are shown as a mean (±SEM) 
from two independent experiments, and the total number of heterokaryons quantitated is denoted 
at the right.  (C and D)  Representative micrographs of peptides exhibiting hyper-shuttling (C; 
IE62∆161-506) or reduced shuttling (D; IE62∆733-995) phenotypes.  In the large panels, a color-
combined image is shown of Hoechst in blue, IE62 in green, and huKu86 in red; while individual 
staining patterns for each in smaller black-and-white panels are indicated by i, ii, and iii, 
respectively.  White arrowheads in colored panels point out murine nuclei contained within each 
heterokaryon.  UT=untransfected; FL=full-length. 
 
4.4.5 Delineation of functional N-terminal domains involved in nuclear retention 
The IE62 N-terminus contains a potent activation domain within the first 83 amino acids (40, 
195), a DBDD between amino acids 468 and 642 (23, 234, 235, 247), and an intervening 
segment involved in binding to multiple cellular transcriptional regulators and viral factors (22, 
37, 157, 194, 209, 225) (see Figure 4-7).  One noteworthy feature of the intervening segment is a 
tract of repeated serines followed by multiple acidic residues, which is a likely site for 
phosphorylation by both cellular casein kinase II (CKII) and the viral ORF47 protein kinase 
(124).  Since only the activation domain remained intact in the IE62∆161-506 peptide, it was 
unclear whether IE62 nuclear retention occurred as a result of its interaction with cellular 
proteins or through its DNA binding activities.  To delineate the regions responsible for nuclear 
retention, we developed plasmids expressing several smaller N-terminal truncations and tested 
peptide shuttling in heterokaryons, as described above (Figure 4-5).  IE62∆161-272 and IE62∆272-347 
exhibited nuclear shuttling in nearly 50% of heterokaryons, similar to full-length IE62, indicating 
that nuclear retention functions were not contained within these regions (Figure 4-5B).  In 
contrast, deletion of a short N-terminal portion of the IE62 DBDD (IE62∆484-515) resulted in 
efficient nuclear shuttling in 100% of heterokaryons (Figure 4-5B and C).  These results indicate 
that IE62 DNA-binding or dimerization activities are responsible for IE62 nuclear retention.  
 105 
Notably, the IE62∆484-515 peptide was distributed in a manner similar to that exhibited by IE62∆26-
602 and IE62∆161-506, indicating that the integrity of the DBDD is critical for the proper 
distribution of IE62 within the nucleus.  
 Unexpectedly, we observed enhanced nuclear retention and association with nucleolar 
foci, combined with no IE62 shuttling for a truncated peptide lacking only the N-terminal poly-
serine/acidic tract (pSAT) (IE62∆352-375) (Figure 4-5B and D).  Since this region includes 11 
serine residues and is likely a significant target for cellular kinases (58), we postulated that its 
contribution to nuclear export may involve phosphorylation.  To test this, we inserted a fragment 
into the IE62∆352-375 deletion mutant plasmid, which encoded poly-alanine (poly-A) in place of 
poly-serine (poly-S) but retained all the natural acidic residues (referred to as IE62∆polyStoA).  In 
heterokaryon analyses, the IE62∆polyStoA protein behaved similar to the IE62∆352-375 truncated 
peptide, indicating that the serine residues in this region are critical for its role in facilitating 
IE62 nuclear export (Figure 4-5B and E).  Some nuclear shuttling ability was rescued in an IE62 
insertion mutant that expressed poly-glutamic acid (E) in place of poly-S (Figure 4-5B), although 
it was inefficient, providing support for the conclusion that phosphorylation of the IE62 pSAT is 
involved in nuclear export. 
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Figure 4-5 Heterokaryon analysis reveals IE62 N-terminal domains involved in both nuclear retention and 
nuclear shuttling 
(A) A map of peptide truncation and insertion locations.  For the pSAT deletion and insertion 
mutations, the modified regions are shown in single letter amino acid code below the respective 
peptide map.  (B) Bar graph of per cent shuttling of each peptide, with the total number of 
heterokaryons quantitated for each peptide indicated above the corresponding bar.  (C-E) 
Representative heterokaryons for IE62∆414-506, IE62∆352-375, and IE62pStoA, respectively.  In the 
large panels, a color-combined image is shown of Hoechst in blue, IE62 in green, and huKu86 in 
red; while individual staining patterns for each in smaller black-and-white panels are indicated 
by i, ii, and iii, respectively.  White arrowheads point out murine nuclei contained in the 
heterokaryons. 
 107 
4.4.6 Short truncations in the IE62 735-995 region reveal unexpected phenotypes in 
interspecies heterokaryon analyses 
Two plasmids expressing IE62 with short deletions in the 735-995 region implicated in nuclear 
export were assessed for shuttling capabilities in heterokaryons (Figure 4-6).  Curiously, an 
IE62∆735-853 peptide was not able to localize to the nucleus at all (Figure 4-6B), despite the 
presence of the IE62 NLS at aa 677-685.  We suspect that deletion of amino acids near to the 
IE62 NLS (aa 677-685) interfered with recognition by karyopherin transport receptors.  In direct 
contrast, deletion of a 26 amino acid segment from IE62 942-968 resulted in highly efficient 
IE62 nuclear export and localization in murine nuclei in every heterokaryon observed (Figure 4-
6C).  Additionally, IE62∆942-968 lacked the ability to form nucleolar foci, implying that nucleolar 
association may be involved in IE62 nuclear retention. 
 108 
 Figure 4-6 Peptides truncated within the first 250 amino acids of IE62 region 3 reveal unexpected behaviors 
in heterokaryon analyses 
 
(A) Map of truncated IE62 peptides.  (B and C)  Representative heterokaryons for IE62∆735-853 
and IE62 ∆942-968, respectively, are shown.  In the large panels, a color-combined image is shown 
of Hoechst in blue, IE62 in green, and huKu86 in red; while individual staining patterns for each 
in smaller black-and-white panels are indicated by i, ii, and iii, respectively. 
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4.5 DISCUSSION 
The data presented here provide the first evidence that IE62 is a nuclear shuttling protein in 
VZV-infected cells, and also strongly suggest that IE62 nuclear exclusion may depend on 
phosphorylation by kinases in addition to ORF66.  Independent deletion of two IE62 segments, 
including an N-terminal poly-S tract and aa 733-995, resulted in abrogation of IE62 nuclear 
export.  The observation that poly-S to A, but not poly-S to E, substitutions resulted in a similar 
inability to undergo nuclear shuttling strongly argue that IE62 nuclear export was regulated by 
phosphorylation in the pSAT region.  Minimal disruption of the IE62 DBDD or deletion of aa 
942-968 induced a hyper-shuttling phenotype, suggesting that IE62 nuclear retention also 
contributes to its steady-state cellular distribution.  These results imply that IE62 cellular 
localization is regulated by a complex cycle of molecular interactions involving nuclear import 
and retention, phosphorylation induced nuclear export, and phosphorylation-dependent nuclear 
exclusion.                
The IE62-ORF66 spatio-temporal relationship in VZV-infected cells suggested that 
factors in addition to ORF66 contribute to the regulation of IE62 cellular location during VZV-
infection.  We demonstrated that ORF66 is expressed with early gene kinetics, as ORF66 
fluorescence became visible 4-8 hpi, after IE62 was expressed and accumulated in the nucleus.  
Since the mechanism of ORF66-mediated nuclear exclusion likely involves inhibition of IE62 
nuclear import, these data implied that IE62 must undergo nuclear export to facilitate efficient 
nuclear clearance during late-stage infection.  Regarding the cellular site of IE62 
phosphorylation, a fraction of ORF66 was observed co-localized with expanding IE62 dots in the 
nucleus in very early infection when both ORF66 and IE62 were exclusively nuclear, and also in 
pre-RC.  These may represent potential sites of IE62-ORF66 interaction and phosphorylation; 
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and as abundant levels of cytoplasmic IE62 were not observed until 12 hpi, this further suggests 
that an additional switch may be required to sever IE62 tethering in the nucleus or promote IE62 
nuclear export during later stages of infection.  Cytoplasmic co-localizations were also observed, 
and thus we cannot rule out the possibility of ORF66-mediated IE62 phosphorylation in this 
compartment.    
Consistent with the indirect immunofluorescence studies, interspecies heterokaryon 
analyses revealed that IE62 undergoes nuclear export both when expressed alone and in the 
context of VZV infection.  However, IE62 nuclear export does not occur through the Crm-1 
export receptor, which mediates cytoplasmic transport of protein cargoes bearing leucine-rich 
nuclear export motifs.  Additional factors involved in mediating nuclear export of cellular 
proteins through the RanGTP-mediated nuclear export pathway include CAS, the specific export 
receptor for karyopherin α; exportin (Exp) 4, which facilitates nuclear export of eIF5a; Exp 6, the 
nuclear export receptor for profilin/actin; and Exp 7, which carries p50RhoGAP and 14–3–3 
sigma proteins into the cytoplasm (reviewed in (140)).  As no specific nuclear export consensus 
motif has been elucidated for any of these, it is currently unclear whether IE62 contains 
sequences responsible for interaction with one of these alternate export factors.  Calreticulin has 
recently been shown to mediate export of many hormone nuclear receptors in a Ca2+-
dependent/Ran-independent manner through recognition of an export signal consisting of the 
DNA-binding domain (25, 98, 99).  However, since the IE62 motifs involved in nuclear export 
(aa 733-995 and the N-terminal pSAT) map to regions outside of the IE62 DBDD, it seems 
unlikely that IE62 utilizes this pathway for nuclear clearance.  Additional pathways exist for the 
nuclear export of RNA species, and one of these is hijacked by the herpesvirus proteins of the 
ICP27 family.  ICP27 and its orthologs transport intronless viral mRNA out of the nucleus, and 
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utilize the cellular mRNA export machinery, including TAP and Aly/REF to facilitate nuclear 
export (36, 159, 245).  IE62 is not an ICP27 ortholog, but we postulate that this pathway could 
be involved in IE62 nuclear export, nonetheless.  The identification of the factors involved in 
IE62 nuclear export is currently under investigation. 
Surprisingly, deletion of the N-terminal pSAT resulted in abrogation of IE62 nuclear 
shuttling abilities and enhanced association with nuclear subdomains that localized at the 
periphery of the nucleolus.  Our data indicate that the serine residues contained within this motif 
are critical for its role in IE62 nuclear export, and IE62 proteins containing phospho-mimetic 
substitutions retained the ability to shuttle in heterokaryon analyses.  This implies that IE62 poly-
S phosphorylation may be involved in the promoting IE62 nuclear export.  We conjecture that 
this could occur through one of three mechanisms: i) the phosphorylated pSAT may be directly 
recognized by a nuclear transport receptor; ii) pSAT phosphorylation may disrupt specific IE62 
interactions that mediate nuclear retention; or iii) pSAT phosphorylation may induce an overall 
conformational change, resulting in unmasking of an IE62 nuclear export motif.  In VZV-
infected cells, the pSAT is likely a major substrate for phosphorylation by both cellular CKII and 
VZV ORF47 protein kinases (58, 120).  Interestingly, VZV expressing kinase inactive forms of 
ORF47 induce enhanced IE62 nuclear accumulation, and it has been hypothesized that ORF47 
kinase activity may be required to release IE62 from the nucleus during late stage infection (22).  
Thus, we postulate that ORF47-mediated phosphorylation of IE62 may function in its nuclear 
export.  This would not explain the ability of IE62 to export in transfected cells expressing only 
the IE62 protein, but since CKII and ORF47 share similar consensus sequences and are known to 
cooperatively phosphorylate VZV protein targets during infection, CKII activity may 
compensate for the absence of ORF47 in transfected cells.  It will be interesting to determine 
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whether co-expression of ORF47 in IE62 heterokaryons induces enhanced IE62 nuclear 
shuttling.    
In addition to nuclear export activities, our studies have revealed that IE62 is retained in 
the nucleus in a manner dependent on the integrity of the DBDD, as IE62 peptides containing 
disruptions in this region exhibited enhanced shuttling in heterokaryon analyses.  This suggests 
that dimerization-dependent protein:protein interactions or an association with DNA may either 
mask the IE62 nuclear export motif or simply override recognition by a nuclear export receptor 
due to a higher affinity interaction.  The fact that the IE62 DBDD contributes to nuclear retention 
in transfected cells also suggests a possible association with cellular DNA in the absence of 
additional VZV gene expression.  Given the proximity of the N-terminal pSAT to the DBDD 
(Figure 4-7), it is possible that pSAT phosphorylation induces a disruption of DBDD-mediated 
interaction in the nucleus.  Surprisingly, an IE62 peptide with a short deletion at aa 942-968, 
within one region determined to be critical for IE62 nuclear export, was independently involved 
in nuclear retention.  While the specific reason for enhanced nuclear export observed with this 
peptide was not entirely clear, it was apparent that its nucleolar targeting ability was lost.  This is 
in direct contrast with the IE62 pSAT mutant, in which enhanced nucleolar accumulation 
correlated with a loss in IE62 shuttling ability.  Thus, by extension this nucleolar targeting may 
be one determinant responsible for IE62 nuclear retention, and a nucleolar targeting sequence 
may exist within the aa 942-968 region. 
The evidence presented here strongly indicates that IE62 undergoes nuclear export in the 
context of VZV infected cells, and that this activity is intrinsic to a structural motif within the 
IE62 protein.  Initially, we identified aa 733-995 as critical for IE62 nuclear export, but 
subsequent deletions in this region revealed unexpected phenotypes, including lack of nuclear 
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import or hyper-shuttling.  Unusual activities imparted by these mutations may reflect disruption 
of IE62 tertiary structure involved in mediating specific protein:protein interactions.  Thus, 
future experiments aimed at further delineation of specific motifs involved in both nuclear export 
and nuclear retention will benefit from more specific amino acid targeting to prevent gross 
changes in IE62 overall structure.  Studies are currently underway to determine whether aa 733-
995 are sufficient for the nuclear exclusion of a constitutively nuclear heterologous control 
protein, and to delineate any specific residues within this region that contribute to nuclear export.        
In sum, we have identified novel nuclear export and nuclear retention motifs for the VZV 
IE62 protein.  For comparison with known IE62 regions required for specific protein:protein 
interactions or functional activities, these are summarized in Figure 4-7.  We propose a model in 
which IE62 localizes to the nucleus during immediate early stages of infection and is excluded 
from the nucleus in late infection due to active nuclear export and cooperative phosphorylation 
by the VZV ORF66 and ORF47 protein kinases.  These interactions ultimately regulate the 
switch between IE62 transcriptional regulatory processes and its subsequent re-direction to the 
cytoplasm for virion assembly. 
 114 
 Figure 4-7 Updated schematic of IE62 protein:protein interaction and functional domains 
 
(A) Scaled representation of the IE62 primary structure, showing regions important for 
interactions with viral regulatory proteins (above) and cellular transcriptional factors (below).  
Five regions of either low (dark gray; regions 1, 3 and 5) or high (light gray; regions 2 and 4) 
homology with the HSV-1 ICP4 ortholog are indicated.  (B) Domains required for IE62 
functional activities, depicted with respect to regions 1-5.  Black boxes indicate previously 
defined functional motifs, while the gray boxes represent novel functional domains described 
herein.  (C) Motifs phosphorylated by viral kinases. 
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5.1 ABSTRACT 
We show here that the varicella-zoster virus (VZV) open reading frame (ORF) 66 protein kinase 
is one mechanism employed to reduce class I major histocompatibility complex (MHC-I) surface 
expression in VZV-infected cells.  Cells expressing enhanced green fluorescent protein-tagged 
functional and inactivated ORF66 (GFP-66 and GFP-66kd) from replication-defective 
adenovirus vectors revealed that ORF66 reduced MHC-I surface levels in a manner mostly 
dependent on kinase activity.  Cells infected with recombinant VZV expressing GFP-66 
exhibited a significantly greater reduction in MHC-I surface expression over that observed in 
cells infected with VZV disrupted in GFP-66 expression.  MHC-I maturation was delayed in its 
transport from the endoplasmic reticulum through the Golgi in both adenovirus-transduced cells 
expressing only GFP-66 and in VZV-infected cells expressing high levels of GFP-66, and this 
was predominantly kinase-dependent.  MHC-I levels were reduced in VZV-infected cells and 
analyses of intracellular MHC-I revealed accumulation of folded MHC-I in the Golgi region, 
irrespective of ORF66 expression.  Thus, the ORF66 kinase is important for VZV-mediated 
MHC-I downregulation, but additional mechanisms also may be involved.  Analyses of the VZV 
ORF9a protein, the ortholog of the bovine herpesvirus 1 (BHV-1) transporter associated with 
antigen processing (TAP) inhibitor, UL49.5, revealed no effects on MHC-I.  These results 
establish a new role for viral protein kinases in immune evasion, and suggest that VZV utilizes 
unique mechanisms to inhibit antigen presentation.  
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5.2 INTRODUCTION 
Varicella-zoster virus (VZV) is the human-restricted member of the herpesvirus subfamily, 
Alphaherpesvirinae, which causes chickenpox upon primary infection and herpes zoster 
(shingles) following reactivation from a prolonged period of neuronal latency in the sensory 
ganglia.  Based on the current model of pathogenesis (137), efficient dissemination, disease and 
establishment of latency within the infected host requires VZV growth in multiple cell types.  
Following inhalation, VZV is spread to epidermal sites of replication by a T-lymphocyte-
associated viremia.  Infection likely occurs in the tonsils, with VZV preferentially infecting 
memory CD4+ T lymphocytes (138).  These T cells can home to and mediate infection of human 
skin allografts in the severe combined immunodeficient (SCID)-hu model of VZV infection 
(139).  In humans, skin lesions occur 10-21 days following the initial inoculation, and VZV 
DNA is detected in peripheral blood mononuclear cells during primary infection (49, 158).  VZV 
accesses axons of innervating sensory neurons in the skin and establishes a life-long latent 
infection in neurons of the dorsal root ganglia.  In contrast with latency of the closely related 
herpes simplex virus type 1 (HSV-1), VZV latency is characterized by persistent transcription, 
and possibly expression, of several viral lytic genes including ORFs 4, 21, 29, 62, 63 and 66 (44, 
45, 170).  This does not appear to stimulate a ganglionic infiltration of T cells (106, 240).  VZV 
may also productively or abortively infect antigen presenting cells, including immature and 
mature dendritic cells (3, 105, 179), monocytes, macrophages and B-lymphocytes (8, 80, 108, 
133).      
The lymphotrophic nature of VZV and its ability to sustain infection in multiple cell 
types over a prolonged period suggest that VZV pathogenesis benefits from immune evasion 
mechanisms that limit antigen presentation.  Several reports have also indicated a possible 
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chronic, non-inflammatory expression of viral lytic antigens during latency (44, 45, 170, 240), 
which may be suggestive of ongoing virus directed immune evasion.  Accordingly, VZV reduces 
the surface expression of CD8+ T lymphocyte (CTL)-restricted class I major histocompatibility 
complexes (MHC-I), both in cultured cells and in thymic T cells in the SCID-hu model (2, 38).  
Two proteins from closely related alphaherpesviruses, HSV-1 and 2 ICP47 and bovine 
herpesvirus 1 (BHV-1) UL49.5, inhibit the TAP complex using distinct mechanisms to prevent 
peptide transport into the lumen of the endoplasmic reticulum (ER) (4, 134, 232).  VZV does not 
encode an ICP47 ortholog, and no function in modulation of antigen presentation has been 
shown for the VZV UL49.5 ortholog, ORF9a (134).  Furthermore, in VZV-infected cells, it has 
been suggested that MHC-I is processed through the cis-Golgi normally, but is prevented from 
accessing the cell surface (2).  These observations imply that VZV–encoded mechanisms of 
MHC-I surface downregulation may be different from those of HSV-1 and 2 and BHV-1.   
A previous study reported that transient expression of the VZV ORF66 protein kinase 
resulted in reduced MHC-I surface expression in human foreskin fibroblasts (HFF) (2).  The 
ORF66 protein is a serine/threonine (ser/thr)-specific protein kinase with homology to the 
alphaherpesvirus US3 kinase family.  Similar to other US3 kinases, ORF66 recognizes and 
phosphorylates serines preceded by several basic amino acids (58).  While VZV that does not 
express ORF66 is only moderately impaired for replication in most cell cultures, ORF66 
expression is required for efficient replication in cultured T-lymphocytes and in thy-liv implants 
in the SCID-hu model (174, 220, 224).   The only known target of ORF66 is the VZV major 
transcriptional regulatory protein, IE62. ORF66 phosphorylates IE62 adjacent to its nuclear 
localization signal, leading to IE62 cytoplasmic accumulation in late-stage VZV-infected cells, 
and allowing for IE62 inclusion into the virion tegument (58, 123, 124).  However, cellular 
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targets of the ORF66 protein kinase have been suggested from recent studies, in that ORF66 may 
contribute to anti-apoptotic mechanisms and evasion of a host cell response to interferon-γ (220).     
In this work, the effects of the ORF66 kinase on MHC-I surface expression were 
characterized both in the context of VZV infection, and in the absence of other VZV proteins.  
Using novel adenovirus vectors and recombinant VZV expressing functional or altered green 
fluorescent protein (GFP)-tagged ORF66 kinase genes, we show that MHC-I surface expression 
is downregulated by ORF66 in a kinase-dependent manner, and that ORF66 contributes to MHC-
I downregulation during VZV infection.  The ORF66 kinase activity delayed MHC-I transport 
through the cis/medial-Golgi complex.  Inhibition of MHC-I surface expression by intracellular 
retention in the early secretory compartment is a function that has not been attributed to any 
other viral protein kinase, and represents a novel role for a US3 family kinase in regulating the 
cellular environment during viral infection.  We also show that VZV has ORF66-independent 
mechanisms that contribute to reduced MHC-I surface expression.  
 
5.3 MATERIALS AND METHODS     
5.3.1 Cells 
The HEK-293 and HEK-293T cell lines (ATCC, Manassas, VA), MeWo cells (kindly provided 
by C. Grose, University of Iowa, Iowa City) and MRC-5 human lung fibroblasts (ATCC) were 
maintained as described previously (58).  
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5.3.2 Antibodies 
The monoclonal antibodies used for flow cytometric analyses were anti-human transferrin 
receptor (TfR1 or CD71) (clone T56/14, IgG1; Caltag Laboratories, Burlingame, CA) (purified, 
R-PE conjugated and used at 1:100 dilution); an antibody recognizing class I heavy chains in 
complex with β-2 microglobulin (β2M) (clone G46-2.6, IgG1κ; BD Biosciences Pharmingen, 
San Jose, CA) (purified, PE-Cy5 conjugated and used at 1:20 dilution); and isotype control 
antibodies consisting of R-PE-conjugated IgG1 (Caltag Laboratories) and PE-Cy5 conjugated 
IgG1κ (BD Biosciences Pharmingen), used at the same respective dilutions. A rabbit polyclonal 
antibody recognizing VZV IE62 and a mouse monoclonal antibody that recognizes the nine 
amino-acid epitope (YPYDVPDYA) from influenza hemagglutinin (HA) have been previously 
described (58).  The mouse monoclonal antibody W6/32 was obtained from Santa Cruz 
Biotechnology (Santa Cruz, CA) and used at 1 µg/ per immunoprecipitation, or at a dilution of 
1:50 for immunofluorescence.  Total class I heavy chains were immunoprecipitated with a 
polyclonal rabbit antibody to class I heavy chain cytoplasmic tail, designated UCSF2, at 1 µl per 
reaction (a kind gift of R. Salter, University of Pittsburgh).  Golgi complexes were identified 
using rabbit anti-mannosidase II (mann II) at a 1:50 dilution (Chemicon, now a part of Millipore, 
Temecula, CA).  A mouse monoclonal anti-α-tubulin (Sigma-Aldrich, St. Louis, MO) was used 
at 1:2000 for western blots and at 1 µg per immunoprecipitation.   Alexa Fluor conjugated Fab 
fragments (goat anti-mouse or goat anti-rabbit; used at 1:400; Invitrogen Corp.) were used for 
secondary detection in immunofluorescence as previously detailed (58).   
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5.3.3 Plasmids 
All plasmids were purified using Qiagen columns (Qiagen, Inc., Valencia, CA), according to the 
manufacturer’s instructions. All oligonucleotides were obtained from IDT Inc. (Coralville, IA).  
The proofreading polymerase Expand (Roche Applied Science, Indianapolis, IN) was used to 
generate all PCR fragments, and accuracy was verified by sequencing.  pGK2-HA66 expressing 
N-terminal HA tagged ORF66, and a similar plasmid expressing ORF66 kinase inactivated by 
D206E and K208R mutations (pGK2-HA66kd) have been detailed elsewhere (124).  A new 
derivative, pGK2-HA66s, was generated from pGK2-HA66 by insertion of a double-stranded 
oligonucleotide that placed stop codons in all three reading frames (5’- 
CGCGCTAGACTAGTCTAG –3’) into the Mlu I site at ORF66 amino acid 84.   To generate 
EGFP-tagged ORF66 fusion proteins, the HA-tagged ORF66 genes from pGK2-HA66, pGK2-
HA66kd and pGK2-HA66s were PCR-amplified using primers that added a unique Bgl II site 
proximal to the initiating ATG and a Hind III site following the stop codon.  Digested PCR 
products were cloned into pEGFP-C1 (Clontech, Mountain View, CA) and the resultant plasmids 
will be referred to as pGFP-66, pGFP-66kd and pGFP-66s.  A plasmid expressing IE62 with an 
in-frame carboxyl-terminal dsRed2 fusion inserted at amino acid 1309 (pCMV62-dsRed2) was 
generated in the previously described pK-CMV62 backbone (124), as follows.  An Mlu I-Tth111 
I fragment representing the C-terminal portion of IE62 was replaced with a PCR-generated 
product that inserted unique Avr II and Bgl II sites at the end of the IE62 open reading frame.  
This allowed the in-frame insertion of an Nhe I-Bgl II fragment containing the entire dsRed2 
gene from pdsRed2-N1 (Clontech), at the unique Avr II-Bgl II sites.  To express VZV ORF9a 
and ORF50, each gene was PCR-amplified using extended oligonucleotide primers to add EcoR 
I and Not I over-hangs, and subsequently cloned into pCDNA3.1 (Invitrogen, Corp.) to generate 
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pKORF9a and pKORF50.  The transfection reporter plasmid pTK-EGFP, which expresses EGFP 
under the control of the HSV-1 thymidine kinase (TK) promoter, has been detailed elsewhere 
(51).  The plasmid expressing the K3 gene from Kaposi’s sarcoma herpesvirus (KSHV) in the 
pCDNA3.1 backbone was a kind gift from F. Jenkins, University of Pittsburgh, Pittsburgh, PA. 
5.3.4 Derivation of replication defective adenoviruses 
Replication defective adenoviruses expressing GFP-66 or GFP-66kd (referred to as Ad.GFP-66 
and Ad.GFP-66kd) were derived using the Adeno-X Tet-Off system (Clontech).  Digestion of 
pGFP-66 and pGFP-66kd with Nhe I and Hind III released the genes for cloning into the 
adenovirus intermediate vector pTRE-Shuttle2. Genes were shuttled into the Adeno-X genome 
as detailed in the manufacturer’s instructions, and recombinant adenoviruses were obtained 
following transfection into HEK-293 cells.  All viruses were assayed for the absence of 
functional replication competent viruses. 
5.3.5 Derivation of recombinant VZV 
Recombinant VZV expressing GFP-66 or GFP-66s were constructed using the VZV parent Oka 
(pOka) cosmid system (Figure 5-1C).  To derive pvSpe23 cosmids in which the native ORF66 
gene (nt 113142-114323) was replaced by the fluorescent versions, a modified pUC19 vector 
was made in which the poly-linker between Hind III and EcoR I was replaced by a double-
stranded oligonucleotide encoding Avr II and Sgr AI sites.  This enabled sub-cloning of the Avr 
II-SgrA I fragment from the pvSpe23 cosmid (nt 112957 to 117458; pUC19-pvSpe23; Figure 
1D). Within this construct, the unique Avr II and Bam HI (nt 114147) sites were used to remove 
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the native ORF66 promoter and part of the gene.  Next, the CMV IE promoter in pGFP-66 and 
pGFP-66s was replaced with a PCR-generated DNA fragment of the ORF66 promoter from the 
Avr II site to the ORF66 ATG, to give plasmid p66prom-EGFP.C1-HA66 or 66s (Figure 5-1D).  
Avr II and Bam HI digestion of these constructs released the ORF66 promoter-GFP/HA tagged 
partial ORF66 gene, which was then used to replace the Avr II- Bam HI fragment in pUC19-
pvSpe23 (Figure 5-1D).  The entire Avr II-SgrA I fragments were then cloned back into 
pvSpe23, and recombinant VZV were generated using the three additional pOka cosmids in 
MeWo cells, as detailed previously (187).  VZV plaques exhibiting GFP fluorescence were 
grown into stocks, and assessed for purity and correct insertion.   
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 Figure 5-1 Schematic for creation of VZV containing GFP-66 or GFP-66s in the native ORF66 locus 
(A) Representation of the domains of the 393 amino acid ORF66 protein showing the positions 
of key amino acid residues and a Bam HI restriction site, as detailed in the text.  (B) Relative 
position of the ORF66 gene in the structure of the VZV genome.  Shown are the Unique long 
(UL) and Unique short (US) regions as well as the terminal (TRL and TRS) and internal (IRL and 
IRS) repeats.  (C) The relative positions of the four pOka cosmids used to construct recombinant 
VZV.  Genome co-ordinates are given with respect to the VZV pOka sequence. (D) Strategy for 
derivation of recombinant VZV expressing the ORF66 gene as an EGFP-tagged fusion protein.  
The ORF66 promoter and ORF are fully contained within a unique Avr II – SgrA I fragment of 
pvSpe23, and this fragment was sub-cloned into a modified pUC19 vector.  The ORF66 
promoter-GFP-66 cassette was inserted into this sub-fragment using Avr II-Bam HI, and then the 
Avr II-SgrA I sub-fragment was re-cloned into pvSpe23 as described in the Materials and 
Methods. 
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5.3.6 Transfections and infections  
Transfections of MeWo, HEK-293 and HEK-293T cells were performed using Lipofectamine 
2000 reagent (Invitrogen Corp.), according to the manufacturer’s instructions and as detailed 
previously (58).   Replication defective adenovirus-mediated expression of ORF66 was achieved 
by infecting MRC-5 cells with 5 plaque forming units (pfu)/cell of trans-gene expressing virus 
(Ad.GFP-66 or Ad.GFP-66kd) and 2.5 pfu/cell of Ad-Tet-Off, which expresses the tetracycline 
regulated transactivator.  Where indicated, 2 µg/ml doxycycline (Sigma-Aldrich) were added to 
the media to fully repress trans-gene expression.  
 VZV growth curves were performed as detailed in similar studies (220). The exact 
infection level of the previously frozen input viruses was confirmed by titration on MeWo cells 
(inocula) in duplicate.  Following fixation in 1% paraformaldehyde, plaques were visualized 
using GFP auto-fluorescence, or following immunofluorescent detection of IE62.   For VZV 
flow cytometry analyses, inoculants of VZV.GFP-66 and VZV.GFP-66s were prepared in MRC-
5 cells to >75% GFP fluorescence (as gauged by UV microscopy), and mixed with uninfected 
cells at a ratio of 1 to 10.  Cells were gently co-pelleted by low speed centrifugation, incubated 
for 30 min at 25ºC, plated and placed at 37ºC.   For metabolic labeling studies, trypsinized VZV-
infected MRC-5 cells were used to infect confluent fibroblast monolayers at a ratio of 1 infected 
cell to 3 uninfected cells, to yield 100% GFP fluorescence by 36 hpi.  Studies using [35S] 
labeling components were initiated as detailed in the text.     
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5.3.7 Flow cytometry and immunoblotting 
Cells for flow cytometry were harvested by dislodging following brief exposure to trypsin 
(MRC-5 cells) or 1X PBS/1 mM EDTA (293T cells).  Cells were washed in FACS staining 
buffer (FSB) (2) and Fc-blocked with 15 µg of normal mouse IgG (Caltag Laboratories) for 10 
minutes on ice.  Cells were stained in FSB containing fluorophore-conjugated antibodies, 
washed, and fixed in freshly prepared 1% paraformaldehyde in 1X PBS.  Isotype control staining 
was performed for each antibody and each condition.  Stained cells were analyzed using a 
Becton Dickinson FACSAria cell sorter and data was analyzed using FACSDiva and WinMDI-
2.8 software.  Surface protein-negative and GFP-negative gates were set using isotype control 
antibodies and non-GFP expressing cells.  To determine the mean fluorescence intensity (MFI) 
value for a cell population, the isotype control MFI was subtracted from the test MFI within 
corresponding GFP-negative or positive gates.  MFI ratios were calculated by dividing the MFI 
of the test population (adenovirus-infected, VZV-infected) by the MFI of the control population 
(mock-infected or vector plasmid-transfected) after isotype control background values had been 
subtracted.  Ratio values were converted to log values before statistical analysis using paired 
Student’s t-test.  For analysis of protein expression in infected or transfected cells, lysates of 
equivalent numbers of cells from each condition were separated by 7.5% sodium-dodecyl-sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE), and analyzed by immunoblotting as previously 
described (58).  Where indicated, membranes were stripped with 0.2 M NaOH for 5 minutes, 
rinsed with dH2O and re-blotted.  Digital images were acquired in the linear range of the film 
using an Epson Perfection 4990 photo scanner with Silver Fast Ai and Adobe Photoshop CS 
imaging software. 
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5.3.8 Immunofluorescence and microscopy 
For immunofluorescence, cells grown on glass coverslips were fixed in 4% paraformaldehyde 
for 15 minutes, permeabilized with 0.2% triton-X-100 for 2 minutes and stained with the 
indicated antibodies as described previously (124).  Cells for MHC-I localization studies were 
fixed with 2% paraformaldehyde for 10 minutes and permeabilized as just described.  Where 
indicated, internal specific MHC-I was detected following a thirty second pre-fixation treatment 
with an acid elution buffer (50 mM glycine, 100 mM NaCl, pH 3.3) to remove β2M from surface 
class I.  Nuclei were stained using Hoechst 33258 (Sigma-Aldrich).  Immunofluorescence in 
fixed cells was observed using a Nikon Eclipse TE2000-E epifluorescent microscope, equipped 
with a xenon lamp and a 40X 1.3 numerical aperture oil objective, and recorded with Metamorph 
7 software.  Where indicated, Z-stacks were acquired at the recommended spacing for each 
fluorescent channel and AutoQuant 9.2 was used to deconvolve Z stacks in ten iterations using a 
blind deconvolution algorithm.  Confocal analyses were performed as previously described (58, 
124). 
5.3.9 Metabolic labeling and immunoprecipitations 
Pulse-labeling of cells and immunoprecipitations were carried out as previously described (115), 
with some modifications.  Cells were first incubated with complete media containing 1% FBS 
and lacking cysteine and methionine (cys/met) for 20 minutes at 37ºC, and then pulsed for 15 
minutes with 0.5 mCi/ml of [35S]-labeled cys/met in cys/met-free media (Expre35S35S Mix, 
Perkin Elmer, Waltham, MA).  Protein labeling was terminated by incubation in growth media 
containing 10-fold excess cold methionine and 10% FBS, and where indicated cells were chased 
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in the same media.  Immunoprecipitations were obtained from soluble cell lysates using an ice-
cold NP40 lysis buffer (115) containing a protease inhibitor cocktail (Complete, EDTA-free, 
Roche Diagnostics).  Soluble fractions were equalized for trichloroacetic acid (TCA) precipitable 
radio-incorporation, and then pre-cleared with an unconjugated mix of proteins A and G 
sepharose (Sigma-Aldrich).  Immunoprecipitations were collected using protein A/G-sepharose; 
washed in ice-cold radio-immunoprecipitation assay buffer (115) containing protease inhibitors; 
and then once in ice-cold 1X PBS.  Precipitates were divided and one aliquot was subjected to 
endoglycosidase H (endo H) digestion, according to the manufacturer’s suggestions (New 
England Biolabs).  Immunoprecipitates were resolved on 10-20% gradient Criterion SDS-PAGE 
gels (Bio-Rad Laboratories, Hercules, CA), transferred to PVDF, and analyzed on a Bio Rad 
Molecular Imager FX using Quantity One software.  In some cases, gels were dried and the 
signals were enhanced using En3hance solution (Perkin-Elmer, Waltham, MA), captured by 
autoradiography with Kodak Biomax MP film and Kodak Biomax LE Transcreens, and 
quantified using ImageJ software.   
5.4 RESULTS 
5.4.1 Expression of functional and point inactivated GFP-tagged ORF66 kinase proteins 
in VZV-permissive cell types 
An earlier study reported that HFF cells transfected with plasmids expressing ORF66 showed 
reduced surface MHC-I  (2).  In this study, it was unclear if the ORF66-induced downregulation 
of MHC-I surface expression was specific to ORF66 expressing cells, as the protein expression 
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and transfection efficiency were not determined.  In particular, HFF cells and lines such as VZV-
permissive MRC-5 fibroblasts are considered highly refractory to efficient transfection.  To 
address this issue, we developed EGFP-tagged forms of ORF66 in plasmids, in replication 
defective adenoviruses and in recombinant VZV.      
To assess the functionality of an amino-terminally EGFP-tagged ORF66 (GFP-66), we 
examined its cellular distribution and ability to exclude IE62 from the nucleus in live cells.  IE62 
nuclear exclusion is dependent on the integrity of ORF66 kinase activity, and is induced by a 
direct ORF66-mediated phosphorylation event adjacent to the IE62 nuclear localization signal 
(58, 124).  We also tested a GFP-66 fusion protein in which two key residues in the ORF66 
catalytic domain, which are absolutely conserved in all ser/thr kinases, were conservatively 
mutated (D206E, K208R; referred to as GFP-66kd).  The HA-tagged version of ORF66-
D206E/K208R has been previously shown to lack the ability to exclude IE62 from the nucleus 
and phosphorylate IE62 peptides (58, 124).  For this live-cell assay, we developed a plasmid 
expressing IE62 with a carboxyl-terminal dsRed2 tag (IE62-dsRed2).  In transfected MeWo 
cells, both GFP-66 and GFP-66kd accumulated in the nucleus, but also displayed cytoplasmic 
forms (Figure 5-2A, panels i-ii).  When expressed alone, IE62-dsRed2 showed a distribution 
pattern identical to untagged IE62 and was predominantly nuclear (Figure 5-2A, panel iii) (58, 
124).  When GFP-66 was co-expressed with IE62-dsRed2, most co-expressing cells exhibited 
strong nuclear exclusion of IE62-dsRed2, which partially overlapped with GFP-66 in the 
cytoplasm (Figure 5-2B).  IE62-dsRed2 nuclear exclusion did not occur in cells expressing GFP-
66kd, indicating the activity was kinase dependent, as expected from previous studies (Figure 5-
2C).  These results established that amino-terminal EGFP-tagging of ORF66 did not interfere 
with its ability to affect IE62 cellular distribution, and that ORF66 kinase activity was intact. 
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Figure 5-2 Live cell imaging to show that GFP-tagged ORF66 retains the ability to exclude IE62 from the 
nucleus 
 
(A) Single panels showing cellular distributions of individually transfected GFP-66 (i), GFP-
66kd (ii) and IE62-dsRed (iii).  (B and C) Images of cells co-expressing IE62-dsRed2 and either 
GFP-66 (B) or GFP66kd (C).  Panel i shows auto-fluorescence of GFP-66 and GFP-66kd, while 
panel ii shows IE62-dsRed2 auto-fluorescence from the same cell.  All transfections were 
performed in MeWo cells, and auto-fluorescence was visualized and captured at 24 hours post-
transfection by confocal microscopy. Cells were transfected with expression plasmids at a 1:1 
ratio. 
 
The GFP-66 and GFP-66kd genes were subsequently inserted into replication defective 
adenovirus vectors under the control of the doxycycline (dox)-repressible promoter (Ad.GFP-66 
and Ad.GFP-66kd, respectively) to enable efficient expression in VZV-permissive fibroblasts.  
The adenovirus vector used lacked large portions of the E1 and E3 genome regions, including the 
MHC-I modulating genes E1A and E3/gp19K (20, 73, 205, 258), and does not have any intrinsic 
effects on MHC-I surface expression.  MRC-5 cells required relatively low multiplicities of 
infection (2-5 pfu/cell) to obtain efficient trans-gene expression in over 80% of cells.  Expression 
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was dependent on co-infection with adenovirus expressing the tetracycline tTa transactivator, 
and the absence of dox.  Immunoblot analyses of Ad.GFP-66 and Ad.GFP-66kd cell lysates 
revealed proteins of the expected size (~75 kDa), which reacted with both anti-HA and anti-GFP 
antibodies (Figure 5-3C) (anti-GFP blot not shown).  The GFP-66kd protein displayed a slightly 
faster mobility in SDS-PAGE compared to GFP-66, as reported previously for HA-tagged 
ORF66kd protein (124, 219).  We also verified that adenovirus transduction and GFP-66 or GFP-
66kd expression did not result in increased levels of apoptotic cells using flow cytometric 
analysis of annexin V surface staining and 7-AAD uptake (data not shown).  These vectors allow 
for both efficient expression and quantitative assessment of ORF66 expression in multiple cell 
types.  
5.4.2 GFP-66 induces kinase dependent downregulation of MHC-I surface expression     
The Ad.GFP-66 and Ad.GFP-66kd viruses were next employed to assess the role of ORF66 
kinase activity in downregulation of MHC-I surface expression.  We report the studies here in 
VZV-permissive MRC-5 fibroblasts, but have found similar effects in MeWo cells and 293T 
cells.  Surface levels of MHC-I were compared to transferrin receptor (TfR1 or CD71), a control 
that is widely used in MHC-I surface studies. 
 MRC-5 fibroblasts infected with Ad.GFP-66 or Ad.GFP-66kd in the presence or absence 
of 2 µg/ml dox were assessed for surface MHC-I and TfR1 levels at 36 hours post infection (hpi) 
(Figure 5-3A).  Representative histograms showing MHC-I fluorescence in GFP-positive cells 
from the Ad.GFP-66 infection revealed that MHC-I surface expression was reduced when GFP-
66 was expressed.  Parallel infected cells grown in media containing dox showed no MHC-I 
downregulation, and GFP-66kd expression did not significantly downregulate MHC-I surface 
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expression in the absence or presence of dox.  From three independent and identical experiments, 
GFP-66 expression induced an average of ~40% reduction of MHC-I surface levels compared to 
a minor 5-11% reduction in GFP-66kd expressing cells (Figure 5-3B).  Analysis of surface TfR1 
revealed no significant downregulation under any conditions (Figure 5-3A and B).  Immunoblot 
analyses of equal numbers of Ad.GFP-66 and Ad.GFP-66kd infected cells from the same 
experiment shown in Figure 5-3A indicated that similar levels of GFP-66 and GFP-66kd were 
expressed (Figure 5-3C).  These data indicate that functional kinase activity is required for 
efficient ORF66-mediated MHC-I downregulation, and implies that ORF66 phosphorylates a 
cellular target to induce the reduction in MHC-I surface expression.   
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 Figure 5-3 GFP-66 induces a kinase dependent and specific downregulation of surface MHC-I 
 
(A) MRC-5 cells were infected with Ad.GFP-66 or Ad.GFP-66kd in conjunction with Ad.Tet-
Off, grown in the presence or absence of 2 µg/ml of doxycycline, and harvested at 36 h post 
infection.  Cells were stained with fluorophore-conjugated antibodies to MHC-I and TfR1 or 
isotype controls, and analyzed using a Becton Dickinson FACSAria.  Histograms of surface 
fluorescence for MHC-I and TfR1 are shown with the infection condition indicated above each.  
The shaded gray histograms represent infected cells that were incubated with 2 µg/ml 
doxycycline.  Cells incubated in the absence of dox were gated on GFP positivity and are 
represented by the solid black line histograms.  The isotype controls antibody levels are shown 
by dotted lines.  (B) Graph depicting the average (+/- SEM) MFI ratios of MHC-I and TfR1 
surface fluorescence from three independent and identical experiments.  (C) Western blot 
analysis of an equal number of cells from the Ad.GFP-66 and Ad.GFP-66kd infections under the 
four experimental conditions were probed with antibodies to the HA epitope, and the proteins 
reacting in the size range expected are shown. 
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5.4.3 Development of recombinant VZV expressing GFP-66 proteins 
In previous studies of VZV and its effects on MHC-I surface expression, the identification of 
VZV infected cells required indirect immunofluorescent detection of surface VZV glycoproteins.  
To more accurately assess infection and correlate the levels of ORF66 expression with levels of 
surface MHC-I during VZV infection, we generated recombinant VZV expressing GFP-66 
(VZV.GFP-66) or one in which protein kinase expression was halted by stop codon insertion at 
ORF66 amino acid 84 (VZV.GFP-66s).  Recombinant viruses were created using wild-type VZV 
(pOka) cosmids (Figure 5-1) and were designed so that GFP-66 or GFP-66s was expressed at the 
native locus and under the natural ORF66 promoter.  Each recombinant was successfully 
generated twice from cosmid-transfected MeWo cells, yielding green fluorescent plaques with no 
visible differences in size, morphology or GFP auto-fluorescence distribution (data not shown).  
The GFP tag enabled VZV infected cells expressing ORF66 to be differentiated in mixed 
populations of infected and uninfected cells, and also reported the relative amounts of ORF66 
expression.  Growth curve analysis in MRC-5 fibroblasts of these viruses indicated that 
VZV.GFP-66 grew with similar kinetics as pOka and achieved equivalent maximal titers (~1 x 
105 infectious foci by 96 hpi; Figure 5-4A). This suggests that the addition of EGFP to ORF66 
had only minimal effects, if any, on virus growth.   VZV.GFP-66s infections were marginally 
impaired, similar to observations from a previous study (220), yielding a 3-4 fold reduction in 
infectious cell titers with respect to pOka and VZV.GFP-66.  
The functionality of the GFP-66 kinase in VZV.GFP-66 and the disruption of ORF66 
kinase expression in VZV.GFP-66s were assessed by examining IE62 localization in infected 
MRC-5 cells (Figure 5-4B).  Consistent with functional ORF66 kinase activity, IE62 was 
predominantly cytoplasmic in late-stage VZV.GFP-66-infected plaques and most nuclei showed 
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only low-levels of IE62 staining (Figure 5-4B, panels ii-iii).  Nuclear IE62 was observed at 
plaque edges where GFP-66 expression was low or absent, as was found for pOka-infected cells 
(219).  GFP-66 exhibited both nuclear and cytoplasmic distributions and was often concentrated 
in discrete nuclear foci that appeared to surround the nucleolus (Figure 5-4B, panel i).  In 
contrast, IE62 in VZV.GFP-66s-infected MRC-5 cells remained strictly nuclear, even in late-
stage infected plaques and syncytia (Figure 5-4B, panels iv-vi), consistent with the lack of 
ORF66 kinase domain expression.  Despite including only the first 83 residues of ORF66, we 
noted a significant overlap between GFP-66s auto-fluorescence and IE62 immunofluorescence in 
the nucleus.  Together, the growth curve analysis and IE62 nuclear exclusion assay validates the 
use of VZV.GFP-66 and VZV.GFP-66s to assess the correlation of ORF66 expression with the 
downregulation of MHC-I surface expression in VZV-infected cells.   
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 Figure 5-4 Characterization of recombinant VZV expressing GFP-66 and GFP-66s 
(A) Growth curve analyses of VZV.GFP-66 (▲), VZV.GFP-66s (▼) and pOka (■).    Parallel 
infections were established on confluent monolayers in MRC-5 fibroblasts, and the amount of 
virus infected cells in each culture produced by each VZV was titrated on MeWo cells after 24, 
48, 72, and 96 hpi.  Mean titers and standard error were deduced from duplicate wells of 
duplicate titrations.  (B) Images showing GFP expression and IE62 cellular localization in fixed 
VZV.GFP-66 (i-iii) and VZV.GFP-66s (iv-vi) infected MRC-5 cells at 48 hpi.  Cells were fixed 
with 4% paraformaldehyde and stained with rabbit anti-62 and Alexa Fluor 546 conjugated anti-
rabbit Fab fragments, and Hoechst dye to identify nuclei.  The depicted auto-fluorescence or 
stained protein is indicated above the panels, and the infection condition is on the left.  Images 
were selected to represent the center of VZV syncytia at approximately the same stage of 
infection. 
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5.4.4 VZV has ORF66-dependent and independent effects on MHC-I and TfR1 surface 
expression 
The cell-associated nature of VZV precludes large-scale synchronous infection, so MHC-I and 
TfR1 surface levels were compared in MRC-5 cells infected with VZV.GFP-66 and VZV.GFP-
66s at a moderate multiplicity of infection (uninfected to VZV-infected fibroblasts at a ratio of 
10:1) over a 72-hour time course.  At 24, 48 and 72 hpi, MHC-I and TfR1 surface expression 
were analyzed by flow cytometry (Figure 5-5).  Mock-infected cells stained with isotype control 
antibodies were used to define the GFP-negative quadrant gate at each time point (Figure 5-5A 
and D, panels a-c).  Uniform levels of surface MHC-I and TfR1 were consistently displayed in 
mock-infected cells (Figure 5-5A and D, panels d-f).  We note that MHC-I level in mock-
infected cells showed a slight increase in over time in culture, but we cannot rule out that this is a 
consequence of experimental variability.  At 24 hpi VZV.GFP-66 infected cells exhibited a range 
of GFP expression levels (Figure 5-5A, panel g).  The GFP-negative population had MHC-I 
surface levels similar to that of uninfected cell controls, whereas most (but not all) cells 
expressing the higher levels of GFP had reduced MHC-I surface expression.  This indicates that 
ORF66 expression did not have an immediate effect on MHC-I surface levels.  At 48 and 72 hpi, 
most cells expressed high amounts of GFP in VZV.GFP-66 infections, and showed more 
downregulation of MHC-I surface fluorescence (Figure 5-5A, panel h-i).  The greatest reduction 
in MHC-I surface expression was consistently observed in high GFP expressers at 72 hpi (Figure 
5-5A, panel i).   Regarding VZV.GFP-66s infections, while fewer cells were infected at 24 hpi, 
MHC-I was still reduced in a fraction of GFP positive cells (Figure 5-5A, panel j).  At later times 
in very high GFP expressers, reduced MHC-I surface expression was also observed (Figure 5-
5A, panels k-l).  These data show that VZV can downregulate MHC-I in the absence of the 
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expression of the ORF66 kinase domain.  We note that the GFP signal in GFP-66s was expressed 
with similar timing and to greater levels compared to that from GFP-66 during VZV infection 
(Figure 5-5F).  The basis of the reduced levels of ORF66 kinase at 72 hours is not yet clear, but it 
is conceivable that the functional kinase has possible auto-regulatory effects on its own 
expression.         
We assume that similar levels of GFP represent similar stages of infection, since the 
native ORF66 promoter controls both GFP-66 and GFP-66s expression.  To determine if there 
were differences in the abilities of VZV.GFP-66 and VZV.GFP-66s to mediate MHC-I 
downregulation, we examined cells exhibiting similar relative GFP intensities.  The same high 
GFP gate was used for all infections at all time points and was defined as cells with 10-fold or 
greater GFP fluorescence compared to mock-infected cells (indicated in each representative 
infection dot-plot; Figure 5-5A, panels g-l).  Similar approaches were recently used to compare 
apoptosis and Stat1 phosphorylation in pOka and pOka66S infected cells (220).  Our data were 
accumulated in three independent experiments. GFP-high cells in VZV.GFP-66 infections 
consistently exhibited a more negative MHC-I surface expression phenotype compared to GFP-
high cells from VZV.GFP-66s infections (Figure 5-5B).  On average, ~75% of GFP-66-high 
cells fell below the MHC-I positive gate at both 48 and 72 hpi, while similar GFP-66s-high cells 
were ~55-60% MHC-I negative.  We also calculated the average MHC-I MFI ratio (relative to 
mock-infected cells) of GFP-high cells from these three experiments and found that GFP-high 
cells in VZV.GFP-66 infections had a lower average MHC-I MFI ratio at all time points 
compared to similar cells in VZV.GFP-66s infections (Figure 5-5C). This difference was 
statistically significant at 72 hpi (p≤0.05).  These analyses indicate that while ORF66-
independent processes negatively influence MHC-I surface expression, more efficient MHC-I 
 139 
surface downregulation in VZV infection requires expression of the functional ORF66 kinase 
domain. 
Surprising results were obtained with TfR1.  Both VZV.GFP-66 and VZV.GFP-66s 
induced an increase in TfR1 surface expression compared to mock-infected cells, with more up-
regulation occurring when the ORF66 kinase activity was intact (Figure 5-5D and E).  A 2.5-fold 
increase in TfR1 expression over mock-infection was observed in the VZV.GFP-66 infection at 
72 hpi, compared to a 1.8-fold increase in VZV.GFP-66s infection.  At all times, the difference 
was statistically significant.  These data indicate that the surface expression of TfR1 is also 
regulated by both ORF66-dependent and independent mechanisms during VZV infection, but is 
affected in an opposite manner compared to surface MHC-I.   The differential regulation of 
outcomes for surface MHC-I and TfR1 implies that ORF66 may have multiple effects on other 
cell surface protein trafficking patterns. 
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Figure 5-5 MHC-I downregulation in VZV infection with and without expression of functional kinase 
MRC-5 cells were infected with VZV.GFP-66 or VZV.GFP-66s at a ratio of 10:1, surface-
stained for MHC-I and TfR1 at 24, 48 and 72 hpi, and analyzed by flow cytometry.  (A) Dot-
plots from a representative experiment depicting MHC-I surface expression as a function of 
GFP-66 or GFP-66s expression.  The analysis time-point is shown to the left of each row, and 
the infection condition is shown above each column.  Quadrant gates to identify MHC-I negative 
and MHC-I positive cell populations were established at each time point using mock-infected 
isotype control stained cells (a-c).  The same quadrant gate was used for mock (d-e), VZV.GFP-
66 (g-i) and VZV.GFP-66s (j-l) infections.  To quantitatively assess differences between 
VZV.GFP-66 and VZV.GFP-66s infections, cells were gated on high GFP fluorescence, 
represented as the right-most vertical line in infected cell dot-plots (g-l).  The GFP negative and 
GFP-high (where relevant) cell populations for each column are indicated below panels c, f, i, 
and l.  The percentage of mock-infected cells exhibiting an MHC-I negative and MHC-I positive 
phenotype is indicated in the upper left and lower left quadrants in panels d-f.  Similar MHC-I 
negative and MHC-I positive cell percentages in GFP-high cells are indicated in the upper right 
and lower right quadrants of panels g-l.  (B) The average percentage (+/- SEM) of MHC-I 
positive (gray) and MHC-I negative (black) cells in the GFP-high gate in each infection 
condition was calculated from three independent experiments.  (C) MFIs of GFP-high cells in 
VZV.GFP-66 (black) and VZV.GFP-66s (gray) infections were expressed as a ratio of the MFI 
of mock-infected cells.  Average ratios (+/- SEM) from three independent experiments were 
compared at each time point, and we found that VZV.GFP-66 exhibited a significant reduction in 
MHC-I surface expression over VZV.GFP-66s at 72 hpi.  (D) TfR1 surface expression dot-plots 
and (E) MFI ratios are shown exactly as described for MHC-I. (F)  Lysates of aliquots of equal 
numbers of cells from each infection condition at each time point were separated by SDS-PAGE 
and analyzed by immunoblot sequentially with mouse anti-HA and then anti α-tubulin 
antibodies.  *p ≤ 0.05, ** p ≤ 0.005 
 
5.4.5 ORF66 kinase delays the biosynthetic maturation of MHC-I 
Molecular mechanisms underlying downregulation of MHC-I by VZV infection and ORF66 
have not been well resolved.  While one study reported no change in MHC-I synthesis levels or 
rate of acquisition of endo H resistance in VZV-infected fibroblasts (2), another study observed a 
modest effect on total class I heavy chain and β2M synthesis at 48 hpi (38).  Our data shows that 
most MHC-I surface downregulation occurred after 24 hpi.  To clearly elucidate the mechanism, 
we undertook an analysis of MHC-I biogenesis in cells expressing the ORF66 kinase 
independently of other proteins, as well as in the context of VZV infection.  
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Pulse-chase studies combined with endo H cleavage analysis were used to address MHC-
I synthesis and maturation in MRC-5 cells infected with Ad.GFP-66 or Ad.GFP-66kd.  Endo H 
resistance is acquired when cis/medial-Golgi enzymes mediate replacement of high mannose 
groups with more complex N-linked glycans on glycoproteins.  Mock or adenovirus infected 
MRC-5 cells were subjected to an [35S] cys/met 15-min pulse and harvested or chased to allow 
maturation of labeled protein.  Equivalent amounts of labeled protein from each infection 
condition were subjected to immunoprecipitation with the W6/32 antibody, which only 
recognizes folded MHC-I molecules that have associated with β2M.  Immunoprecipitations 
performed with non-specific isotype control antibodies did not result in significant amounts of 
precipitated radio-labeled protein (data not shown).   
Comparison of the SDS-PAGE resolution of immunoprecipitates obtained at the end of 
the pulse (0 min) revealed that expression of functional or kinase inactive ORF66 had no effect 
on the levels of MHC-I complexes, as compared to that obtained from mock-infected cells, and 
that MHC-I from all conditions was completely sensitive to endo H cleavage (Figure 5-6A-C, 
lanes 1 and 2).  These observations indicate that ORF66 does not modulate expression of MHC-I 
components or its initial assembly into heavy chain (HC)-β2M heterodimers.  The amount of 
MHC-I HC was also found to remain relatively stable in chase conditions up to 120 min, 
indicating that ORF66 does not induce MHC-I degradation.  However, ORF66 expression clearly 
delayed MHC-I acquisition of endo H resistance.  In mock-infected cells, heavy chains were 
~53% resistant to endo H cleavage at 30 minutes, ~78% at 60 minutes, and 98% resistant by 120 
minutes of chase (Figure 5-6A and D).  In contrast, MHC-I from Ad-GFP-66 infected cells 
demonstrated only ~11% and 16% endo H resistance at 30 and 60 min of chase, respectively 
(Figure 5-6B and D).  By 120 minutes of chase, most heavy chains remained sensitive to 
 144 
cleavage, with only 26% exhibiting resistance.  In Ad.GFP-66kd infected cells, MHC-I acquired 
endo H resistance at a rate more similar to that observed in mock infections, with 35% resistance 
at 30 min, 52% at 60 min, and 74% at 120 min (Figure 5-6C and D).  In a similar experiment, 
Ad.GFP-66 infection induced a comparable reduction in MHC-I maturation relative to mock 
infection, but no impairment was observed when infections were incubated in the presence of 2 
µg/ml dox (data not shown).  These data indicate that MHC-I maturation through the cis/medial-
Golgi compartment is impaired predominantly as a result of ORF66 kinase activity. 
 145 
 Figure 5-6 GFP-66 expression induces a delay in MHC-I maturation in MRC-5 fibroblasts 
(A) Mock-infected, (B) Ad.GFP-66-infected or (C) Ad.GFP-66kd-infected cells were pulse-
labeled with [35S] cys/met, chased in media containing cold cys/met, and folded MHC-I was 
immunoprecipitated and subjected to endo H digestion.  Autoradiographs of proteins separated 
by SDS-PAGE are shown.  The chase time and presence (+) or absence (-) of endo H is indicated 
above each lane, and lane numbers are shown at the bottom.  Class I molecules that are resistant 
to endo H cleavage migrate more slowly through the gel, and are designated by the letter R to the 
side of each radiograph.  Sensitive molecules migrate more quickly and are indicated by the 
letter S.  Protein size standards were run with each gel and are shown (in kDa) to the left.  (D) 
The rate of acquisition of endo H resistance was quantified for mock infections (■), Ad.GFP-66 
infections (▲) and Ad.GFP-66kd infections (▼) using autoradiography.  The percent of the total 
MHC-I molecules exhibiting resistance was plotted as a function of time. 
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5.4.6 VZV affects early events in MHC-I biogenesis 
The ORF66-mediated delay of MHC-I maturation prompted a reassessment of MHC-I 
maturation in VZV-infected cells.  Infection conditions for the two VZV were carefully 
normalized to be equivalent, and  VZV-infected MRC-5 fibroblasts were established at relatively 
high VZV-infected cell multiplicity (3 uninfected cells to 1 infected cell) to ensure efficient 
infection.  Cells were pulse labeled at 36 hours post infection, when all cells were GFP-positive.  
Immunoblot analysis of infection lysate supernatants indicated that GFP-66s was expressed to a 
greater level compared to GFP-66 under these conditions (see Figure 5-8A).   
In two independent and identical experiments, SDS-PAGE separated immunoprecipitates 
for each infection condition revealed that pulse-labeled class I heavy chains in uninfected cells 
were completely sensitive to endo H cleavage at 0 minutes, but became almost fully resistant by 
180 minutes of chase (Figure 5-7A). Labeled MHC-I levels remained relatively stable for the 
duration of the experiment, suggesting there was no turnover.  In VZV-infected cells, there was a 
consistent reduction in the rate of class I maturation compared to uninfected cells, with a greater 
degree of delay in VZV-infected cells expressing the functional ORF66 kinase (Figure 5-7B-D).  
On average, after 30 minutes of chase only 31% of the total precipitated MHC-I heavy chains 
from VZV.GFP-66-infected cells exhibited endo H resistance, whereas greater than 60% were 
resistant in uninfected cells.  VZV.GFP-66-infected cells were 51% and 72% resistant at 60 and 
180 minutes of chase, respectively, compared to 78% and 85% resistance in uninfected cells at 
the same times.  MHC-I in VZV.GFP-66s-infected cells was marginally delayed in acquisition of 
endo H resistance, but not to the level seen in VZV.GFP-66 infection, showing an average 58% 
resistance at 30 min, 67% at 60 min, and 82% after 180 min of chase.  These data indicate that 
the greatest delay in acquisition of endo H resistance for MHC-I occurs when the ORF66 kinase 
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is expressed and functional.  This correlates with the observed delay in cells expressing the 
ORF66 kinase in the absence of other VZV proteins.  Thus, the ORF66 kinase delays MHC-I 
maturation in a predominantly kinase-dependent manner and contributes to the reduced MHC-I 
phenotype seen in VZV-infected cells.  
 
 
 148 
 Figure 5-7.  GFP-66 mediates a delay in MHC-I maturation in the context of VZV infection 
Endo H resistance analysis was performed for MHC-I molecules from (A) Mock-infected, (B) 
VZV.GFP-66-infected and (C) VZV.GFP-66s infected cells.  Chase times and treatment with 
endo H are shown above each radiograph and lane numbers are shown below.  Protein size 
markers are specified in kDa to the left, and endo H resistant (R) or sensitive (S) forms are 
indicated to the right.  (D) The rate of MHC-I maturation was determined by phosphorimager 
analysis from two independent but identical experiments, and is plotted as a function of time for 
mock infections (■), VZV.GFP-66 infections (▲) and VZV,GFP-66s infections (▼). 
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 Additional VZV activities contributing to the delay of MHC-I on cell surface were also 
indicated in these studies.  Specifically, we noted that the levels of β2M associated class I 
immunoprecipitated by the W6/32 antibody from both VZV.GFP-66 and VZV.GFP-66s 
infections were greatly reduced at all time points compared to that from uninfected cells, even 
though all immunoprecipitations were normalized for equal amounts of labeled protein in the 
cleared lysates.  The TCA-precipitable material was substantially reduced in both VZV.GFP-66 
and VZV.GFP-66s infected cells, over that in uninfected cells (data not shown).  This likely 
reflects a VZV-induced global reduction in host protein synthesis that may affect MHC-I 
component expression.  To determine if VZV induces a specific reduction in MHC-I synthesis, 
we performed parallel immunoprecipitations from longer-term radio-labeled (6 hour) extracts of 
uninfected cells or  cells equally infected with VZV.GFP-66 or VZV.GFP-66s, using antibodies 
that recognized folded MHC-I (W6/32), total class I heavy chains or α-tubulin.  Equivalent levels 
of TCA-precipitable counts were used for each immunoprecipitation.  The SDS-PAGE resolved 
immunoprecipitates revealed that α-tubulin synthesis was reduced in both infection conditions 
compared to uninfected cells, consistent with global reduction in host protein expression (Figure 
5-8B, lanes 1-3).  Quantification of total MHC-I heavy chain synthesis by phosphorimager 
analysis revealed a 45-50% reduction relative to uninfected cells in both infections (Figure 5-8B, 
lanes 4-6).  However, folded MHC-I heavy chains precipitated with W6/32 were more reduced 
(~65%) than that predicted by heavy chain levels in both VZV-infected cell populations (Figure 
5-8B, lanes 7-9).  While modest, this difference was consistently detected in replicate 
experiments, suggesting an additional impairment in the formation of the heavy chain-β2M 
heterodimer.  Altogether, the biochemical analyses of MHC-I from VZV-infected cells strongly 
indicated that VZV uses multiple processes to impede MHC-I surface levels. 
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 Figure 5-8 VZV infection reduces class I synthesis and impairs the association of class I heavy chains with 
β2M 
 
Total α-tubulin and class I heavy chain, as well as folded class I heavy chain levels were 
compared by parallel immunoprecipitation from either mock-infected cells (M) or cells infected 
with VZV.GFP-66 (66) or VZV.GFP-66s (66s), following a 6-hour [35S] cys/met label.  (A) 
Western blot analysis of cleared infected cell lysates showing the level of GFP-66 and GFP-66s 
protein expressed in each infection condition.  The infection condition is indicated at the top.  (B) 
Autoradiographs of each set of parallel immunoprecipitations.  The antibody used and infection 
condition are labeled above the radiograph, and lane numbers are shown below.  Protein size 
markers (in kDa) are shown to the left.  The relative amounts (%) of proteins expressed in 
infected cells compared to uninfected cells for both VZV.GFP-66 and VZV.GFP-66s are shown 
under lane numbers 2-3, 5-6, and 8-9.  The * indicates a reproducible co-precipitating band of 
~75 kDa, which was apparent in the α-tubulin immunoprecipitation of VZV.GFP-66 infected 
cells.  This band did not react with antibodies to HA; its identity is currently unknown. 
5.4.7 Intracellular retention of MHC-I in VZV-infected cells 
A previous study suggested that MHC-I is processed correctly, but retained in the Golgi 
apparatus in VZV-infected HFF cells (2).  Given our new observations that VZV delays MHC-I 
early maturation, we re-evaluated the distribution of MHC-I in VZV infections in both the 
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presence and absence of the ORF66 kinase.  Immunolocalization of MHC-I and its association 
with cis/medial-Golgi in MRC-5 fibroblasts was determined using the conformation dependent 
W6/32 antibody and anti-mannosidase II (mann II) antibodies.  To facilitate specific detection of 
intracellular MHC-I, cells were treated briefly with a mild acid buffer (228) prior to fixation and 
permeabilization, to dissociate β2M from surface class I heavy chains and render surface MHC-I 
unrecognizable by W6/32.  In uninfected, untreated cells, surface MHC-I displayed finely 
punctate distribution with more concentrated staining at cellular boundaries (Figure 5-9A, panel 
i).  Uninfected cells subjected to acid treatment lacked a similar pattern of surface staining and 
had a characteristic peri-nuclear distribution of MHC-I that was proximal to, but did not 
completely overlap, mann II staining.  There were also obvious peripheral vesicular cytoplasmic 
foci, which may represent MHC-I en route to or recycling from the cell surface (Figure 5-9A, 
panels ii-iv).   
 For comparison of MHC-I localization in VZV.GFP-66 and VZV.GFP-66s infections, we 
assessed late-stage multi-nucleate syncytia, which expressed abundant levels of GFP-66 or GFP-
66s and retained clear cellular morphology.  Syncytia were randomly selected and mann II and 
MHC-I staining patterns were documented. Representative VZV.GFP-66 and VZV.GFP-66s 
syncytia are shown in Figure 5-9B, with high-level GFP fluorescence indicating similar late 
infection stages (panels i and v).  Surface MHC-I in VZV.GFP-66 and VZV.GFP-66s infections 
were distributed similar to uninfected cells, although the signal was clearly consistently reduced 
(data not shown).  In the VZV.GFP-66 syncytium, nuclei were arranged in central clusters and 
the Golgi apparatus was significantly rearranged, consistent with previous observations (79, 89, 
172).  Two populations of mann II became disjointed: some localized to foci closely apposed to 
the nucleus, while the remainder was distributed in a ringed structure in the center of the syncytia 
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(Figure 5-9B, panel ii).  Golgi rearrangement resulted in a central pool of intracellular MHC-I, 
which partially overlapped the mann II staining, but also showed independent accumulation at 
the center of the mann II ring (Figure 5-9B, panels iii-iv).  Little or no MHC-I was observed 
outside of the mann II staining region, in contrast to the abundance of punctate foci observed 
throughout the periphery of uninfected cell cytoplasm.  In VZV.GFP-66s syncytia, a similar 
central mann II ring formed (Figure 5-9B, panel vi).  MHC-I showed accumulation in this region, 
but was disorganized and exhibited a remarkable lack of overlap with mann II staining (Figure 5-
9B, panels vi-viii).  Additional undefined populations of MHC-I were consistently observed 
throughout the VZV.GFP-66s cytoplasm (Figure 5-9B, panel vii).  These did not co-localize with 
mann II or other cytoplasmic organelle markers for cis-Golgi (GM130), trans-Golgi network 
(p230), ER (Erp29), early endosomes (EEA-1), or lysosomes (Lamp-1) (data not shown).  The 
localization and organization of MHC-I in infected cells supports a role for ORF66 in MHC-I 
retention in the cis/medial-Golgi, and indicate that other factors may influence the distribution of 
intracellular MHC-I during VZV infection. 
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Figure 5-9 MHC-I localization in VZV infection with and without ORF66 expression 
Cells on cover-slips were either surface stained for MHC-I or stripped of surface β2M, 
permeabilized and stained for intracellular folded MHC-I (W6/32) and rabbit anti-mann II 
combined with anti-mouse Alexa-Fluor 647 and anti-rabbit Alexa-Fluor 546, respectively.  All 
cells were stained with Hoechst 33258 to identify nuclei.  Z-stacks were acquired and 
deconvolved for each fluorescent channel.  MHC-I, mann II and Hoechst stains were pseudo-
colored to promote simultaneous observance of each channel in the merged images.  (A) MHC-I 
expression profile in uninfected MRC-5 fibroblasts.  MHC-I surface fluorescence is shown as an 
image merged with Hoechst (i).  A similar staining pattern was not observed in β2M-stripped 
cells, which exhibited low levels of peri-nuclear MHC-I that partially overlapped with 
mannosidase II staining (ii-iv).  Individual stains are indicated above each micrograph panel.  (B) 
Comparison of intracellular MHC-I distribution in late-stage VZV.GFP-66 (i-iv) and VZV.GFP-
66s (v-viii) infected syncytia.  Each set of panels shows a representative syncytium.  Stains are 
indicated above each micrograph.  In both (A) and (B), arrows highlight specific features that are 
discussed in the text. 
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5.4.8 Assessment of expression of additional VZV ORFs on MHC-I surface expression 
As our data clearly indicate that ORF66-independent mechanisms regulate MHC-I surface levels, 
we evaluated select VZV genes for abilities to affect MHC-I.   A panel of plasmids expressing 
VZV ORFs 0, 1, 2, 7, 9, 11, 17, 21, 23, 32, 40, 44, 46, 58, 64 and 65 revealed no ability for any 
gene to downregulate MHC-I (data not shown).  VZV encodes an ortholog to the BHV-1 UL49.5 
TAP inhibitor (VZV ORF9a) (134), and we also addressed the ability of ORF9a protein to 
downregulate MHC-I in VZV-permissive cells (Figure 5-10).  For this study, test plasmids were 
co-transfected in 293T cells with an equal amount of a plasmid expressing low levels of EGFP 
under the control of the weakly constitutive HSV-1 thymidine kinase promoter (pTK-EGFP), 
and MHC-I surface expression was analyzed in EGFP-positive cells by flow cytometry.  Cells 
transfected with plasmid vector lacking any viral ORF were considered the negative control, and 
we utilized plasmids expressing either ORF66 or the KSHV K3 protein as independent positive 
controls.  EGFP-positive cells from both ORF66 and K3 transfections yielded significantly 
reduced MHC-I surface levels (p<0.05) relative to vector control transfections, indicating that the 
pTK-EGFP co-transfection successfully reported test plasmid uptake.  No significant MHC-I 
downregulation was observed in ORF9a transfections, supporting data from a previous study in 
which ORF9a failed to mediate MHC-I downregulation in human melanoma (Mel JuSo) cells 
(134).  This indicates that the ability of ORF9a to inhibit TAP either may not be conserved or 
may require the expression of additional VZV genes.  Little is known of the functions of VZV 
ORF9a during infection, but the pseudorabies virus (PrV) ORF9a ortholog (gN) is disulfide-
linked to PrV gM (VZV ortholog: ORF50) in infected cells (113).  We considered the potential 
ORF9a:ORF50 interaction as the most likely to affect ORF9a’s functions, and we thus assessed 
the effect of combined ORF9a and ORF50 expression on MHC-I surface expression.  Neither 
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ORF50 alone nor ORF9a and ORF50 in combination resulted in significant MHC-I 
downregulation, either.  While we could not confirm the expression of ORF9a due to lack of an 
ORF9a antibody, similar negative results were observed in cells transfected with an EGFP-
tagged version of ORF9a (data not shown).  Therefore, VZV genes other than the ORF66 kinase 
and ORF9a are likely involved in the regulation of MHC-I surface expression. 
 
Figure 5-10 The VZV ortholog to BHV-1 UL49.5, ORF9a, does not mediate downregulation of MHC-I 
surface expression 
 
HEK-293T cells were co-transfected with an EGFP-expressing marker plasmid (pTK-EGFP) and 
plasmids expressing untagged versions of ORF9a, ORF50 or ORF9a and ORF50 in combination.  
Empty vector co-transfection was used as a negative control, and co-transfections with plasmids 
encoding the KSHV K3 MHC-I downregulator or VZV ORF66 served as the positive controls.  
At 48 h post-transfection, cells were stained for MHC-I and analyzed by flow cytometry.  The 
average MFIs (+/- SEM) of GFP-positive cells from four independent experiments are shown.  
MFI data from each test transfection condition was compared against that of the negative control 
using the paired Student’s t-test, and the results are indicated above corresponding bars.  An 
equal level of pTK-EGFP was maintained in all transfection conditions. NS=not significant.    
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5.5 DISCUSSION 
The data presented here indicate a new role for the VZV ORF66 protein kinase in inhibition of 
MHC-I surface presentation, and also strongly suggest that VZV possesses additional ORF66-
independent mechanisms to modulate surface MHC-I in VZV-infected cells.  Novel recombinant 
VZV expressing GFP-66 proteins allowed highly accurate measurement of VZV infection and 
clearly demonstrated that the most efficient MHC-I downregulation was concurrent with 
extensive ORF66 expression at later stages of VZV infection.  VZV reduced the rate of MHC-I 
transport from the ER to the cis/medial-Golgi, induced a reduction in MHC-I heavy chain 
synthesis, and caused a moderate but consistent decrease in levels of folded hetero-dimerized 
class I heavy chains.  ORF66 appeared to act predominantly by inducing a delay in MHC-I 
transport from the ER to the cis/medial-Golgi.  While two previous studies have reported that 
VZV inhibits MHC-I surface expression, our study provides a more coherent portrait of MHC-I 
regulation during VZV infection and begins to clarify the VZV genes that are involved.   
 Abendroth, et. al. (2) reported no decrease in MHC-I synthesis or transport through the 
cis/medial-Golgi at 24 hpi, but indicated that the major bulk of intracellular MHC-I was retained 
in the more peripheral stacks of the Golgi complex.  It is clear from studies presented here that 
VZV infection does not immediately induce a surface downregulation of MHC-I, as is seen with 
ICP47 expression during the immediate early stage of HSV infection.  Rather the modulation of 
MHC-I surface expression correlates more closely with later stages of infection and high levels 
of ORF66 expression.  While we did observe intracellular accumulation of MHC-I in the Golgi 
region, we also detected an ORF66-dependent retention preceding the cis/medial-Golgi complex, 
which was concomitant with the lowest levels of MHC-I surface expression in VZV-infected 
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cells.  Since the former study was performed at 24 hpi, ORF66 expression most likely did not 
reach significant enough levels to affect MHC-I processing.  The data from a second study 
suggested that MHC-I heavy chain and β2M synthesis were lower at 48 hpi (38), and our data are 
in agreement with this, since we observed an ORF66-independent reduction in MHC-I synthesis 
in cells expressing high levels of GFP.  While a non-specific mechanism of global protein 
synthesis reduction is almost certainly involved, our data also suggest that VZV may impair 
MHC-I heavy chain and β2M association, since levels of folded hetero-dimerized heavy chains 
were consistently lower than total class I heavy chains.  The consistent upregulation of TfR1 
surface expression in VZV-infected cells was unexpected, and contrasts with data from the two 
previous studies (2, 38).  We suspect that differences in the experimental approaches used may 
account for this.  For example, Abendroth, et. al. (2) reported no effects on TfR1 surface 
expression in VZV-infected fibroblasts analyzed at 24 hpi.  While we observed some effect on 
TfR1 at 24 hpi, the greatest upregulation was observed at 48 and 72 hpi, indicating that this is 
predominantly a late-stage infection phenomenon. This adds to the complexity of the VZV 
program for controlling surface protein expression in infected cells.  
The specific mechanism by which ORF66 affects MHC-I surface levels remains unclear 
at this time.  Expression of functional ORF66 kinase resulted in impaired MHC-I maturation, but 
did not affect MHC-I synthesis, degradation or association with β2M.  The successful association 
of class I heavy chains with β2M suggests that ER-resident chaperone machinery (including 
calnexin, calreticulin and Erp57) may function normally in the presence of ORF66 expression.  
Our evidence do not suggest a close association of ORF66 with either folded MHC-I or total 
class I heavy chains, as ORF66 did not co-precipitate with MHC-I and did not co-localize with 
MHC-I in VZV-infected cells.  Inactivation of the ORF66 kinase domain abrogated most of its 
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ability to mediate MHC-I downregulation, suggesting that phosphorylation of a host cell protein 
is involved.  However, the slight reductions in MHC-I maturation and surface expression 
observed in the presence of the GFP-66kd protein do imply a possible dominant-negative 
interaction with a cellular protein involved in MHC-I biosynthesis.  Two commonly used viral 
mechanisms that inhibit MHC-I maturation in the early secretory compartment are inhibition of 
the TAP complex (68, 93, 96, 134, 148), which transports proteasomally-derived peptides into 
the ER; and inhibition of tapasin (20, 191), which bridges TAP to MHC-I and mediates the 
transfer of peptides from TAP to the MHC-I binding groove.  While neither TAP nor tapasin 
exhibits motifs similar to those phosphorylated by the ORF66 kinase (58), we hypothesize that 
ORF66 may activate host kinase cascades with downstream effects that dysregulate TAP or 
tapasin function.  Interestingly, it has been reported that phosphorylated TAP complexes bind 
peptides and ATP but cannot transport peptides without being dephosphorylated (152).  We 
speculate that ORF66 induces a hyper-phosphorylated state of the TAP that may lock the 
complex in a peptide-bound state.  An alternative scenario is that ORF66 causes aberrant 
phosphorylation of MHC-I cytoplasmic tails or the cellular machinery involved in vesicular 
transport between the ER and the cis/medial-Golgi.  This is prompted by the observations that 
cellular protein kinase A (PKA) is known to phosphorylate MHC-I tails (85, 200), and the US3 
kinase of HSV-1 (orthologous to ORF66) has been shown to induce phosphorylation of some 
cellular PKA targets (19).  Known ORF66 targets are highly similar to the optimized target motif 
of HSV-1 US3 kinase (145), suggesting that some PKA targets could also be targets of ORF66.  
MHC-I cytoplasmic tail phosphorylation normally occurs at the cell surface or in late or 
recycling endosomes (30, 57, 115, 154).  Thus, aberrant phosphorylation of pre-Golgi MHC-I 
could result in deviations from normal trafficking early in its secretory transport.   Studies to 
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address ORF66-mediated effects on the peptide loading complex and ORF66-directed 
phosphorylation of MHC-I are in progress.  
The ORF66 kinase modulates several aspects of the cellular environment to facilitate 
VZV infection, but cellular proteins that are targeted for direct phosphorylation by ORF66 
remain unknown.  In VZV-infected T lymphocytes, ORF66 inhibits activation of caspase 3 and 
interferon γ (IFNγ)-mediated Stat1 phosphorylation (220).  One consequence of IFNγ signaling 
is the upregulation of MHC-I surface expression, through increased transcription from the human 
leukocyte antigen (HLA) locus (160).  Here, we demonstrate that ORF66 modulates MHC-I 
surface expression independently of IFNγ signaling.  However, it will be interesting to address 
the effects of ORF66 on both induced MHC-I transcription and post-translational membrane 
trafficking in response to both type I and type II IFN treatment.  The identification of host cell 
proteins phosphorylated in the presence of the ORF66 kinase and the effects of ORF66 
expression on the cellular transcriptome are currently under investigation.   
VZV lacking ORF66 expression maintains the ability to induce MHC-I downregulation, 
and therefore VZV must encode one or more additional genes that affect MHC-I surface 
expression.  Several alphaherpesviruses, including HSV-1, negatively regulate MHC-I through 
the virion host shutoff (vhs) gene, which mediates a global reduction of cellular protein 
expression (82, 97, 135, 231).  VZV also causes a reduction in cellular protein synthesis that may 
contribute to the reduction in MHC-I surface levels in infected cells.  The VZV vhs ortholog 
(ORF17) is known to induce mRNA degradation, albeit to a lesser extent compared to its HSV-1 
counterpart, but its role in silencing cellular protein expression during VZV infection remains 
unclear (217).  VZV ORF9a, the ortholog of the BHV-1 UL49.5 TAP inhibitor, was previously 
assessed for effects on MHC-I surface expression in a human melanoma cell line (Mel JuSo) and 
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was found to have no effect (134).  Our analyses also indicated no ability to induce MHC-I 
surface downregulation, even when ORF9a was expressed with its possible chaperone ORF50.  
However, we note that the HCMV US10 protein is able to bind MHC-I and impede its maturation 
through the Golgi, but does not affect the surface expression of MHC-I detected by pan-specific 
HLA antibodies (69).  The identities of additional VZV genes involved in MHC-I 
downregulation remain to be elucidated.   
We conjecture that ORF66-induced MHC-I downregulation could be important at 
multiple stages of VZV pathogenesis.  Viruses lacking ORF66 expression show only minor 
reductions in growth in several VZV-permissive cell types in culture, but are growth-restricted in 
T-lymphocytes in the SCID-hu model of VZV infection (174, 220, 224).  This restriction has 
been attributed to, at least in part, ORF66-mediated inhibition of apoptosis, as a greater 
percentage of cells showed increased caspase 3 activation when ORF66 expression was lacking 
(220).  Thus, one role for the ORF66 kinase is to promote T-lymphocyte survival and the 
subsequent transfer of infectious virus to skin cells during the viremic stage of VZV infection.  
While we do not know whether ORF66 induces MHC-I downregulation in T cells, we suggest 
that this ORF66 function could serve to further enhance T cell survival by allowing avoidance of 
immune surveillance.  The ORF66 induced downregulation of MHC-I surface expression may 
also be critical during VZV growth in skin cell layers.  ORF66 is not required for pathogenesis in 
human skin implants in the SCID-hu mouse (174, 220), but this model lacks a fully competent 
immune system.  Recent evidence suggests that epidermal cells are infected shortly after 
inoculation and undergo a prolonged infection period before producing infectious lesions at the 
skin surface (139).  Since VZV-specific-immunity may become well developed during later parts 
of the skin infection phase, evasion of adaptive immunity could be important for survival of 
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infected skin cells.  Finally, ORF66 may affect MHC-I presentation in VZV-infected sensory 
neurons during latency.  Several VZV lytic antigens, in addition to ORF66, are transcribed and 
may be expressed during latent infection, and these include ORFs 4, 21, 29, 62, and 63 (45, 170).  
Memory CTL that recognize ORFs 4, 10, 29, and 62 can be detected in VZV immune subjects 
(12), but human ganglia have been found to lack VZV specific CTL infiltration (106, 240).  The 
latter study also shows that human ganglia harboring latent HSV-1 contain HSV-1 specific CTL, 
clearly implying that antigens can be properly presented in neurons.  Hence, the expression of 
ORF66 may be required for two roles during VZV latency: one may be to suppress the nuclear 
localization and nuclear functions of the major VZV transcriptional transactivator by promoting 
cytoplasmic location (58), and the other may be to prevent antigen presentation of latency 
associated VZV antigens.   
 In summary, VZV appears to attack MHC-I using a multi-faceted approach that includes 
the ORF66 kinase.  Similar functions have not been described for orthologous US3 kinase family 
proteins, and as no other viral kinase has been shown to impair MHC-I transport through the 
Golgi complex, this represents a novel role for kinases in viral immune evasion.  ORF66’s ability 
to delay MHC-I maturation in VZV-infected cells may contribute to VZV pathogenesis by 
promoting efficient dissemination, survival during the extended incubation period and 
persistence in latently infected ganglia. 
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6.1 ABSTRACT 
In this study, we utilized recombinant varicella-zoster virus (VZV) expressing enhanced green 
fluorescent protein (EGFP)-tagged ORF66 kinase proteins to investigate novel ORF66 
trafficking behavior in relation to catalytic activity and time.  EGFP-66 localized to bright foci 
(i.e. “speckles”) at the periphery of the nucleolus and throughout the nucleoplasm in early and 
late stages of infection.  Using live-cell time lapse imaging, we showed that the nucleolar 
speckles remained mostly immobile, while nucleoplasmic speckles exhibited high-velocity 
trajectories that moved throughout nucleoplasm in a directed manner.  Nucleoplasmic speckles 
exhibited fusion and the ability to traffic to the nucleolus.  Cytoplasmic speckles were also 
observed in some cells expressing high levels of ORF66, but these moved more slowly and less 
erratically.  A sub-population of ORF66 speckles associated with ND10 domains during very 
early infection, but most were associated with the surfaces of VZV replication or capsid 
assembly compartments.  In contrast, VZV expressing a kinase inactivated version of ORF66 
(EGFP-66kd) failed to form nucleoplasmic speckles and exhibited abnormal accumulation in 
both RC and nuclear regions containing mislocalized major capsid protein (MCP).  Furthermore, 
EGFP-66kd was recruited from RC at very late times post-infection and accrued with the MCP at 
the periphery of the nucleus, suggesting a high-affinity association with a capsid component.  
EGFP-66 nuclear speckles were efficiently formed in the absence of additional VZV protein 
expression, and these were also juxtaposed to ND10 domains, indicating that speckle formation 
and ND10 association are intrinsic properties of ORF66.  Together, these results demonstrate 
highly novel nuclear interactions for the VZV ORF66 protein kinase, and suggest that ORF66 
may use nucleoplasmic trafficking and sequential localization to mediate multiple functions in 
VZV-infected nuclei, including a potential role in capsid morphogenesis. 
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6.2 INTRODUCTION 
The human herpesvirus, varicella-zoster virus (VZV), causes chickenpox in naïve individuals, 
establishes latency in sensory neurons, and can reactivate in response to immunosuppressive 
stimuli to induce herpes zoster (shingles).  VZV is classified among the herpesvirus subfamily 
Alphaherpesvirinae, which includes two additional human pathogens, herpes simplex virus type 
1 and 2 (HSV-1 and HSV-2).  Alphaherpesviruses uniquely encode a serine/threonine (Ser/Thr) 
protein kinase gene within the unique short (US) region of the genome and collectively, these are 
referred to as the US3 kinase family.  The VZV US3 ortholog is the ORF66 protein kinase.  US3 
kinases are multi-functional and are known to phosphorylate cellular factors to prevent apoptosis 
(53, 71, 74, 112, 149, 188); alter the actin cytoskeleton to promote cell-to-cell spread (63, 221, 
237); modify the cellular histone deacetylase (HDAC) machinery, possibly to promote viral gene 
expression (84, 201); modulate interferon signaling (198); and facilitate capsid egress through 
the nuclear lamina by phosphorylation of multiple laminar proteins (131, 144, 178, 181, 212, 
215, 221, 241).  In VZV-infected cells, ORF66 has been shown to prevent activation of caspases 
and phosphorylation of Stat1 in response to γ-interferon, implying that ORF66 may prevent 
apoptosis and immune-mediated cellular signaling (219, 220).  However, the effects of ORF66 
on other US3 kinase targets have not been reported.      
VZV lacking ORF66 expression replicate in many cell types in culture, but are 
attenutated in T lymphocytes both in culture and in thy-liv implants from the severe combined 
immunodeficient (SCID)-hu model of in vivo VZV infection (174, 220, 224).  VZV expressing 
point-inactivated versions of ORF66 do not compensate replication in T cells, and this suggests 
that phosphorylation of either a viral or host cell target is critical (219).  Two unique functions 
have been described for the ORF66 kinase in VZV infected cells: phosphorylation and nuclear 
 165 
exclusion of the VZV major transcriptional regulator, IE62, in late-stage infection (58, 124); and 
downregulation of class I major histocompatibility complex surface expression (59).  IE62 is an 
essential viral transactivator, which uniquely exhibits abundant association with the viral 
tegument (125).  To facilitate IE62 tegument incorporation, ORF66 directly phosphorylates IE62 
immediately adjacent to its nuclear localization signal, resulting in IE62 nuclear exclusion and 
accumulation in the trans-Golgi network (TGN) (58, 127) (see also Chapter 4).  Regarding 
MHC-I, ORF66 modulates the host cell environment in a kinase activity-dependent manner, such 
that MHC-I trafficking through the Golgi complex is impaired, resulting in a reduction in the 
total MHC-I surface levels (59).  Since MHC-I is crucial for the activation of CD8+ T cells 
(CTL) and subsequent elimination of infected cells, this may represent a highly novel means of 
evasion of adaptive immunity.  The cellular targets involved in MHC-I downregulation have not 
been determined.     
  We have recently reported the derivation of recombinant VZV expressing functional or 
catalytically inactive EGFP-tagged ORF66 kinase proteins (VZV.GFP-66 and VZV.GFP-66kd, 
respectively), which are regulated by the native ORF66 promoter (59, 61).  Using these, we have 
demonstrated for the first time that ORF66 is expressed with typical US3 kinetics, beginning at 4-
8 h post-infection, and exhibits diffuse nuclear and cytoplasmic localization (Chapter 4).  In 
addition, highly unique nuclear distributions were observed at later times, including 
accumulation in bright foci (i.e., “speckles”) throughout the nucleoplasm and formation of ringed 
structures that surrounded the putative nucleolus ((59) and Chapter 4).  Since ORF66 does not 
co-localize with IE62 in nuclear speckles (Chapter 4), this suggests an alternate nuclear function 
for ORF66 during late-stage VZV infection.  Similar distributions have not been reported for any 
other US3 kinase.    
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 In this study, we utilized the EGFP-66 viruses in fixed and live cell microscopy assays to 
investigate ORF66 speckle trafficking as a function of kinase activity and time during VZV 
infection.  We reveal novel ORF66 associations with cellular and viral nuclear domains, as well 
as dynamic trafficking throughout the nucleus and to the nucleolus.  These results suggest a high 
level of multi-functionality for ORF66 during VZV infection, and imply that ORF66 may be 
involved in capsid maturation, similar to other US3 kinases. 
6.3 MATERIALS AND METHODS 
6.3.1 Cells and chemicals 
MRC-5 human lung fibroblasts (ATCC, Manassas, VA) and human melanoma cells (kindly 
provided by C.Grose, University of Iowa, Iowa City, IA) were maintained as previously 
described (59).  To completely repress trans-gene expression from replication defective 
adenovirus vectors, we used doxycycline at a concentration of 0.5 µg/ml. 
6.3.2 Viruses 
Recombinant VZV-pOka and VZV expressing EGFP-tagged ORF66 (VZV.GFP-66) or 
ORF66kd (VZV.GFP-66kd) have been previously described (59, 61).  VZV.GFP-66 and 
VZV.GFP-66kd were derived from pOka cosmids and express in-frame EGFP-ORF66 or 
ORF66kd (EGFP-66, EGFP-kd) fusion proteins in place of the wild-type ORF, and under the 
control of the natural promoter.  In VZV.GFP-66kd, the ORF66 gene encodes point mutations at 
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two critical kinase domain residues (D206E and K208R), which render the kinase inactive (59, 
124).  VZV expressing kinase active ORF66 with an N-terminal hemagglutinin (HA) epitope tag 
(YPYDVPDYA) (referred to as VZV.HA-66) was derived in a manner similar to that of 
VZV.GFP-66 (59).  For this, we created a modified pGK2-HA66 plasmid (124), in which the 
human cytomegalovirus (HCMV) IE promoter was replaced with PCR-amplified native ORF66 
promoter, from the Avr II site (nt 112957) through the natural ORF66 ATG, with Hind III and 
Pst I restriction endonuclease overhangs (p66prom-HA66).  The 66prom-HA66 cassette was 
digested out of this plasmid backbone using unique Avr II and Bam HI restriction sites, and used 
to replace the corresponding ORF66 fragment in the pUC19-pvSpe23 shuttling vector (59).  The 
entire Avr II-SgrAI fragment from pUC19-pvSpe23, containing HA-66, was cloned into the 
pvSpe23 cosmid (pvSpe23.HA-66), and isogenic viruses were obtained after co-transfection of 
pvSpe23.HA-66 with the remaining VZV pOka cosmids (pvFsp73, pvSpe14, and pvPme2) and 
pCMV62 (expresses the VZV transactivator IE62) in MeWo cells.  All VZV infections for live 
and fixed cell microscopy were initiated with active MRC-5 cultures of cell-associated VZV, at a 
ratio of one infected cell to 50 uninfected cells, and were incubated for 48 h preceding fixation.  
A replication defective adenovirus vector expressing EGFP-66 from a tet/DOX-repressible 
promoter was used to infect MRC-5 cells as previously described (59). 
6.3.3 Antibodies, immunofluorescence and microscopy of fixed specimens 
Indirect immunofluorescence was performed as previously described (59).  A monoclonal mouse 
antibody to the VZV ORF66 protein was kindly provided by A. Baiker (Ludwig-Maximilians-
Universität München, München, Germany).  Polyclonal rabbit antiserum to VZV IE62 (1:800) 
and ORF29 (1:500), and monoclonal mouse anti-HA antibodies (1:400) have been previously 
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described (58, 124, 126). A mouse monoclonal antibody to the VZV major capsid protein (MCP, 
ORF40; Virusys Corporation, Sykesville, MD) was used at 1:400.  In some studies, we used a 
mouse monoclonal antibody against VZV IE62 (Advanced Biotechnologies, Inc., Columbia, 
MD).  Antibodies for detection of host cell nuclear antigens were as follows: monoclonal mouse 
anti-C23-nucleolin (nucleolus; used at 1:1000), rabbit anti-coilin (Cajal bodies; used at 1:200), 
and mouse anti-PML (ND10 domains; used at 1:500) (Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA).  For secondary detection of cellular and VZV antigens, Alexa Fluor (AF) conjugated 
goat anti-mouse or goat anti-rabbit Fab fragments (Invitrogen Corporation, Carlsbad, CA) were 
used at 1:400.  Excitation (ex) spectra are indicated in the Figure Legends.  Nuclei were stained 
using Hoechst 33258 (Sigma-Aldrich).  Epifluorescent microscopy was performed as previously 
described (59). 
6.3.4 Live-cell time-lapse microscopy and object tracking analysis 
MRC-5 cells were seeded to confluency on glass-bottomed culture plates (Bioptechs, Butler, PA) 
and allowed to equilibrate for 24-48 h, at which time they were infected with cell-associated 
VZV.GFP-66 or VZV.GFP-66kd.  For time-lapse imaging of live infected cells, dishes were 
placed on a Delta T Stage open heating system (Bioptechs), which was mounted on a Nikon 
TE2000 epifluorescent microscope.  This heating system was modified by the manufacturer to be 
semi-closed by the addition of a water-tight gasket in the system lid.  Cells were maintained at 
37ºC with continuous medium recycling and an atmosphere of 5% humidified CO2.  Metamorph 
7.2 software was used to control time-lapse imaging, and micrographs of equal exposure were 
acquired every 5 minutes using a 20X air objective with a correction collar, and image stacks 
were converted into AVI files for visualization. 
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 For object tracking analysis, time-lapse stacks were manually aligned in Metamorph 
using the nucleolus as a reference point.  Fluorescence images were inverted, corrected for 
shading, and the background flattened to facilitate observance of individual EGFP-66 foci 
(speckles).  The trajectories and velocities of 12 independent nuclear speckles and 17 
independent cytoplasmic speckles were quantified using the Track Objects algorithm and 
analyzed using GraphPad Prism 4 software. 
6.4 RESULTS 
6.4.1 VZV ORF66 localizes to the nucleolar periphery 
In VZV.GFP-66-infected cells, we have reported a high proportion of EGFP-66 in the nucleus, 
as well as novel speckles in the nucleoplasm and in ring-shaped structures that surround the 
putative nucleolus (59) (see also Chapter 4).  A similar distribution has not been reported for any 
other US3 kinase.  To ensure that this EGFP-66 distribution resulted from specific ORF66 
activities and to assess any relationship with the nucleolus, we performed indirect 
immunofluorescence analyses in cells infected with VZV.GFP-66, VZV expressing an HA-
tagged version of ORF66 (VZV.HA-66) and VZV pOka.  Infected MRC-5 cells were left 
unstained or stained with an antibodies to C23-nucleolin (VZV.GFP-66), the HA epitope tag 
(VZV.GFP-HA), or a monoclonal antibody recognizing the wild-type untagged ORF66 protein 
(VZV pOka).  All cells were stained with Hoechst to identify nuclei.  Protein localizations were 
determined by epifluorescent microscopy.   
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 As expected, EGFP-66 was highly nuclear in most cells and often exhibited both 
nucleoplasmic speckles and speckles that associated in a ring at the periphery of the nucleolus 
(Figure 6-1A and B).  Nucleolar speckles did not localize within the nucleolus, as determined by 
Z-section analysis (Figure 6-1B).  Nucleoplasmic speckles varied in size and number and were 
often distributed unevenly throughout the nucleus (Figure 6-1A and B).  HA-66 detected by 
indirect immunofluorescence was similarly distributed, with predominant nuclear localization, 
nucleoplasmic speckles and ORF66 accumulation at the nucleolus (Figure 6-1C).  HA-66 
nucleolar rings consisted of independent speckles, similar to those observed for EGFP-66.  
Importantly, wild-type ORF66 detected by a monoclonal antibody was more abundantly 
localized to the nucleus compared with the cytoplasm, and accumulated preferentially in the 
nucleolar regions (Figure 6-1D), but high resolution identification of individual speckles was 
impeded by high background staining.  These results indicate that the determinants within the 
ORF66 kinase protein and not the EGFP epitope tag are responsible for novel ORF66 nuclear 
distributions in VZV-infected cells. 
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Figure 6-1 Wild-type and epitope-tagged ORF66 localize to the nucleolar periphery in VZV infected cells 
MRC-5 cells grown on coverslips were inoculated with VZV.GFP-66 (A and B), VZV.HA-66 
(C), or VZV-pOka (D) and fixed at 48 hpi.  In (A), no indirect immunofluorescence was 
performed.  In the remaining panels, cells were stained with monoclonal mouse anti-C23 and 
Alexa-Fluor 647 conjugated secondaries (AF 647) (B); anti-HA and AF 488 (C); or anti-ORF66 
and AF 488.  In A, C, and D, the enlarged micrograph depicts a color combined image of ORF66 
expression in green and Hoechst 33258-stained nuclear chromatin in blue.  Smaller black and 
white panels show individual ORF66 and Hoechst staining patterns.  In B, a color combined 
image of EGFP-66 (green), C23 (red), and Hoechst (blue) fluorescence is depicted, with YZ and 
XZ orthogonal planes through the nucleolar region of a partial Z-stack of a VZV.GFP-66-
infected cell, to the right and at the bottom, respectively. 
6.4.2 Intranuclear EGFP-66 speckles exhibit dynamic trafficking including fusion, 
association with the nucleolus and directed trajectories 
The unique nuclear speckles exhibited by ORF66 prompted an investigation of ORF66 
trafficking in VZV infection.  We reasoned that a better definition of ORF66 activities may 
provide clues into the nature of ORF66 speckle functions.  For this, we exploited the intrinsic 
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auto-fluorescent property of EGFP-66 and live-cell time-lapse imaging to assess changes in 
ORF66 distribution over time.  The cell-associated nature of VZV does not allow the 
establishment of high multiplicity synchronous infections.  Thus, to facilitate time-dependent 
visualization of EGFP-66 in infected MRC-5 fibroblasts, autofluorescence was captured at the 
edges of established VZV.GFP-66 plaques for an extended time-course of >24 hours.  Similar 
studies were performed with VZV.EGFP-66kd to determine any role in ORF66 trafficking that 
could be attributed to kinase activity.  Movies of EGFP fluorescence in representative cells 
infected with VZV.GFP-66 or VZV.GFP-66kd are shown in Supplemental Figs. 1 and 2, 
respectively: VZV-GFP66.AVI and VZV-GFP66kd.AVI.  An overview of the EGFP-66 and 
EGFP-66kd localization patterns is exhibited in Figure 6-2.  For clarity, we note that many 
VZV.GFP-66-infected cells exhibited reduced levels of EGFP-66 fluorescence relative to that 
shown, although trafficking patterns were similar.  We believe these differences are likely due to 
differences in the relative multiplicity of infection for each cell.   
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Figure 6-2 Overview of EGFP-66 and EGFP-66kd localizations in VZV-infected cells imaged by live-cell time-
lapse microscopy 
MRC-5 fibroblasts were plated on Bioptechs glass-bottomed dishes and infected with cell-
associated VZV.GFP-66 (A-C) or VZV.GFP-66kd (D) at a ratio of 1 infected cell to 50 
uninfected cells.  At 24 hpi, a dish was placed on heated stage system, and medium was 
maintained at 37ºC with a continuous 5% humidified CO2 perfusion.  Micrographs of equal 
exposure were captured at the edge of a developing plaque every 5 minutes for 26-27 h.  EGFP-
66 and EGFP-66kd localizations are shown for single cells that began to exhibit nuclear and 
cytoplasmic fluorescence at approximately the same time after initiation of time-lapse capture.  
The time elapsed is indicated in the upper left of each panel.   
 174 
 In VZV.GFP-66 infections, EGFP-66 initially exhibited diffuse nuclear and cytoplasmic 
fluorescence, although nuclear fluorescence was more prominent (Figure 6-2A).  This is 
consistent with the EGFP-66 fluorescence pattern exhibited in fixed cells at the edges of VZV-
infected plaques (i.e., early stage infection), as well as the EGFP-66 distribution pattern observed 
from 4-8 hpi in low multiplicity “cell-free” VZV infections (Chapter 4).  The next significant 
feature we observed was a peri-nuclear cytoplasmic dot, which exhibited higher fluorescence 
compared to the surrounding cytoplasm and the nucleus.  Again, this was consistent with peri-
nuclear dots observed in cell-free infections, which co-localized with the VZV IE62 protein 
(Chapter 4).  EGFP-66 then accumulated in several areas in the nucleoplasm, and this was 
followed by the appearance of nucleolar speckles.  Nucleoplasmic speckles were apparent 
thereafter, and many exhibited rapid and erratic trafficking patterns with trajectories that covered 
large areas of the nucleus.  Concurrent with the appearance of motile nucleoplasmic speckles, 
EGFP-66 was also observed in speckles in the distal areas of the cytoplasm; in the previously 
described cytoplasmic dot, which was significantly larger and more amorphous; and in a 
juxtanuclear region on the opposite side of the nucleus.  The latter distribution patterns are 
consistent with a late infection stage, as cell-free infections exhibited this phenotype at only >12 
hpi.  Notably, EGFP-66 nucleolar speckles appeared to remain relatively stationary throughout 
the time course.  Time-lapse analysis of EGFP-66kd in infected cells established that the absence 
of functional kinase activity resulted in a lack of motile nucleoplasmic speckles and faulty 
accumulation in expanding nuclear compartments (Figure 6-2).  Similar results were observed in 
independent cells at other stage positions in the same experiment and in replicate experiments.  
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To emphasize specific features of ORF66 nucleoplasmic trafficking, we have shown 
enlarged sequential frames of the VZV.GFP-66 infected nucleus over a 55 minute period 
beginning ~14 h after the initiation of the time-lapse capture (Figure 6-3A).  Two speckles that 
began on opposite sides of the nucleolus exhibited high motility (Figure 6-3A, frames 0, 5, 10, 
and 15; white and black arrows) and fused near the nuclear boundary at the top of the nucleus 
(Figure 6-3A, frame 20, white arrow with black border).  Fusion was confirmed by the increased 
size and brighter fluorescence of the remaining speckle.  Within 10 minutes, the fused speckle 
trafficked into the periphery of the nucleolus, remained stationary for an additional 10 minutes, 
and subsequently began a slow ascent away from the nucleolus and into the nucleoplasm (Figure 
6-3A frame 30, 35, 40, 45, 50 and 55).  Fusion among cytoplasmic speckles was less obvious, 
and some of these may have been derived from the amorphous ORF66 cytoplasmic structure 
(Figure 6-3B).           
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Figure 6-3 EGFP-66 speckles are highly dynamic 
(A) Trafficking of specific EGFP-66 nucleoplasmic speckles over a 1 h time-frame.  The first 
frame (0) is an enlarged image of the nucleus shown in Figure 6-2A, and each subsequent frame 
shows the same nucleus 5 minutes later.  The total number of elapsed minutes is shown in the 
upper left corner.  White and black arrows point to individual motile EGFP-66 speckles in each 
frame.  These two speckles fused after 20 minutes, and were subsequently demarcated by a white 
arrow with a black border.  Arrowheads point to a relatively stationary speckle. (B) EGFP-66 
cytoplasmic speckles.  The first frame (0) is an enlarged image of the left-most cytoplasm shown 
in Figure 6-2A, and each subsequent frame shows the same region, with the elapsed minutes 
shown in the upper left corner.   
 
To more quantitatively characterize EGFP-66 nuclear and cytoplasmic trafficking, we 
tracked the trajectories of 12 independent nuclear speckles representing nucleolar and 
nucleoplasmic populations, as well as 17 individual cytoplasmic speckles.  Speckle trajectories 
for each are shown in Figure 6-4A and B.  Sample trajectories of representative nuclear speckles 
 177 
and several cytoplasmic speckles were plotted as a function of time (Figure 6-4C and D).  
Clearly, nucleolar speckles were relatively stationary and did not appreciably move away from 
their points of origin (Figure 6-4C, green trajectory).  In contrast, nucleoplasmic speckles 
exhibited a variety of motions and some of these appeared to be directed, since bursts of high 
velocity movement away from the points of origin were readily detected (Figure 6-4C, majenta 
trajectory).  Nucleoplasmic speckles also exhibited some retrograde movements, suggesting they 
may interact intermittently with nuclear structures that obstruct forward motion.  The maximum 
velocity observed among nucleoplasmic speckles was 0.01454 µm/sec (0.8724 µm/min).  EGFP-
66kd cytoplasmic speckles collectively moved away from points of origin, and did not generally 
exhibit trajectories suggestive of directed motion (Figure 6-4B and D).  The maximum velocity 
observed for a cytoplasmic speckle was 0.002127 µm/sec (0.12762 µm/min).     
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Figure 6-4 Quantitative analysis of ORF66 speckle trafficking 
Frames representing the last 117 images (9.75 h or 585 min) from the VZV.GFP-66 time-lapse 
experiment shown in Figure 6-2 were inverted, corrected for shading, and flattened; and then 
aligned by hand with Metamorph 7.2 software, using the nucleolus as a reference.  Speckle 
trajectories and velocities were quantified for the nucleus (A) or the cytoplasm (B) using the 
Metamorph Track Objects function.  Enlarged images show individual speckle trajectories in 
multiple colors, as well as the region of the cell that was mapped.  In (A), an outline of the 
nuclear boundary was artificially added for ease of reference.  (C) The displacement of 4 sample 
nuclear speckles and 1 cytoplasmic speckle with respect to their origins were plotted as a 
function of time, and are color-coded to match the corresponding speckle trajectories in (A).  
Nuclear speckles were selected to represent distinct areas of the nucleus, and these are indicated 
on the legend.  In (D), 5 sample cytoplasmic speckles were analyzed as described in (C), except 
that displacement curves are not color coded. 
 
 These data indicate a highly dynamic nature for ORF66 nucleoplasmic speckles, 
emphasize a high level of ORF66 multi-functionality, and are suggestive of a new role for 
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ORF66 in regulating aspects of the nuclear environment in VZV-infected cells.  In addition, 
ORF66 kinase activity is clearly critical for its proper localization and trafficking. 
6.4.3 A sub-population of ORF66 nuclear speckles associates with ND10 domains, but not 
Cajal bodies 
Cellular Cajal bodies (CB), a nuclear sub-domain implicated in the storage and trafficking of 
small nuclear ribonucleoproteins (snRNP) and formation of transcriptosomes are known to 
associate with the nucleolus; have the ability to join to form larger CBs or split into smaller CBs; 
and exhibit high velocity directed trafficking patterns at a rate of up to 0.9 µm/min (199, 262).  
Given the similarity with the observed trafficking patterns of EGFP-66, we assessed the 
possibility that EGFP-66 speckles associated with CB in VZV-infected cells.  For this, we 
infected MRC-5 fibroblasts with cell-associated VZV.GFP-66 and stained fixed cells with 
antibodies against a major CB component, p80 coilin.  The previously established time-
dependent localization pattern for EGFP-66 was utilized to identify cells at specific stages of 
infection in mixed cultures.  Uninfected MRC-5 cells exhibited coilin staining in a speckled 
pattern evenly distributed throughout the nucleus, with some brighter foci apparent in the region 
around the nucleolus (Figure 6-5A).  As expected, there was no specific accumulation in the 
nucleolar interior.  In marked contrast, coilin was drastically redistributed in VZV-infected cells, 
initially accumulating in the nucleolus (Figure 6-5B), followed by exclusive localization in 5-20 
nucleoplasmic speckles (Figure 6-5C).  Some nucleoplasmic speckles were observed at the 
nucleolar periphery, but none of the coilin-positive speckles co-localized with EGFP-66 
speckles.  Coilin speckles remained in late-stage infections, although their number and size was 
reduced (Figure 6-5D). Thus, EGFP-66 speckles are not CB.  Notably, there was no difference 
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coilin localization in VZV.GFP-66kd-infected cells, indicating that coilin redistribution was 
induced by viral factors other than the ORF66 kinase. 
 
Figure 6-5 ORF66 speckles are not Cajal bodies 
MRC-5 fibroblasts were left uninfected or infected with VZV.GFP-66 and fixed as described 
above, and stained with antibodies against the major CB component, p80 coilin.  (A) Mock-
infected cells with typical coilin staining pattern. Arrows poin out coilin foci in the region of the 
nucleolus.  (B-D) Coilin localization at different stages of VZV infection.  Stages are indicated at 
the top.  Large color-combined panels depict EGFP-66 in green and coilin in red.  Smaller black 
and white images show individual staining patterns, which are indicated for each panel.  
 
 We also assessed any possible EGFP-66 co-localization with ND10 domains, as these are 
known to associate ICP4 foci that eventually expand into replication compartments (RC) (62).  
For this, we performed similar infections, but stained cells with antibodies against the ND10 
constituent, PML, and the VZV IE62 protein, which is the ortholog to HSV-1 ICP4.  Abundant 
PML-reactive nuclear domains similar to those in mock-infected cells were observed at early 
times post-infection, when ORF66 was expressed at low levels and was predominantly 
nucleoplasmic.  In these cells, minute EGFP-66 speckles were observed in association with IE62 
foci at the nuclear edge and also juxtaposed to PML independently of IE62 staining (Figure 6-
6B).  However, co-localization was not observed between PML and EGFP-66 nucleoplasmic or 
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nucleolar speckles.  Later, PML was observed adjacent to expanding IE62 nuclear staining 
(Figure 6-6C), and EGFP-66 speckles were also associated with IE62 in these regions.  No 
juxtaposition or co-localization was observed between PML and EGFP-66 in more prominent 
nuclear dots in other cells (data not shown).  PML-positive foci persisted into late stage 
infection, albeit to reduced levels (Figure 6-6D).  These results indicate that EGFP-66 speckles 
may be involved in the subversion of host processes regulated by ND10 domains or in the 
formation of VZV replication compartments.  However, the the failure of these two proteins to 
exhibit any co-localization in later stages of infection imply that EGFP-66 speckles have 
additional, unrelated functions. 
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 Figure 6-6 A sub-population of EGFP-66 speckles localize adjacent to ND10 domains 
MRC-5 fibroblasts were left uninfected or infected with VZV.GFP-66 and fixed as described 
above, and stained with antibodies against the major ND10 component, PML (AF 647), and 
VZV IE62 (AF 546).  (A) Uninfected cells exhibit many bright PML foci throughout the 
nucleus.  Image depicts a coolr combine overlay of PML and Hoechst.  (B-D) PML distribution 
in VZV.GFP-66-infected cells at different stages.  Stages are indicated at the top.  Large color-
combined panels depict EGFP-66 in green, PML in red and IE62 in blue.  Smaller black and 
white images show individual staining patterns, which are indicated for each panel. 
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6.4.4 ORF66 decorates the surface of VZV replication compartments (RC) in early 
infection, but aberrantly accumulates within RC in the absence of kinase activity 
The above studies did not identify EGFP-66 speckles in association with cellular nuclear bodies, 
but did imply a possible association with RC.  The HSV-1 ICP4 protein is a major component of 
RC, and here we observed IE62 nuclear staining reminiscent of this type of localization (Chapter 
4).  In addition, some EGFP-66 speckles appeared to associate with IE62 exhibiting RC-like 
staining patterns.  To more specifically delineate the level of EGFP-66 association with VZV 
RC, we performed similar indirect immunofluorescence analyses in VZV.GFP-66-infected cells 
stained for both the IE62 protein and the VZV ORF29 protein.  ORF29 is the VZV single 
stranded DNA-binding protein and a putative early gene involved in VZV genome replication 
(126).  ORF29 exhibits punctate nuclear localization within structures nearly identical in 
appearance to HSV-1 RC (46).  As we observed EGFP-66kd accumulation in large nuclear 
structures in live-cell analysis, we also performed VZV.GFP-66kd infections to assess any kinase 
activity dependent associations with this compartment.     
As described in previous studies (Chapter 4) (127), IE62 was predominantly nuclear 
during early infection stages, exhibiting diffuse nucleoplasmic fluorescence and accumulation in 
multiple foci.  Here, we demonstrate that IE62 foci co-localize with ORF29, suggesting they 
represent pre-replicative compartments (pre-RC) (Figure 6-7A).  Faint EGFP-66 speckles were 
observed in the putative pre-RC region; but EGFP-66 was also observed in low levels at the 
nucleolar periphery, throughout the nucleoplasm and in the cytoplasm.  Later, when abundant 
levels of cytoplasmic IE62 were detected, VZV RC expanded, coalesced and contained the 
majority of nuclear IE62 (Figure 6-7B).  ORF66 speckles decorated the outer surface of RC but 
did not co-localize with punctate ORF29 staining or diffuse IE62 staining.  Small ORF66 
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speckles were observed throughout the nucleoplasm and some were also distributed at the 
nucleolar periphery.  As the RC continued to expand, EGFP-66 accumulated at the nucleolus, but 
also continued to decorate the RC (Figure 6-7C).  Finally, in very late-stage infected cells, the 
RC occluded most of the nucleus and lacked high levels of IE62 staining (Figure 6-7D).  EGFP-
66 often appeared to be restricted to the nucleolar area and usually did not decorate the RC 
surface.  These results indicate that EGFP-66 associates with IE62+ RC in VZV-infected nuclei 
during intermediate stages of development, and with nucleoli at both early and later stages of 
infection, and suggests ORF66 performs overlapping functions in each of these locations.   
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 Figure 6-7 ORF66 associates with VZV nuclear replication compartments during early stages of VZV 
infection 
MRC-5 fibroblasts grown on coverslips were infected with VZV.GFP-66 (A-D) or VZV.GFP-
66kd (E-H) at a ratio of 1 infected cell to 50 uninfected cells.  At 48 hpi, cells were fixed with 
4% paraformaldehyde and stained with a rabbit polyclonal antibody to VZV ORF29 protein and 
a mouse monoclonal antibody to VZV IE62.  Viral protein localizations were visualized by 
indirect immunofluorescence after staining with secondary Alexa Fluor-conjugated antibodies 
(goat anti-rabbit 546 and goat anti-mouse 647).  For each micrograph grouping, the enlarged 
merged image depicts pseudocolored fluorescence for EGFP-66 (green), ORF29 (red) and IE62 
(blue).  Smaller panels show individual protein distributions in black and white: i) GFP-66 or 
GFP-66kd, ii) IE62, and iii) ORF29.  The infection condition is indicated at the top of each 
column of panels. 
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EGFP-66kd in VZV.GFP-66kd infections exhibited marked differences in localization 
compared with the functional EGFP-66.  Specifically, EGFP-66kd did not exhibit nucleoplasmic 
speckles that decorated the RC surface, and instead aberrantly accumulated in a diffuse manner 
similar to that of IE62 in expanding RC (Figure 6-7F and G).  At a later stage, EGFP-66kd was 
often prominently observed in nucleolar-associated foci, indicating that this was not dependent 
on functional kinase activity.  Additional nuclear accumulations independent of ORF29 and IE62 
also suggested that EGFP-66kd may associate with other structures in VZV-infected nuclei 
(Figure 6-7G).  In very late-stage infection, EGFP-66kd aberrantly accumulated at the edges of 
ORF29/IE62-defined RC near the nuclear membrane and did not appear to be significantly 
localized in the nucleolar region (Figure 6-7H).  The aberrant accumulations were either in the 
form of discrete circular foci in several areas or massive accumulations to one side of the 
nucleus.  These results clearly demonstrate that ORF66 lacking kinase activity exhibited atypical 
trafficking in VZV-infected cells: initially accumulating within RC rather than to speckles at RC 
surface, and later accumulating at the nuclear periphery rather than at the nucleolus.  In 
particular, the aberrant accumulation in RC indicated a possible protein:protein interaction that 
could not be interrupted in the absence of kinase activity.   
6.4.5 ORF66 lacking kinase activity exhibits specific co-localization with the VZV major 
capsid protein in large nuclear inclusions and at the nuclear periphery 
Since EGFP-66 and EGFP-66kd in VZV-infected cells were not always associated with RC or 
the nucleolus, we also investigated the possibility that these proteins associated with nuclear 
compartments involved in capsid morphogenesis.  For this, we performed indirect 
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immunofluorescence and epifluorescent microscopy analyses of VZV.GFP-66 and VZV.GFP-
66kd-infected cells stained with antibodies against IE62 and the VZV major capsid protein 
(MCP).  In late-stage infected nuclei exhibiting only low levels of IE62 expression, MCP could 
be observed distributed in large lobes throughout the nucleus (Figure 6-8A). In this example cell, 
several minute MCP foci are apparent at the extreme top of the nucleus, and these may represent 
capsids budding from the nuclear membrane (upper arrowheads).  EGFP-66 speckles were 
largely accumulated in the nucleolar region, but small EGFP-66 foci were also observed at the 
edges of MCP-containing compartments, and one EGFP-66 speckle on the lower side of the 
nucleus was co-localized with a putative budding nucleocapsid (lower arrowhead).  However, no 
significant co-localization was observed between EGFP-66 and MCP.  In direct contrast, VZV 
expressing EGFP-66kd exhibited aberrant MCP accumulation at the edge of the nucleus, nearly 
perfectly overlapping with EGFP-66kd autofluorescence (Figure 6-8B).  Less EGFP-66kd was 
observed in other regions of the nucleus, suggesting that EGFP-66kd interacts with MCP or 
another capsid related factor, and that this interaction may be involved in aberrant EGFP-66kd 
trafficking to the RC periphery in late stages of infection. 
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 Figure 6-8 VZV major capsid protein is aberrantly distributed in fibroblasts infected with VZV.GFP-66kd 
MRC-5 cells were infected with VZV.GFP-66 or VZV.GFP-66kd and fixed as described above.  
Cells were stained with rabbit poly-clonal anti-IE62 (goat-anti-rabbit 546) and mouse 
monoclonal antibody to the VZV MCP (goat-anti-mouse 647), and visualized by epifluorescent 
microscopy.  Close-up images of VZV.GFP-66 (A) and VZV.GFP-66kd (B) late-stage nuclei 
show marked differences in MCP localization and co-localization with GFP-66kd.  Late-stage 
VZV.GFP-66 (C) and VZV.GFP-66kd (D) syncytia exhibit nuclei with varying ORF66 and MCP 
localizations.  In all cases, the color-combined panel shows pseudo-colored EGFP-66 or EGFP-
66kd in green, MCP in red and IE62 in blue.  Individual staining profiles for (A-D) are shown in 
black in white to the right of each colored panel: i) EGFP-66 or EGFP-66kd; ii) IE62; iii) MCP.  
Enlarged nuclei from VZV.GFP-66 and VZV.GFP-66kd syncytia are shown in (E) and (F), 
respectively. 
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  VZV.GFP-66 and VZV.GFP-66kd-infected syncytia were imaged to highlight the myriad 
of nuclear distributions observed for the EGFP-66 kinase proteins and MCP in late-stage infected 
cells (Figure 6-8C and D).  IE62 cellular distribution was predominantly cytoplasmic in a 
representative micrograph depicting VZV.GFP-66 (Figure 6-8C, panel ii) and localized to large 
nuclear RC in VZV.GFP-66kd infections (Figure 6-8D, panel ii), indicating these cells were 
indeed in late-stage infection (panel ii for both).  Interestingly, MCP was distributed throughout 
the nucleus with accumulation at the nucleolus in many VZV.GFP-66-infected cells (Figure 6-
8C, panel iii), suggesting a possible role for the nucleolus in capsid assembly and egress.  
Occasionally, in cells expressing high levels of MCP, accumulations were observed at the 
nuclear edge, in structures reminiscent of “assemblons” observed in HSV-1-infected cells 
(Figure 6-8C, panel iii) (244).  EGFP-66 displayed bright foci that accumulated in the 
nucleoplasm and at the nucleolus, but never co-localized with MCP in these structures.  Two 
VZV.GFP-66-infected nuclei from the syncytium in Figure 6-8C are enlarged for enhanced 
viewing of EGFP-66 and MCP localizations (Figure 6-8E).  In VZV.GFP-66kd syncytia (Figure 
6-8D), many late-stage nuclei exhibited EGFP-66 and MCP co-localization at the nuclear edge 
(arrowheads), similar to the micrograph shown in Figure 6-8B.  However, cells at an earlier 
infection stage, as indicated by only partial occlusion of the nucleus by RC-associated IE62, also 
displayed significant co-localization between EGFP-66kd and MCP in many structures 
throughout the nucleoplasm (Figure 6-8D, arrows), and this did not usually occur at the 
nucleolus.  These nuclei were enlarged for better visualization of EGFP-66kd/MCP co-
localization and are shown in Figure 6-8F.  Interestingly, abundant levels of EGFP-66kd 
remained associated with RC at these times, and thus ORF66 may interact with multiple nuclear 
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compartments simultaneously during VZV infection.  Of note, we also observed bright EGFP-
66kd autofluorescence in cytoplasmic foci in close proximity to some nuclei in syncytia (Figure 
6-8D, far right; also in Figure 6-8F).  As postulated for EGFP-66kd association with RC, the 
aberrant accumulation in capsid assembly compartments indicated a novel protein:protein 
interaction that was enhanced in the absence of kinase activity.  Furthermore, as EGFP-66kd 
staining in VZV RC was reduced in favor of association with MCP in late-stage infected cells, 
this implies that EGFP-66kd may have been recruited directly from RC, possibly through 
interactions with the MCP or another capsid assembly component. 
6.4.6 EGFP-66 nuclear speckle formation does not require expression of additional VZV 
proteins 
To determine whether ORF66 speckles could form in the absence of additional VZV gene 
expression, we analyzed EGFP-66 distribution in MRC-5 cells infected with replication defective 
adenoviruses expressing EGFP-66 from a DOX-repressible promoter.  Control infections were 
performed in the presence of DOX to assess any affects induced by the adenovirus vector.  For 
these studies, we also stained cells for antigens that localize to CB and ND10 domains, as just 
described for VZV-infected cells.  EGFP-66 formed nuclear speckles that localized at the 
periphery of the nucleolus (nucleolar stain not shown) and throughout the nucleoplasm when 
expressed in the absence of additional VZV gene expression, indicating that the ability to 
localize in this manner was an intrinsic property of the ORF66 protein (Figure 6-9).  Speckles 
were more prominent in cells expressing high levels of ORF66 (as determined by EGFP 
fluorescence) and were less apparent with lower expression.  In many cells, prominent EGFP-66 
speckles were juxtaposed to ND10 domains, and PML appeared to be highly distributed in 
 191 
grainy speckles throughout the nucleus.  This suggests a subtle disbursement of PML in the 
presence of ORF66 expression.  Of note, many EGFP-66 speckles were also observed 
independently in the nucleoplasm (Figure 6-9A).  As was the case for VZV-infected cells, 
EGFP-66 displayed no co-localization with CB (Figure 6-9B).  Importantly, distal cytoplasmic 
speckles were not observed in cells expressing only EGFP-66.  Thus, EGFP-66 nuclear speckles 
either associated with a currently unknown cellular nuclear structure or formed de novo 
following EGFP-66 accumulation, while cytoplasmic speckles were a derivative of some process 
of VZV infection.         
 
Figure 6-9 ORF66 expressed in the absence of other VZV genes associates with the nucleolus and forms 
nuclear foci that partially overlap with ND10 domains 
 
MRC-5 cells were mock-infected or infected with 2 pfu/cell of Ad.GFP-66 and Ad.tTa and 
incubated in the presence or absence of 0.5 µg/ml DOX.  At 24 hpi, cells were fixed and stained 
with antibodies to PML (AF 647) (A), or Cajal bodies (AF 647) (B).    In both (A) and (B), 
mock-infected and infected cells that either lack or show nuclear speckles are displayed.  In all 
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panels, the enlarged micrographs depict a color combined image of EGFP-66 (green), PML or 
coilin as indicated (red), and Hoechst-stained chromatin (blue).  Smaller black and white panels 
show individual fluorescence patterns as indicated. 
6.5 DISCUSSION 
In this study, we have extended previous observations indicating novel nuclear 
distributions for the VZV ORF66 protein kinase, and we provide evidence to suggest that ORF66 
associates in a temporally-defined manner with specific nuclear sub-domains to coordinately 
affect multiple aspects of the VZV replication cycle.   
In very early stages of infection, nuclear EGFP-66 was predominantly diffusely localized, 
but minute speckles were consistently observed adjacent to ND10 domains, independent of the 
asymmetrically distributed IE62 foci at the periphery of the nucleus.  At a slightly later time-
point, IE62 foci coalesced into pre-RC/RC, and EGFP-66 speckles were observed decorating the 
pre-RC surface while ND10 domains were associated with its boundary.  Thus, one possible 
function for ORF66 could be to facilitate ND10 trafficking to sites of viral transcription and 
genome replication, either by dispersing ND10 components or actively inducing ND10 transport.  
In HSV-1 infected fibroblasts, ND10 are formed de novo adjacent to RC from components in the 
nuclear milieu in response to HSV-1 genomes, rather than by active ND10 trafficking to sites of 
viral transcription and replication (62).  Our immunofluorescence analyses of ND10 structures in 
cells expressing only the ORF66 protein suggest that ORF66 may function to disperse ND10 
components, thus providing some circumstantial support for the former possibility.  Interestingly, 
PML is also essential for type I and II interferon-mediated programmed cell death (243).  As it is 
known that ORF66 inhibits caspase activation in VZV-infected T-lymphocytes treated with type 
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II interferon (220), it is possible that ORF66 association with ND10 is related to this function.  A 
similar association with ND10 has not been described for the HSV-1 US3 kinase, and cellular 
distribution studies using antibodies against US3 have revealed only nuclear membrane, and not 
nucleoplasmic, association (212).  Thus, this observation may be representative of a unique 
function for the ORF66 protein kinase in VZV-infected cells. 
EGFP-66 nucleolar association was observed during very early stages of infection and 
persisted even when IE62 was completely excluded from the nucleus, implying involvement in a 
critical function independent of IE62 in the VZV replication cycle.  This function may be distinct 
from that of nucleoplasmic speckles, as nucleolar speckles remained relatively immobile at the 
nucleolar periphery.  Under normal physiological conditions, the nucleolus functions in 
transcription and processing of ribosomal RNA, biogenesis and nuclear export of pre-ribosomal 
particles, and intranuclear and nucleocytoplasmic transport of nuclear proteins (262).  As a result 
of the primary role in formation of ribosomes, many nucleolar proteins have RNA recognition 
motifs.  The EGFP-66 association with the nucleolus was astonishingly reproducible, and 
independent of both ORF66 kinase activity and the expression of additional VZV proteins.  
However, it is not yet clear whether ORF66 binds RNA or participates in modulation of any of 
the normal nucleolar processes.       
In a previous study, cell-free VZV infections clearly demonstrated that ORF66 
expression and nuclear localization was not sufficient for IE62 nuclear exclusion, and these two 
proteins did not co-localize in VZV-infected nuclei before RC formed (Chapter 4).  In the more 
detailed studies we presented here, EGFP-66 speckles were observed decorating the surface of 
VZV pre-RC and RC, where abundant levels of IE62 accumulated, and this association was 
concurrent with IE62 nuclear exclusion.  However, ORF66 did not appear to associate with RC 
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at very late times post-infection when IE62 was completely cytoplasmic.  This suggests that 
EGFP-66 specifically localizes to RC to mediate IE62 phosphorylation.  In support of this, VZV 
lacking kinase activity abnormally accumulated in RC and co-localized with the diffusely 
distributed IE62 there.  We suggest this occurs due to enhanced affinity for IE62 in the absence 
of the ability of ORF66 to mediate phosphorylation, similar to what is observed in cells infected 
with VZV expressing point-inactivated ORF47 (22).  Interestingly, the HSV-1 ICP4 NLS is a 
phosphorylation target for the US3 kinase in transfected cells (unpublished observations, M. B. 
Yee and P. R. Kinchington) but ICP4 is not an abundant cytoplasmic protein in HSV-1 infection, 
suggesting that specific compartmentalization of ICP4 (nucleoplasmic) and US3 (nuclear 
membrane) may preclude US3-mediated ICP4 phosphorylation and nuclear exclusion.  These 
observations provide support for the idea that ORF66 nuclear distribution patterns are reflective 
of unique ORF66 functions during VZV infection.  While we suggest that IE62 is the major 
target for the ORF66 protein kinase in VZV RC, we cannot rule out the possibility that additional 
VZV proteins may be phosphorylated there, as well.      
 Similar to the situation in RC, EGFP-66 speckles decorated capsid assembly 
compartments demarcated by the VZV MCP, while the EGFP-66kd protein aberrantly 
accumulated in this region.  Interestingly, EGFP-66kd was simultaneously associated with RC, 
MCP and nucleoli when RC only partially occluded the nucleus (early infection); but was 
exclusively associated with mislocalized MCP near the nuclear membrane when RC completely 
occluded the nucleus (late-stage infection).  This implied that a high-affinity association occurred 
between EGFP-66kd and MCP or another capsid component, and further suggested that VZV 
capsids may associate with both RC and nucleoli before proceeding to the nuclear membrane for 
export.  In support of this, some MCP accumulation was observed at the periphery of the 
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nucleolus in VZV.GFP-66-infected cells, and to a lesser extent in VZV.GFP-66kd infected cells.  
The VZV ORF33.5 capsid scaffolding protein contains an ORF66 consensus motif 
(176RRRRVSPS184), which is also an exact match to the optimal consensus for HSV-1 and 2 US3 
kinases (47, 206, 207).  We suggest that the ORF33.5 protein may be a novel target for the 
ORF66 kinase, and that interaction with this motif may override other interactions in the RC or 
the nucleolus.  Small, motile EGFP-66 foci reminiscent of nucleocapsids were also present in the 
distal cytoplasm of VZV-infected cells, and importantly, these were not observed in cells 
expressing only EGFP-66.  Thus, we consider it possible that these may represent cytoplasmic 
virion particles.  In support of this, it has been previously reported that ORF66 is a tegument 
protein (123).  Collectively, these observations imply a possible association between ORF66 and 
the VZV capsid that is enhanced by ablation of ORF66 kinase activity, and suggest a role for 
ORF66 in capsid morphogenesis.  Lastly, the accumulation of EGFP-66kd and MCP at the 
nuclear periphery may imply that ORF66 kinase activity is important for nucleocapsid egress.  In 
particular, MCP often appeared to accumulate in clusters, similar to what has been observed for 
HSV-1 capsids with viruses lacking US3 expression.  Electron microscopy (EM) performed in T 
cells and melanoma cells infected with VZV lacking ORF66 expression did not show any 
nucleocapsid accumulation in the peri-nuclear space (219, 220), but comparative nucleocapsid 
egress studies have not been performed in fibroblasts.  Thus, it is possible that the methods of 
nucleocapsid exit in each cell type are different.  
The question remains: how and why are ORF66 speckles trafficking around the nucleus?  
At this time there is no clear explanation, but several relevant points may provide some insight 
into potential future experiments aimed at answering these questions:   
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i) The ability of ORF66 to traffic around the nucleus and associate with multiple nuclear 
sub-domains suggests it may be involved in communication between these compartmentalized 
regions, or function in delivery of cargoes from one nuclear region to another.  We hypothesize 
that one cargo could be VZV nucleocapsids, and we are currently deriving recombinant, dual-
fluorescent VZV (mRFP-ORF66/ORF23-EGFP) to address this possibility.  Alternatively, 
nucleoplasmic trafficking may be a simple means for ORF66 to travel to different sub-domains 
where it can mediate phosphorylation of specific compartmentalized targets.     
ii) The high velocity and directed manner in which EGFP-66 speckles traffic in the 
nucleoplasm is suggestive of an energy-dependent process.  We are currently testing this 
hypothesis using live-cell imaging studies combined with ATP depletion and temperature 
reductions. 
iii) ORF66 may utilize the nucleoskeletal network for nucleoplasmic trafficking.  By 
electron microscopy (EM), the nucleoskeleton has been suggested to consist of the nuclear 
lamina at the nuclear edge, core filaments which radiate from the nucleolus to the nuclear 
periphery near the nuclear pore complex, and a diffuse meshwork skeleton that interconnects 
each of the components (104, 262).  Recently, an EGFP-tagged version of the cell cycle 
regulatory phosphatase, CDC14b, was reported to exhibit this type of nuclear localization in live 
cells, confirming that observations made by EM were not artefactual (184).  The nucleoskeleton 
is involved in nuclear compartmentalization and is probably critical for both DNA replication 
and RNA polymerase II transcription.  These functions are all important for efficient viral 
replication, and thus modulation of the nucleoskeleton could prove to be a major determinant of 
the efficiency of VZV replication.  HSV-1 is known to regulate components of the nuclear 
lamina (144, 178, 181), but no role in regulation of the interior nucleoskeleton has been reported.     
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In sum, these data provide a platform for understanding the complex interactions between 
ORF66, the cellular environment, and other VZV proteins.  We propose a model in which 
ORF66 localizes to the nucleus and initially interacts with ND10 domains to either promote their 
association with RC or inhibit an antiviral response; subsequently associates with RC to mediate 
IE62 phosphorylation and nuclear exclusion; and finally facilitates either nucleocapsid 
morphogenesis or egress from the nucleus.  Future efforts aimed at understanding the nature of 
ORF66 nuclear localizations will provide important insights into the mechanisms of VZV 
pathogenesis and the molecular differences between HSV-1 and VZV infection. 
 
 
 198 
7.0  PERSPECTIVE AND DISCUSSION OF FUTURE DIRECTIONS 
Overall, the results described herein represent a significant contribution to VZV biology and 
expand our understanding of a critical mediator of VZV pathogenesis, the ORF66 protein kinase.  
Previous to this work, the role of the ORF66 kinase in VZV pathogenesis had been well-
characterized, but the molecular functions of the ORF66 molecule were mostly unknown.  I have 
described the first ORF66 in vitro kinase assay; the first ORF66 viral protein target, IE62; and 
the first ORF66 substrate motifs (within IE62), which appear to resemble the optimum 
phosphorylation consensus for the related HSV-1 and 2 (47, 206, 207).  In addition, my work has 
identified mechanisms in addition to ORF66 that regulate IE62 nuclear versus cytoplasmic 
localization in VZV-infected cells.  Since IE62 nuclear exclusion may involve phosphorylation 
by ORF47 for nuclear release, this is the first indication of specific, cooperative activities by the 
VZV kinases in promoting a single outcome.  I have also extended a previous observation that 
ORF66 contributes to immune evasion by inducing downregulation of MHC-I.  These studies not 
only identified the general mechanism whereby ORF66 influences MHC-I, but also significantly 
enhanced our understanding of the regulation of MHC-I surface presentation in VZV-infected 
cells, and further suggested that additional VZV genes may be involved.  I have used VZV 
expressing EGFP-tagged ORF66 kinase proteins to demonstrate novel nuclear distribution and 
trafficking for ORF66, and I reveal a potential new role for ORF66 in capsid morphogenesis 
during VZV infection.  Thus, ORF66 affects multiple, seemingly unrelated proteins during 
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infection that are both viral and cellular in nature, in line with the multi-functionality of 
orthologous US3 kinase proteins.   
My in vitro kinase assay not only established that ORF66 was a functional protein kinase, 
but also identified the first substrate for ORF66 phosphorylation, and delineated two specific 
target motifs within the IE62 protein.  The IE62 motifs phosphorylated by ORF66 include 
RKRKS686QPVand KRRVS722EPV, and these were phosphorylated with similar efficiency in in 
vitro reactions.  Based on this, I define a minimum consensus for ORF66 phosphorylation as: 
R/K3-X-S, where X=Val or R/K (or potentially other amino acids).   In the IE62 genome, there 
are six additional proteins (ORFs 1, 4, 9, 22, 33.5 and 49) that carry at least three consecutive 
basic amino acids upstream of serine or threonine residues, which represent putative targets for 
ORF66-mediated phosphorylation and regulation in VZV-infected cells (Figure 7-1).  Potential 
phosphorylations of these proteins are currently being assessed by other members of the 
laboratory utilizing in vitro kinase assays based on the conditions derived in this study.  Of 
particular interest will be the ORF33.5 capsid scaffold protein, as ORF66 was implicated as 
potentially affecting nucleocapsid morphogenesis in ORF66 nuclear trafficking studies reported 
here.  In addition to assessing potential VZV protein targets, the kinase assay may also be used to 
assess phosphorylation of putative cellular phosphorylation candidates.   
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Figure 7-1 Comparison of known ORF66 phosphorylation motifs with predicted viral target motifs   
ORF66 phosphorylates two residues in the IE62 sequence.  Based on a loose consensus of R/K3-
X-S/T, six other VZV ORFs are predicted to have ORF66 phosphorylation motifs, and these are 
shown in single letter amino acid code.  The phosphorylated IE62 targets are included for 
reference.  The predicted phosphorylation site is underlined, and the placement in the context of 
the primery amino acid sequence is indicated. 
 
Given the importance of ORF66 kinase expression and catalytic activity for VZV 
survival in T lymphocytes, small molecule inhibitors of ORF66 could pose a potential novel 
avenue for development of a specific VZV antiviral.  The purification of the ORF66 kinase and 
identification of an ORF66 substrate and autophosphorylation activity presented here provide the 
basis for the development of an ORF66 inhibition screening assay.  However, the implications of 
ORF66’s biological activities and the potential effects on VZV pathogenesis must be carefully 
considered before such an inhibitor could be implemented.  T lymphocytes are likely infected 
shortly after VZV infection (137, 139), and thus an ORF66 inhibitor would have to be utilized 
upon exposure to prevent T-cell mediated dissemination to the skin, where such an inhibitor 
would likely be less effective in controlling VZV replication.  Since ORF66 expression may be 
important for the maintenance of latency by maintaining IE62 nuclear exclusion, inhibition of 
ORF66 kinase activity could potentially instigate VZV reactivation in individuals where it would 
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normally not occur.  Thus, an ORF66 inhibitor would not be appropriate for use in controlling 
zoster infections.  One controlled situation where an ORF66 inhibitor may be beneficial is if used 
in combination with the varicella vaccine.  The vaccine consists of live virus, which is known to 
infect T lymphocytes and cause severe disseminated disease in some at-risk individuals (78).  
Thus, simultaneous vaccination and ORF66-based anti-VZV treatment could significantly 
minimize the risks associated with vaccine-associated disease. 
ORF66-mediated IE62 phosphorylation represents an unprecedented interaction that has 
not been reported for any other alphaherpesvirus.  We hypothesized that this may be critical for 
regulation of the viral transcriptional program; efficient transactivation of VZV gene expression 
immediately upon infection and especially in the absence of the α-TIF ortholog, ORF10; and 
potentially for the maintenance of VZV latency.  The generation of VZV mutants lacking both 
ORF10 expression and the IE62 S868 residue, the critical determinant of ORF66-mediated IE62 
nuclear exclusion, should allow us to test the hypothesis that IE62 tegument association 
compensates for the lack of ORF10 expression and tegument association in cell culture.  
However, it will be much more difficult to test the hypothesis that ORF66-mediated 
phosphorylation of IE62 is involved in maintaining cytoplasmic IE62, and possibly latency, in 
VZV-infected ganglia.  One would expect to see an increased capacity for reactivation in viruses 
lacking ORF66 expression if this is the case, but such studies require a model for both VZV 
latency and VZV reactivation, and this is not currently available.    
We have hypothesized that ORF66-directed IE62 phosphorylation results in the 
impairment of importin α binding to the IE62 NLS through steric inhibition of the protein:protein 
interaction.  While intramolecular masking by phosphorylation is a commonly used mechanism 
in the regulation of nuclear import and export, few proteins have been shown to be nuclear 
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import impaired upon phosphorylation downstream of the NLS (88).  Thus, the ability of IE62 to 
interact with importin proteins should be assessed not only to clarify the mechanism for nuclear 
exclusion, but also because this ORF66-mediated IE62 phosphorylation event could provide a 
model of nuclear exclusion by C-terminal NLS phosphorylation.  An alternative explanation for 
IE62 nuclear exclusion is that the NLS becomes masked by an intermolecular interaction with a 
cytoplasmic anchor, which recognizes the ORF66-phosphorylated/NLS motifs, thereby 
preventing importin α recognition.  Support for this stems from the observation that both ORF66 
phosphorylation motifs are an exact match for the 14-3-3 recognition consensus (R-X-X-X-pS/T-
X-P, where pS=phospho-serine or threonine and X= any amino acid) (28).  Thus, the ability of 
phosphorylated IE62 to bind 14-3-3 proteins should also be assessed.        
Additional investigations of the nucleocytoplasmic trafficking of IE62 revealed that a 
complex interplay likely regulates IE62 cellular distribution, dependent upon ORF66 
phosphorylation-mediated inhibition of nuclear import, IE62 nuclear export through a nuclear 
export motif, and a possible novel coordinate ORF47 or CKII phosphorylation; which 
collectively result in IE62 nuclear exclusion.  We were particularly intrigued by the possibility of 
ORF47 poly-S phosphorylation-induced nuclear exclusion, since it may represent a novel, 
cooperative effort by the ORF66 and ORF47 kinases in contributing to a common outcome.  
Future experiments will be aimed at determining specific IE62 residues phosphorylated by the 
ORF47 protein kinase, and the effects of N-terminal poly-S mutation in the context of VZV 
infection.  Since the poly-S tract is likely phosphorylated by cellular CKII as well, a CKII 
inhibitor should be utilized in the context of wild-type VZV infection to determine if CKII 
contributes to IE62 nuclear exclusion, or if this is primarily a function of the combined activities 
of ORF47 and ORF66 protein kinases.  Furthermore, it will be interesting to determine any 
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effects of the C-terminal poly-S tract on IE62 cellular location.  Interestingly, ORF47-mediated 
phosphorylation of the VZV gE protein facilitates the recruitment of gE into the TGN (119), the 
site of virion assembly.  Thus, I speculate that IE62 poly-S phosphorylation by ORF47 could 
also result in TGN recruitment once IE62 has been excluded from the nucleus.    
 I have clearly demonstrated a kinase activity-dependent role for ORF66 in modulation of 
MHC-I surface expression in VZV-infected cells, but the mechanism is not entirely resolved.  
Potential pathways through which this could occur have already been discussed (i.e., through 
inhibition of the TAP complex or inhibition of MHC-I vesicular transport).  Alphaherpesvirus 
proteins that specifically affect MHC-I biogenesis (as opposed to global effects induced by host 
protein shutoff) are involved in inhibition of the TAP complex, but it is not known whether VZV 
affects TAP activity.  TAP inhibition would result in a delay in MHC-I maturation, and I 
consider this as the most likely mechanism for MHC-I subversion induced by the ORF66 
protein.  Future experiments aimed at more specifically elucidating the mechanism of ORF66-
mediated MHC-I downregulation should assess TAP function using the peptide transport assay 
originally described for the determining ICP47’s role in MHC-I downregulation (96).  However, 
as multiple effects on the PLC could potentially lead to the delay in MHC-I transport, the overall 
components of the PLC and early events in the assembly of MHC-I heavy chain molecules 
should be assessed in parallel, complimentary experiments using metabolic labeling and co-
immunoprecipitation analyses of individual PLC components.  MHC-I thermostability can also 
be assessed by incubating lysates at 37°C for one hour preceding immunoprecipitation with the 
conformationally-dependent W6/32 antibody: peptide-loaded MHC-I will remain folded and will 
immunoprecipitate, while MHC-I lacking peptides will dissociate from MHC-I heavy chains and 
fail to precipitate.  This experiment will assist in determining if the delay in MHC-I maturation is 
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due to faulty assembly by the peptide loading complex (PLC) or aberrant trafficking through the 
cis/medial-Golgi.   
Of particular interest for the role of ORF66 in VZV pathogenesis is the ability of ORF66 
to mediate MHC-I downregulation in the context of VZV-infected T lymphocytes.  Interestingly, 
the human immunodeficiency virus (HIV) nef protein, which is a well-established mediator of 
MHC-I downregulation, can induce MHC-I downregulation in several transformed cell lines, but 
functions significantly more efficiently in T lymphocytes, which are also one of the HIV natural 
reservoir cell types (114).  ORF66 expression and kinase activity is known to promote T-
lymphocyte survival in the face of type II interferon treatment (219, 220), but MHC-I 
downregulation could confer enhanced survival for VZV-infected T lymphocytes trafficking 
through lymphoid tissues in the presence of many additional immune cells.  It will be difficult, 
however, to assess the role of ORF66-mediated MHC-I downregulation for in vivo VZV 
pathogenesis in T lymphocytes or any other VZV-permissive cell type, as  the only well-
established model of VZV infection is the SCID-hu mouse, which lacks an adaptive immune 
system.  
Viral proteins that mediate MHC-I downregulation are known to impair CTL-mediated 
lysis of infected cells, and this establishes functional significance in viral immune evasion.  It 
will be important to establish a functional role for the ORF66 protein in protecting VZV-infected 
cells from CTL-mediated lysis.  The highly restricted human tropism of VZV is a severe 
limitation in testing this function of ORF66 in the context of infection.  However, VZV-specific 
human T-cell clones have been created and used with autologous B cells to study the immune 
recognition of specific VZV antigens expressed by vaccinia virus vectors (167, 168).  This 
system could be utilized to determine the ability of ORF66 to prevent T-cell activation in 
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response to specific VZV antigens in the absence of additional VZV gene expression.  
Importantly, it should be noted that the orthologous HSV-1 US3 kinase inactivates CTL and 
prevents apoptosis induced by cytolytic granule release (13, 223).  While it is unknown whether 
this function is conserved for the ORF66 kinase, this possibility should be considered when 
evaluating any results from this assay.            
Additional VZV genes may be involved in mediating MHC-I downregulation, but these 
have not yet been identified.  The vast majority of herpesvirus proteins that induce MHC-I 
downregulation are relatively small membrane proteins.  Thus, candidate screening analysis for 
additional VZV mediators of MHC-I subversion should include VZV glycoproteins, especially 
those for which no known function has been described.  A potential major obstacle in this 
approach may occur if the VZV protein involved in MHC-I downregulation works only in 
concert with other VZV proteins.  Thus, another approach to identifying the additional genes 
involved could include random mutagenesis of the VZV genome using the VZV bacterial 
artificial chromosome, combined with a large-scale screen of mutants for any differences in their 
abilities to affect MHC-I surface expression.  Our studies and those of others have indicated that 
the VZV ORF9a protein, the ortholog of the varicellovirus TAP inhibitor, does not appear to be 
functional when expressed alone in transformed cells (59, 136).  While this may be due to lack of 
conservation of MHC-I modulatory activity or inability to affect MHC-I in the absence of an 
unknown viral protein, an additional explanation for this observation is that ORF9a affects 
specific MHC-I allotypes.  If this were the case, downregulation may not be observed if MHC-I 
surface expression is assessed with pan-specific anti-MHC-I antibodies.  Thus, an assessment of 
ORF9a’s ability to mediate downregulation of specific MHC-I allotypes could potentially lead to 
identification of an immunomodulatory activity.  Notably, herpesviruses are known to more 
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efficiently target MHC-I allotypes that present peptides to CTL (e.g., HLA-A and HLA-B), 
rather than those that are dominant natural killer (NK) cell ligands (e.g. HLA-C) (155).   
ORF66 trafficking studies indicated a possible novel role for nucleocapsid 
morphogenesis in VZV-infected fibroblasts.  Orthologous US3 kinases have been implicated in 
faciliting nucleocapsid egress from the nucleus through phosphorylation of several components 
of the cellular nuclear lamina (144, 178, 181).  Given the unique distribution of ORF66 in VZV-
infected cells, I propose that ORF66 mediates this effect through novel intranuclear interactions 
and phosphorylation activities.  Interestingly, while the ORF66 and HSV-1 US3 kinase domains 
are >40% identical and >60% similar, a BLAST query of the ORF66 N-terminal domain against 
that of the HSV-1 US3 kinase revealed no significant homology (unpublished results).  In 
addition, ORF66 encodes a unique C-terminal 15 amino acid motif (379PDPYPNPMEVGD393).  
These unique regions may confer different cellular localization abilities or interactions with 
unique protein targets to facilitate specific ORF66 functions during VZV infection.  Future 
experiments should be aimed at identifying specific interactions between ORF66 and VZV 
capsid proteins, as well as any effects ORF66 has on trafficking of nucleocapsids in VZV-
infected nuclei.  
Since the ORF66 protein is ~48 kDa and larger than the size constraint for free diffusion 
across the nuclear pore complex, active nuclear import is implied.  While no classical R/K-rich 
nuclear import motifs are present in the ORF66 sequence, this does not exclude the possibility 
that ORF66 utilizes an importin β-specific import pathway, or potentially binds to another 
protein to piggy-back a ride into the nucleus.  Interestingly, ORF66 encodes a putative nuclear 
export motif (178LPICDILAI186), implying potential nuclear shuttling activities; this is supported 
by the abundant ORF66 nuclear and cytoplasmic localization in VZV-infected cells.  The 
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availability of EGFP-tagged ORF66 kinase proteins will allow the assessment of ORF66 
nucleocytoplasmic trafficking by physiologically relevant approaches such as fluorescence 
recovery after photobleaching (FRAP) methodologies.  
 While several properties of ORF66 have been clearly defined by the studies presented 
here, a more comprehensive understanding of the roles of ORF66 in VZV pathogenesis will 
require identification of cellular protein interaction partners and phosphorylation substrates.  For 
this reason, intensive future efforts should be aimed at identifying these interactions and 
assessing the role of the ORF66 protein kinase on the cellular phospho-proteome. 
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